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8Abbreviations
BMP bone morphogenetic protein
CGH comparative genomic hybridisation
cDNA complementary DNA
CLIM cofactors of LIM homeodomain proteins
CLIM1 carboxy terminal LIM domain protein 1 (LDB2)
CLIM2 carboxy terminal LIM domain protein 2 (LDB1)
COL4A3 α3 chain of type IV collagen protein
COL4A3 Homo sapiens COL4A3 gene
Col4a3 Mus musculus Col4a3 gene
COL4A3 α4 chain of type IV collagen protein
COL4A4 Homo sapiens COL4A4 gene
Col4a4 Mus musculus Col4a4 gene
CrC creatinine clearance
dpc days post coitum
ESRD end-stage renal disease
FGF fibroblast growth factor
FISH fluorescence in situ hybridisation
GBM glomerular basement membrane
GFR glomerular filtration rate
GPS genitopatellar syndrome
HD homeodomain
IOP intra-ocular pressure 
LDB1 LIM domain-binding factor 1 protein (CLIM2)
LDB2 LIM domain binding factor 2 protein (CLIM1)
LIM acronym of Lin-11, Is1-1, and Mec-3 genes
LPM lateral plate mesoderm
LMX1B LIM homeobox transcription factor 1 beta protein
LMX1B Homo sapiens LMX1B gene
Lmx1b Mus musculus Lmx1b gene
MGS Meier-Gorlin syndrome
MLPA multiplex ligation-dependent probe amplification 
NPS nail patella syndrome
NTG normal-tension glaucoma
OAG open-angle glaucoma
OMIM Online Mendelian Inheritance in Man
PCR polymerase chain reaction
RECQL4 Homo sapiens RecQ protein-like 4 gene
RT-PCR PCR of reverse-transcribed RNA
PTC premature termination codon
PTLAH patella aplasia-hypoplasia, isolated
POAG primary open-angle glaucoma
SNPs single nucleotide polymorphisms 
SPS small patella syndrome
SSCP single-strand conformation polymorphism
9TBX4 T-box transcription factor TBX4 protein (T-box protein 4)
TBX4 Homo sapiens TBX4 gene
Tbx4 Mus musculus Tbx4 gene
VAS visual analogue scale
Y2H yeast two-hybrid
ZonMw The Netherlands Organisation for Health Research and Development,
Zorgonderzoek Nederland Medische wetenschappen
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Chapter 1 General introduction, Aims and outline of the study
1.1 Human syndromes with congenital patellar malformations 
and the underlying gene defects
Adapted from Clin Genet 2005;68(4):302-319
1.2 Aims and outline of the thesis
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1.1 Human syndromes with congenital patellar malformations and the
underlying gene defects 
1.1.1 Limb development: new molecular players from studies on congenital absent
or small patellae 
Limb malformations are among the most common human birth defects, with
an estimated prevalence of 1 in 500 to 1 in 1,000 live births.1 Exact data on the
prevalence rate of absent or small patellae (kneecaps) in live born are not availa-
ble as yet and are difficult to obtain since the patellae are completely cartilagi-
nous at birth and ossify from the end of the second year onwards. It is also
unknown which proportion of congenital patellar malformations is part of a
genetic developmental disorder. More than 35 dysmorphic entities with absent
or small patellae are distinguished in the Winter-Baraitser Dysmorphology
Database (WBDD), version 1.0.4, London Medical Databases. In June 2005, the
on-line version of Mendelian Inheritance in Man (OMIM) included 41 genetic
disorder entries comprising absent or small patellae.2,3
Parents of a child with congenital patellar malformations, close relatives 
and adult patients more frequently ask for genetic counselling in order to be
informed about the molecular cause, the recurrence risk in future offspring, the
individual risk of the patients to develop associated organ system complications,
and therapeutic possibilities. Accurate genetic counselling is highly dependent
on the knowledge of the natural history and variability of the phenotype, the
underlying gene defect, and possible modifying factors involved in the expres-
sion and progression of organ system complications.
The knowledge of the molecular players involved in embryonic limb patter-
ning has fuelled both opportunities and challenges to understand the funda-
mental genetic programs of limb development in the past decades. Normal
limb development requires a complex orchestration of interplay between 
transcription factors, signalling molecules, and structural proteins. One of the
major causes of congenital limb malformations are mutations in single genes,
reflecting the critical role of these specific genes in the molecular networks 
of limb development. Several key molecular players in limb development have
already been uncovered by studying rare monogenic human syndromes with
limb malformations, yet causative genes for many more such syndromes await
to be identified and their complex interactions in the developmental pathways
deciphered. 
Patellar development involves different molecular and cellular mechanisms
regulating dorso-ventral patterning, cartilage and bone formation along endo-
chondral ossification pathways, and growth. Human genetic disorders compri-
sing patellar malformations and mutant animal models of congenital patella
dysplasia are instrumental to create more insight into these aspects of limb
development. Moreover, investigation of the complete phenotype of human 
syndromes and animal genetic models may reveal novel insights into the 
pleiotropic roles of the responsible genes in the normal development of other
organ systems.
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1.1.2 Patella
The patella (kneecap) is the largest sesamoid bone of the skeleton that is formed
and located within the tendon of the quadriceps femoris muscle. Its principal
role is to facilitate the extensor function of the quadriceps muscle and to protect
the ventral cartilage surfaces of the knee joint. The critical characteristics of the
knee, with the exception of the patella, were probably well established about
320 million years ago.4 According to fossil analysis, the patella evolved indepen-
dently in many mammalian, avian, and reptilian knees about 65 to 70 million
years ago. Evolutionarily, the patella is considered as the last major osteological
addition to the tetrapod knee. The importance of this unique sesamoid bone 
for the function of the knee is emphasized by its continued presence among 
a broad spectrum of tetrapod vertebrate species. The patella commonly arises
from a single ossifying nucleus, but secondary centres of ossification may occur
which usually fuse to form a single bone. During human embryonic development,
chondrification of the patella begins in week 10 of human embryonic develop-
ment5 and the patella ossifies between the second and sixth year.6
1.1.3 Congenital malformations of the patellae
Congenital malformations of the patellae can manifest as complete agenesis
(patella aplasia) or underdevelopment of the entire patellae resulting in a small
size of the patellae (patella hypoplasia).7 Anatomic variants of patella morpho-
genesis include aberrant shapes of the patellae and partite patellae, including
double-layered patellae in the coronal or transversal plane.8 Patients with 
congenital patellar malformations may have knee instability, recurrent patellar
(sub)luxations, and/or knee pain resulting from secondary patellofemoral 
dysfunction, chondromalacia, or gonarthrosis.
1.1.4 Limb patterning
Limb development involves a cascade of morphogenetic processes, including
the specification of limb fields, the induction of the limb buds, and the initiation
and patterning of limb bud outgrowth. Human embryonic development of the
limbs begins with mesenchyme cell condensations which protrude as small
buds at the appropriate rostrocaudal levels of the lateral body wall by the end 
of the fourth week.9,10 The limb bud core of undifferentiated mesenchymal cells
is encased by ectodermal cells. The mesenchymal cells that originate from the
lateral plate mesoderm give rise to bone, cartilage, and tendons of the appendi-
cular skeleton. The limb muscle precursor cells emerge from the dorsal part 
of the somites (dermamyotome) and migrate into the mesenchyme of the early
limb bud.11
The spatial patterning of the lower limb bud can be viewed along three 
primary axes: the proximo-distal (pelvis-digit direction), the antero-posterior
(great toe-little toe direction), and the dorso-ventral (back of feet-plantar direc-
tion) figure 1. During human embryonic development, limb patterning along three
axes is accompanied by rotation of the limbs. Initially, the upper and lower limb
buds extend laterally from the body wall with the thumb and great toe facing
rostrally and the flexor surfaces face ventrally. Subsequently, the limbs shift into
a more ventral position with both the thumb and great toe still facing rostrally,
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but the flexor surfaces now facing medially. The limbs rotate around their
proximo-distal axis between the sixth and eighth weeks of embryonic develop-
ment. The upper and lower limbs rotate in opposite directions, the upper limbs
rotate dorsally, and lower limb rotation occurs in the ventral direction. At this
end stage of limb rotation, the flexor/palmar surfaces of the hands face ventrally
and the flexor/plantar surfaces of the feet dorsally, the elbows and knees face
outward. Consequently, the patella, which primordial anlage is a dorsal structure,
comes to lie ventrally during limb development.
Vertebrate limbs comprise three skeletal elements: a single proximal segment
(stylopod; humerus/femur); paired middle elements (zeugopod; radius/ulna
and tibia/fibula); and several distal elements of the hand and foot (autopod;
figure 1
The skeletal compartments (zeugopod, stylopod, and autopod) of the human legs and the three developmental axes of
asymmetry (proximo-distal, dorso-ventral, and antero-posterior) of the human lower limbs. The proximo-distal axis runs
from the pelvis to the toes, the anterior-posterior axis from the great toe to the little toe, and the dorso-ventral axis
from the back of the feet to the plantar surface. The skeletal structures aberrant in nail patella syndrome (NPS), small
patella syndrome (SPS), Meier-Gorlin syndrome (MGS), patella aplasia or hypoplasia (PTLAH), RAPADILINO syndrome
(RAPADILINO), and genitopatellar syndrome (GPS) are depicted in grey. 
PosteriorAnterior
Ventral
Dorsal
stylpod
zeugopod
autopod
Proximal
Distal
NPS
NPS, SPS, PTLAH, MGS, 
RAPADILINO, GPS
SPS
SPS
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(meta)carpals/tarsals and digits) figure 1. The patella is a unique sesamoid bone 
of the lower limb that has no homologous structure in the upper limb. Patellar
development involves different molecular and cellular mechanisms regulating
dorso-ventral patterning, cartilage and bone formation along endochondral
ossification pathways, and growth. 
1.1.5 Human developmental disorders with congenital patellar malformations 
Congenital patellar malformations have been described as isolated hereditary
diseases or associated with complex genetic disorders. Exact prevalence data 
of syndromes characterised by congenital patellar malformations are lacking
addendum 1. Genetic conditions with congenital patellar malformations belong to a
clinically diverse and genetically heterogeneous group of osteochondrodysplasias.
A selection of recurrent pattern syndromes with congenital patellar anomalies
recorded in the Winter-Baraitser Dysmorphology Database (WBDD) and OMIM
is listed in table 1. Within the skeletal dysplasia classification of the recent
Classification of Constitutional Disorders of Bone (2001), a distinct group for
patella dysplasia syndromes has been expanded to include “ischiopubic patella
dysplasia” (“small patella syndrome”), “patella aplasia/hypoplasia”, “ear, patel-
la, short stature syndrome” (“Meier-Gorlin syndrome”), and “genitopatellar 
syndrome” in addition to “nail patella syndrome” in the former revision
(1997).12,13 The molecular basis has been uncovered in only few of these con-
ditions. Human developmental syndromes with patellar malformations may be
caused by single gene defects or result in some cases from chromosomal abnor-
malities, such as mosaic trisomy 8. In addition to the molecular genetic aetiology
of congenital limb malformations, teratogens such as thalidomide, amniotic
constriction bands, and vascular disruption, and are well-known environmental
factors that may disrupt normal limb development. However, these factors are
major causes of (asymmetrical transversal) limb reduction defects and have 
not been shown to play a role in causing congenital patellar malformations.
Here, we discuss the clinical and molecular aspects of complex genetic 
disorders in which patella aplasia or hypoplasia is one of the hallmark features,
including the nail patella syndrome, small patella syndrome, Meier-Gorlin 
syndrome (also known as “ear-patella-short stature syndrome”), RAPADILINO
syndrome, and genitopatellar syndrome tables 1-3.
Nail patella syndrome and LXM1B
Phenotype
The most common and well-known syndrome with congenital patella aplasia or
hypoplasia and best example of defective dorso-ventral limb patterning is the
nail patella syndrome (NPS). NPS is an autosomal dominant pleiotropic disorder
clinically characterised by dysplasia of dorsal soft-tissue limb structures, skeletal
anomalies, glaucoma, nephropathy, and peripheral neurological deficits tables 2
and 3.14 The classical tetrad of limb and additional skeletal features consists of
nail dysplasia figure 2a, absent or small patellae figure 2b , elbow dysplasia, and
exostoses (“horns”) of the ilia figure 2c.15,16 Bilateral small patellae are observed in 
the great majority of cases and absent patellae only in a minority. In two NPS
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patients, an extreme congenital exorotation position of the lower limb was
observed figure 2d.Bongers, unpublished data
From birth onwards, renal manifestations and glaucoma may develop or
progress.14,17 In NPS kidneys, disrupted structure and function of the glomerular
basement membrane and podocytes are responsible for changes in glomerular
filtration.18-21 Renal symptoms range from transient asymptomatic proteinuria
to renal failure which may be life-threatening.22 In addition to glaucoma and 
the risk of subsequent blindness, ophthalmologic anomalies include congenital
cataract and increased ocular pressure. Recent studies indicate that peripheral
neurological symptoms, such as sensory dysfunction, are also part of the syn-
drome.14,23 Clinical manifestations are extremely variable in both frequency and
severity.
Genotype
The underlying gene, LMX1B on chromosome 9q34.1, is a LIM-homeodomain
transcription factor. Heterozygous loss-of-function mutations in LMX1B are
suggested to cause NPS by haploinsufficiency, but dominant negative/gain-of-
function mechanisms can not be ruled out for most LMX1B mutations.12,23-25
Genotype-phenotype associations could not be established in the first LMX1B
mutation analysis studies of NPS by Dreyer et al. (1998), Vollrath et al. (1998),
and McIntosh et al. (1998).24-26
Molecular studies of Lmx1b-/- mice have demonstrated that Lmx1b is requi-
red for normal development of dorsal limb structures, the glomerular basement
membrane and podocytes of the kidney, the anterior segment of the eye,
dopaminergic and serotonergic neurons of the brain, and dorsal interneurons
of the spinal cord.27-33 The spectrum of limb malformations in NPS correlates
well with the expression pattern of Lmx1b in mice. In developing murine limbs,
Lmx1b is first expressed at embryonic day 8.5 in the lateral plate mesoderm.34
Subsequently, expression is restricted to the dorsal mesenchymal tissues of the
upper and lower limb giving rise to the dorsal aspects of the limb such as the
patellae, the tendons, ligaments, and joints, but not in myogenic precursor
cells.35 Regression of expression occurs when limb structures maturate and
after embryonic day 18.5 Lmx1b is no longer expressed in the proximal limb.35
figure 2 
Phenotypic characteristics of the nail patella syndrome.
(a) Ulnar hemianonychia of thumb nails, (b) small patella, (c) iliac horns (arrrows) and (d ) exorotation of lower limbs. 
a b c d
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table 1
Human genetic disorders with patella aplasia, hypoplasia, dislocation, or duplication
Human developmental disordera MIM Gene Chromosome
Syndromal patella aplasia or hypoplasia
Aniridia and absent patella, AD 106220
Baller-Gerold syndrome, AR 218600 RECQL4 8q24.3
Campomelic dysplasia (surviving), AD 114290 SOX9 17q24.3
Coffin-Siris syndrome, AR 135900
Genitopatellar syndrome, AR 606170
Guadalajar camptodactyly, type II, AR 211920
Idaho syndrome I, AR -
Kuskokwim syndrome, AR 208200
Meier-Gorlin syndrome, AR 224690
Microcephay with chemotactic defect and transient 
hypogammaglobulinemia, AR 251240
Multiple pterygium syndrome, AR 265000
Nail patella syndrome, AD 161200 LMX1B 9q34.1
Neurofibromatosis type I, AD 162200 NF1 17q11.2
Patella aplasia, coxa vara, and tarsal synostosis, AD 168850
Penoscrotal transposition/diphallus, AD/?
RAPADILINO syndrome, AR 266280 RECQL4 8q24.3
Rotmund-Thomson syndrome, AR 268400 RECQL4 8q24.3
Scholte syndrome, AR 181515
Small patella syndrome, AD 147891
Trisomy 8 mosaicism 8
Isolated patella aplasia or hypoplasia
Familial isolated patella aplasia-hypoplasia, AD 168860 17q21-q22
a AD, autosomal dominant inheritance; AR, autosomal recessive inheritance.
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Associated features References
Aniridia, cataract, glaucoma 120
Radial ray defects, craniosynostosis, typical facial appearance, small and malformed ears, short stature,
poikiloderma 86
Defective ischiopubic ossification, hypoplastic lesser trochanters, elongated femoral necks, kyphoscoliosis,
short stature, talipes, congenital subluxation or dislocation of the hips, dislocation of radial heads, characteristic 
facial features, developmental delay 121,122
Nail aplasia/hypoplasia, typical facial appearance, developmental delay, elbow dislocation 123,124
Arthrogryposis of the hips and knees, scrotal hypoplasia, renal anomalies, typical facial appearance, mental 
retardation 89
Camptodactyly of all fingers, brachydactyly of toes, short stature, microcephaly, cuboid vertebral bodies 125
Dislocated knees, sagittal synostosis, small or malformed ears, micrognathia, camptodactyly, mental retardation 126
Multiple congenital contractures comprising the knees, elbows, and hips, pedes planovalgus deformities,
spondylolisthesis 127,128
Microtia, short stature, typical facial appearance, skeletal anomalies, (uro) genital anomalies, mammary
gland hypoplasia 58,59
Short stature, micocephaly, large protruding ears, flexion contractures, small external genitalia in males,
deficient leucocyte chemotaxis, mental retardation 129,13
Multiple pterygia, flexion deformity of digits, short stature, typical facial appearance, urogenital anomalies,
vertebral and other skeletal anomalies 131,132
Nail dysplasia, iliac horns, elbow dysplasia, glomerulopathy, glaucoma, peripheral neurological symptoms 14,24,25 
Neurofibromas, café-au-lait spots, Lisch nodules, axillary and inguinal freckling
Absent/delayed ossification of the ischiopubic junction, coxa vara, bilateral absence of one metatarsal,
talocalcaneal synostosis 51
Penoscrotal transposition, renal defects, central nervous system and cardiac anomalies, imperforate anus,
preaxial limb defects
Radial aplasia or hypoplasia, cleft or high arched palate, diarrhea, dislocated joints, short stature, limb 
malformations, facial characteristics 75,78
Skin anomalies including poikiloderma congenitale, nail anomalies, postnatal growth retardation, skeletal 
malformations including radial ray defects and osteopenia, juvenile cataract, hypogonadism
Mental retardation, early balding, small hands and feet, hypogonadism, muscular hypotrophy 133,134
Disrupted ossification of the ischiopubic junction, infra-acetabular axe cut notches, an increased space 
between first and second toes, short fourth and fifth rays of the feet 49,5
Limited elbow supination, nail anomalies, typical feacial appearance, camptodactyly, progressive joint
restriction, learning difficulties
- 57
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Interestingly, Lmx1b expression is persistent and elevated in patellar mesenchy-
me and distal dorsal mesenchyme of first and second digits during develop-
ment.36
In the kidney, Lmx1b is initially expressed in the S-shaped bodies at embryo-
nic day 13.5 and expression has been shown to continue in the podocytes at
least until birth.27 Studies in Lmx1b-/- murine kidneys indicated that Lmx1b
regulates the expression of genes critical for glomerular basement membrane and
podocyte development and function, including Col4A3 and Col4A4 encoding
the α3 and α4 chains of type IV collagen, Nphs2 encoding podocin, and Cd2ap
encoding CD2-associated protein.30,31,37
The pathogenetic mechanisms underlying NPS nephropathy and glaucoma
remain to be elucidated. In the central nervous system of Lmx1b-/- mice, Lmx1b
has been shown to play a role in the development of dopamine and serotonergic
neurons by Shh acting upstream and Ptx3 downstream of Lmx1b, respective-
ly.29,38 Psychological evaluation of self-report questionnaires completed by 10
females with NPS revealed depression in five out of 10 cases and anxiety symp-
toms in five out of eight subjects, respectively.39 Animal models for NPS and the
peripheral neurological phenotype of NPS patients indicate that Lmx1b is also
crucial in dorsal spinal cord formation.28,40
Small Patella syndrome 
Phenotype
Small patella syndrome (SPS) is a dominant skeletal dysplasia affecting the lower
limbs and the pelvis.41-50 SPS is also named “ischio-pubic-patellar syndrome”
and “Scott-Taor syndrome” after the authors of its first description in 1979.49
Human developmental disordera MIM Gene Chromosome
Syndromal patellar dislocation
Desbuquois syndrome, AR 251450 17q25.3
Familial recurrent dislocation of the patella, AD 169000
Kabuki syndrome, AD 147920
Larsen syndrome, AD 150250 FLNB 3p14.3 
Larsen syndrome, AR 245600
Prieto X-linked mental retardation syndrome, X-linked 309610 Xp11.2-p21.1
recessive
Pseudodiastrophic dysplasia, AR 264180
Triphalangeal thumb and patellar dislocation, AD 190650
Double-layered patellae
Multiple epiphyseal dysplasia, type 4, AR 226900 DTDST 5q32-q33.1
Multiple epiphyseal dysplasia, type 2, AD 600204 COL9A2 1p33-p32.2
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Small or absent patellae associated with abnormal ossification of the ischiopubic
junction and/or infra-acetabular axe cut notches are critical findings for the clinical
diagnosis of SPS tables 2 and 3, figure 3a. Foot abnormalities, including a wide space
between the first and second toes, short fourth and fifth metatarsals of the feet
figure 3b, and pes planus are common but non-essential features. No complaints
related to pelvis and foot anomalies have been reported in SPS. Distinctive facial
characteristics including a high nasal bridge, micrognathia, and a high-arched
Associated features References
Micromelic dwarfism, narrow chest, vertebral and metaphyseal abnormalities, advanced carpal and tarsal 
bone age, supernumerary phalanges 135-137
Hypertelorism, short IV and V metatarsus, genu valgum 138,139
Typical facial appearance, mental retardation, short stature, joint laxity, skeletal anomalies, congenital heart
defects 140
Multiple congenital joint dislocations, flattened facies, short fingernails, short metacarpals and metatarsals,
spatulate thumbs, talipes 141,142
Multiple congenital joint dislocations, flattened facies, short fingernails, short metacarpals and metatarsals,
spatulate thumbs, talipes 143
Typical facial appearance, ear malformations, abnormal growth of teeth, clinodactyly, dimpled skin at the 
lower back 144,145
Rhizomelic short limbs, proximal interphalangeal and metacarpophalangeal joint dislocations, elbow
dislocations, severe talipes deformity, typical facial appearance 146
Triphalangeal thumbs, polydactyly, brachy- and camptodactyly, short stature 129
Short stature, epiphysial anomalies, shortened ulna, brachydactyly, shortened metacarpals 147,148
Short stature, epiphysial anomalies, varus/valgus knee deformity, osteoarthritis, mildly short hands 149
figure 3 
Phenotypic characteristics of the small patella syndrome.
(a) Absence of the ischiopubic junction (arrows) and (b) an increased space between the first and second toes, and short
fourth and fifth rays of adult patients.
a b
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palate have been mentioned in a minority of cases and may be part of the syn-
drome. In addition to the first description of SPS by Scott and Taor in 1979 until
2000, 38 subjects from six families and eight sporadic cases have been reported
in total.41-45,47-52 SPS needs to be differentiated from isolated hereditary Patella
Aplasia Hypoplasia (PTLAH), a rare autosomal dominant disorder in which
congenital patella dysplasia is the only clinical and radiographic characte-
ristic.53-57 A gene for PTLAH has been mapped to chromosome 17q21-22 in a
large Italian family with four affected generations.57
Meier-Gorlin syndrome
Phenotype
Meier-Gorlin syndrome (MGS) is an autosomal recessive pleiotropic condition,
originally described by Meier and Rothschild in 195958,59 and by Gorlin et al. in
1979.58,59 MGS is a rare disorder, as only 23 cases have been reported at the start
Organ structure Nail patella syndrome Small patella syndrome
Skeleton
Upper limb Radial head hypoplasia -
Radial head (sub)luxation
Lower limb Patella a-/hypoplasia Patella a-/hypoplasia
Wide space between first and second toes
Short fourth and fifth rays
Pelvis Iliac horns Absent/hypoplasia of the ischiopubic junction
Height - -
Ectodermal -
Hair High implant at temples
Skin
Nail Dysplasia and dystrophia
Breast
Ear Hearing impairment
Craniofacial - -
Other -
Kidney Glomerulo- and podocytopathy
Eye Glaucoma
Genital anomalies
table 2
Main phenotypic characteristics of human syndromes with patella aplasia or hypoplasia
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of the research described in this thesis.60-64,64-67 Since then, seven additional
individuals have been published by other groups.68-72 The syndrome is also
named “ear, patella, short stature syndrome”, synonymous for the classical
triad of bilateral microtia, patella aplasia or hypoplasia, and severe pre- and
postnatal growth retardation.66 Associated manifestations include a typical faci-
al appearance figure 4, mammary hypoplasia, genitourinary tract anomalies, vari-
ous skeletal anomalies, and delayed motor development table 2. In MGS, absent
patellae were found more frequently as compared to small patellae. Patellar
anomalies may be associated with various malformations of both the appendi-
cular and the axial skeleton and delayed skeletal maturation table 3. The facial
characteristics at early infancy comprise microstomia, full lips, micrognathia,
and a beaked nose figure 4. The most common genital abnormalities comprise
cryptorchidism and underdeveloped labia majora/minora at young age in males
and females, respectively. Renal anomalies including hydronephrosis and car-
Meier-Gorlin syndrome RAPADILINO syndrome Genitopatellar syndrome
- A-/hypoplasia of the radii -
Thumb a-/hypoplasia
Patella a-/hypoplasia Patella a-/hypoplasia Patella a-/hypoplasia
- Ischia/iliac bone hypoplasia
Short stature Short stature -
- -
Thin
Breast hypoplasia
Microcephaly Long slender nose Microcephaly
Microtia
Microstomia
Micrognathia Micrognathia
Hydronephrosis (Uretero) Hydronephrosis
Multicystic kidneys
Cryptorchidism Cryptorchidism
Scrotal hypoplasia
Small labia majora/minora Prominent/small clitoris
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Radiographs Nail patella syndrome Small patella syndrome
Kneea
Antero-posterior Patella a-/hypoplasia Patella a-/hypoplasia
Lateral (flexed at 30 degrees) Underdeveloped lateral Prominent lateral femoral and tibial condyles
femoral condyles
Prominent medial Underdeveloped medial
femoral condyles femoral and tibial condyles 
Dysplasia of the epiphyses of the proximal 
fibulae
Hip
Antero-posterior Iliac horns Absent/irregular ossification of the 
ischiopubic junction
Iliac bone hypoplasia Infra-acetabular axe cut notches
Iliac bone flaring Elongated and narrow femoral necks
Flattened and widened proximal femoral 
epiphyses 
Hypoplasia of the lesser trochanters
Ankle and feet -
Antero-posterior feet Short fourth and fifth metatarsals
Lateral feet Tarsal coalition or synostosis
Lateral ankle Broad neck of the talus
Elbow -
Lateral (flexed at 90 degrees) Radial head hypoplasia
Antero-posterior Radial head dislocation
Capitellum hypoplasia
Hand - -
Antero-posterior
Calvicula, scapula - -
Thorax  - -
Antero-posterior
table 3
Radiological features contributing to the clinical diagnosis of nail patella syndrome, small patella syndrome,
Meier-Gorlin syndrome, RAPADILINO syndrome, and genitopatellar syndrome
a Under age five or six years ultrasound examination of the knee is recommended for investigating the absence or
presence of patellar cartilage or bone.
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Meier-Gorlin syndrome RAPADILINO syndrome Genitopatellar syndrome
Patella a-/hypoplasia Patella a-/hypoplasia Patella a-/hypoplasia
- -
Ischia and iliac bone hypoplasia
Inferior pubic rami hypoplasia
- - -
-
A-/hypoplasia of the radii
Radial head dislocation Bowing of the ulnae
-
Delayed bone age Thumb a-/hypoplasia
Hook shaped clavicles - -
Flat or absent glenoid fossae
Gaps in ribs, short and/or absent ribs - -
Thin, gracile bones
26
diac anomalies comprising atrial and ventricular septal defects have been repor-
ted sporadically.60 The most serious aspects of MGS are feeding difficulties and
frequently recurring respiratory infections in early infancy. Growth hormone
analysis appeared to be normal in most cases and growth hormone therapy did
not reveal improvement in growth.60-62,73,74 Despite a catch-up of growth during
adolescence, adult height is below the third percentile. The majority of cases have
normal intelligence but present a delayed motor development. Cytogenetic analysis
was normal in all cases investigated. In the absence of a specific molecular marker,
the diagnosis is established on the classical triad of clinical features and a charac-
teristic facial appearance. 
RAPADILINO syndrome and RECQL4
Phenotype 
RAPADILINO syndrome is another autosomal recessive disorder in which 
patellar malformations are accompanied by short stature and external ear 
malformations. The acronym RAPADILINO stands for the characteristic main
figure 4 
Facial characteristics of the Meier-Gorlin syndrome at young age. 
(a and b ) A 5 year old boy, (c and d ) a 4 year old girl, and (e and f ) a 7 year old girl showing small and simple formed ears,
a beaked nose, full lips, and micrognathia.
a c
b d
e
f
C
hapter 1.1
H
um
an syndrom
es w
ith congenital patellar m
alform
ations and the underlying gene defects
27
features: RAdial and patella aplasia or hypoplasia, cleft or
highly arched PAlate, infantile DIarrhea and DIslocated
joints, LIttle size and LImb malformation, and long slender
NOse and NOrmal intelligence figure 5.75 Additional frequent
findings comprise absent thumbs, micrognathia, dysmor-
phic auricles including dysmorphic ear lobes and partial 
unfolded ear helices, a high-pitched voice, and metatarsus
varus. Sporadically, segmental vertebral deformations,
absent coccyx, mesomelic shortening of both legs,
calcaneonavicular fusion, hydronephrosis, atrial septal
defects, and anal malformations have been noted in 
individuals with this syndrome. Variable expressivity is 
well recognised. Kääriäinen et al.75 first described this 
malformation syndrome in 1989. Since then, 17 cases 
have been published which predominantly originate 
from Finland.75-78
Although there is clinical overlap with MGS, none of
the RAPADILINO patients were reported to have microtia.
Conversely, radial defects and thumb aplasia or hypoplasia,
which are typical for RAPADILINO syndrome, have not
been described in MGS patients to date. RAPADILINO 
syndrome also has similar features to the autosomal 
recessive disorders Rothmund-Thomson syndrome 
(RTS) and Baller-Gerold syndrome (BGS), such as 
patella aplasia, radial ray defects, and short stature, 
but RAPADILINO patients do not have poikiloderma 
which is a feature of both the RTS and BGS phenotype.79-82
Genotype
Based on the phenotypic overlap between RAPADILINO syndrome and RTS, 
the RECQL4 gene, which is mutated in some RTS patients, was proposed as 
a candidate gene for RAPADILINO.83 RECQL4 is a member of the RecQ gene 
family encoding helicases involved in unwinding DNA structures.84,85
In 13 patients from 10 Finish RAPADILINO families, four different RECQL4
mutations were identified comprising three nonsense mutations and one 
splice-site mutation.78 None of the RECQL4 mutations found in RAPADILINO
syndrome patients have been previously reported in RTS patients. Recently, 
three novel RECQL4 mutations were found in five patients with BGS from two
unrelated families, including a missense, frameshift, and splice-site mutation.86
The overlapping phenotype of RAPADILINO syndrome, RTS, and BGS indicates
that a wide spectrum of patellar malformations and radial ray defects may 
result from RECQL4 gene defects. Genotype-phenotype evaluations within the
RECQL4 mutation spectrum have not been performed as yet. The pathogenic
mechanisms responsible for the different features of these syndromes, 
including patellar malformations remain to be elucidated.87
figure 5 
Phenotypic characteristics of the 
RAPADILINO syndrome.
(a) Note the long nose and small chin in a 
5 year old girl, and (b) short forearms, missing
thumbs, malposition in knee joints and meta-
tarsus varus in a 4 year old girl. (Photographs 
in figure 5 are reproduced from the original
work of Kääriäinen et al. (2003)75 with permis-
sion from the Professor H. Kääriäinen, the 
parents of patients, and Wiley publishers.)
a b
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Genitopatellar syndrome
Phenotype
Genitopatellar syndrome (GPS) is an autosomal recessive disorder, in which
patella aplasia or hypoplasia is associated with arthrogryposis of the hips and
knees, genital anomalies, renal anomalies, a distinctive facial appearance, and
mental retardation. To date, eight sporadic cases and two sibling pairs from
unrelated families have been reported.88-93
Skeletal anomalies are restricted to the lower limbs and pelvis, except for
brachydactyly of the upper limbs. Patella aplasia or hypoplasia may be accom-
panied by hypoplasia of the iliac and ischiac bones and of the inferior pubic
rami.89 Congenital flexion deformities of the knees and hips were observed in
all patients and talipes in the majority. Genital anomalies comprise scrotal
hypoplasia and cryptorchidism in males. In females, both hypoplastic clitoris
and labia minora as well as prominent clitoris and labia minora have been 
described.89,91 Multicystic kidneys and/or (uretero)hydronephrosis were found
in all but one case. In addition to the clinical manifestations of multiple organ
systems of mesodermal origin, mild manifestations of ectodermal dysplasia
such as sparse thin scalp hair and delayed tooth eruption have been reported in
two cases. Craniofacial features include microcephaly, a large and broad nose
with a high nasal bridge, and micrognathia. Corpus callosum agenesis and
severe psychomotor retardation are common findings, with absence of 
speech or walking inability and hypotonia in some GPS patients.89,91 Short 
stature and congenital heart defects have been mentioned in a minority of 
individuals.90,91 Swallowing and feeding difficulties may complicate the
neonatal period. The most serious and life-threatening complications are the 
respiratory problems. Three patients died before age 3 years, two of them due 
to apnoea.90,91 Pulmonary hypoplasia was found in three cases by necropsy.89
All cases had normal karyotypes. The underlying molecular cause has not yet
been identified.
1.1.6 Developmental roles of genes in the pathways of limb patterning
Much of the current insight in limb patterning has been obtained from studying
limb development in chicken and mouse embryos. A detailed overview on the
current knowledge of the role of signalling molecules, transcription factors, and
structural proteins in the limb developmental programs of animals has been
provided by excellent reviews published elsewhere.94-96 However, the picture is
far from complete since many more genes need to be discovered and their 
complex interactions in the entire developmental pathways unravelled. To 
further understand the function of some of the genes encoding signalling 
molecules or transcription factors involved in the human developmental 
mechanisms of limb formation, we briefly discuss some of the molecular 
pathways of limb patterning along the three primary axes of asymmetry. 
Proximo-distal patterning
A complex interplay of members of the T-box gene family (Tbx) of transcription
factors with the fibroblast growth factor (Fgf ) and the wingless (Wnt) family of
growth factors drives the initiation and outgrowth of limb structures along the
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proximo-distal axis in chicken.97-105 In the early stages of lower limb development
in chicken, Tbx4 in the lateral plate mesoderm specifically induces Wnt8c-Fgf8/10
signalling that feedbacks on to Fgf10 in the mesenchyme maintaining outgrowth
of the limb bud.104,104-106 A similar signalling cascade is assumed for upper
limb development, in which Tbx5 interacts with Wnt2b in regulating Fgf8/10
signaling.104,107,108 Misexpression of Tbx5 and Tbx4 genes results in a wingless
and legless phenotype during early developmental stages in chicken, respectively.
104,109 Disruption of Tbx4 expression during later developmental stages causes a
significant reduction in leg outgrowth, absent pubis, and hypomorphic ilium
and ischium.104 In murine Tbx4 mutants, manifestations of defective late skeletal
development could not be studied due to embryonic lethality caused by failure
of chorioallantoic fusion.110 As yet, no Wnt genes have been identified in mice
and human that have similar functions as Wnt8c and Wnt2b in chicken. In
contrast to chicken, investigations in mice did not reveal a determining role for
Tbx4 and Tbx5 in the specification of limb-type identity.111 Molecular studies in
mice demonstrated that Tbx4 is capable of rescuing initiation and maintenance
of forelimb outgrowth in Tbx5-/- mice embryos, indicating that there is high
degree of functional redundancy between Tbx4 and Tbx5. These findings are
consistent with the conserved developmental mechanisms of pattern formation
in which these genes share several target genes.112
Specification of limb-specific morphologies are thought to be regulated by
Hox genes at the axial rostrocaudal levels and by the paired-type homeodomain
transcription factor Pitx1 at the caudal level in the lateral plate mesoderm.111
Pitx1 also induces Tbx4 gene expression in lower limb fields, but has no role 
in the initiation of limb outgrowth in mice.109,111,113 Interestingly, the limb 
malformations in Pitx1-/- mice, such as the absence of the patellae and ilium 
and smaller hindlimbs, are less severe than in Tbx4-/- mice, suggesting that 
the expression of Tbx4 is regulated by other pathways as well.114
Dorso-ventral patterning
The asymmetrical dorso-ventral identity of the limb is specified by reciprocal
interactions between limb bud ectoderm and mesenchyme with Wnt7a expressed
in the dorsal ectoderm, Lmx1b expressed in the dorsal mesenchyme, and the
homeobox containing transcription factor Engrailed-1 expressed in the ventral
ectoderm.27,34,36,115-117 Wnt7a induces the initial expression of Lmx1b in the lateral
plate mesoderm of the presumptive forelimb of mice at embryonic day 8.5 and
in the dorsal mesenchyme of the forelimb and hindlimb buds through develop-
ment until embryonic day 18.5, when expression no longer persists.34,36
However, Lmx1b expression persists in the patellar mesenchyme which ultimate-
ly gives rise to the patella and patellar tendon.36 Lmx1b plays a pivotal role in the
formation of dorsal limb structures such as nails and patellae.9,27,115 The prolonged
expression of Lmx1b in the patella and tendinous patella precursor is consistent
with the patellar phenotype in Lmx1b-/- mice. These animal models develop
zeugopods and autopods with absent patellae, a double ventral phenotype, and
ulnar reduction.27,115 No down-stream targets of Lmx1b in the developing limb
have been identified as yet.35
30
Antero-posterior pattering 
Antero-posterior limb patterning is regulated by Shh signalling mediated by
regulatory loops between Fgfs and the transcription factors Gli3 and dHand.110
Additionally, Hoxd genes encoding homeobox containing transcription factors
act upstream and downstream of Shh.118 Studies of mutant animal models have
shown that both Lmx1b and Tbx4 are involved in antero-posterior patterning of
the autopods.36 The level of Lmx1b expression is diminishing from the anterior
to the posterior aspect of the distal limb.36 The gradient of the concentration of
Lmx1b expression correlates with the limb phenotypes of NPS, such as a gradu-
al decrease of the severity of nail malformations in the antero-posterior directi-
on in individuals with LMX1B mutations.36
Electronic-Database Information
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim/ 
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1.2 Aims and outline of the study
The research described in this thesis was initiated in September 2000, 
almost two centuries after the first description of the nail patella syndrome,119
two years after the discovery of the LMX1B gene responsible for this syndrome,24,25
and two and four decennia after the clinical recognition of the small patella
syndrome 49 and the Meier-Gorlin syndrome,58,59 respectively.
With the identification of LMX1B mutations in nail patella syndrome, questions
raised as to whether the LMX1B genotype could be involved in the pathogenic
mechanisms underlying the highly variable phenotype of this syndrome, whether
the individual genotype could predict the risk of developing organ complications,
and/or whether modifying genes might play a role in the presence and severity
of nephropathy. While previous studies showed that mutations in the LMX1B
gene affect the development of the patellofemoral joint in nail patella syndrome,
24,25,27 the molecular basis of congenital patellar malformations in small patella
syndrome and Meier-Gorlin syndrome remained to be elucidated. 
The present study on human genetic disorders with congenital patella aplasia 
or hypoplasia comprises a clinical and molecular part. 
The clinical investigations aimed to gain insight into: 
1). The complete phenotype of nail patella syndrome, small patella syndrome,
and Meier-Gorlin syndrome; 
2). The clinical manifestations of nail patella syndrome based on advanced
knowledge of the function and expression of the underlying gene in 
different organ systems including the limbs and kidneys; and 
3). Possible genotype-phenotype correlations of nail patella syndrome, 
small patella syndrome, and Meier-Gorlin syndrome. 
The molecular research aimed at the identification of the genes underlying small
patella syndrome and Meier-Gorlin syndrome and investigation of candidate
modifying genes involved in the clinical variability of nail patella syndrome. 
The ultimate goal of this research project was to make a significant contribution
to unravelling the molecular pathways of limb and kidney development and to
apply this knowledge to the diagnosis, clinical management, and genetic coun-
selling of patients with genetic disorders with congenital patellar anomalies
and their families.
The first part of this thesis describes the studies on nail patella syndrome
(Chapter 2), the second part on small patella syndrome and isolated hereditary
patella aplasia or hypoplasia (Chapter 3), and the third part on Meier-Gorlin
syndrome (Chapter 4). 
Chapter 2.1 presents the knowledge of the clinical and molecular aspects of nail
patella syndrome available in 2002. Chapter 2.2 describes the identification of
the first mutations in eight Dutch nail patella syndrome families, including the
family that was originally described in 1972 by the deceased Drs B.G.A. ter Haar
en Drs. F.E. van Dam. In Chapter 2.3, the molecular pathologic studies of 
32
kidneys of individuals with nail patella syndrome nephropathy is described.
Chapter 2.4 reports on the molecular investigation of candidate modifying
genes in a Dutch family with high prevalence of nail patella syndrome nephro-
pathy. Chapter 2.5 presents detailed genotype and phenotype studies of an
extended series of 32 Dutch families with nail patella syndrome expanding 
the clinical spectrum and revealing a first genotype-phenotype association
involving nail patella syndrome nephropathy. 
In Chapter 3.1, clinical and haplotype studies of small patella syndrome families
are reported and diagnostic criteria of small patella syndrome are defined.
Chapter 3.2 describes the discovery of human TBX4 mutations underlying small
patella syndrome and the role of TBX4 in the development of pelvis, patellar,
and (meta)tarsal bones. Chapter 3.3 focuses on haplotype analysis of a candidate
chromosome region for isolated patella aplasia-hypoplasia and the region
encompassing LMX1B in a British family with isolated patella aplasia-hypoplasia.
Chapter 4 presents the meticulous clinical characterisation of eight patients
with Meier-Gorlin syndrome. 
In the final discussion (Chapter 5), it is emphasized how clinical and molecular
studies of human genetic disorders and animal models with limb malformations,
in particular patella aplasia or hypoplasia, have contributed to the current
knowledge on the development of the limbs and other organ systems. 
In the Addenda, recommendations for diagnostic work-up and clinical 
management and aspects in genetic counselling of patients with inherited 
disorders with congenital patella aplasia or hypoplasia and their families 
are presented.
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Abstract
Nail patella syndrome (NPS) is a rare autosomal dominant pleiotropic disorder
characterised by dysplasia of the nails, patella aplasia or hypoplasia, iliac horns,
dysplasia of the elbows, and frequently glaucoma and progressive nephropathy.
The recent identification of the causative gene for this syndrome has initiated
further studies of the phenotype and molecular pathogenesis of kidney disease
in NPS. The gene underlying NPS, LMX1B, encodes a LIM-homeodomain 
transcription factor involved in normal patterning of the dorso-ventral axis of 
the limb during development and early morphogenesis of the glomerular 
basement membrane. Molecular studies of Lmx1b, combined with genetic and
immunohistochemical investigation of different alpha chains of type IV collagen
in the Lmx1b-/- mice kidney, a mouse model for NPS, have provided evidence
that Lmx1b is involved in the pathogenesis of NPS glomerulopathy. At present
evidence for a correlation between the presence and severity of the renal and
extrarenal anomalies and LMX1B genotype is lacking. This review focuses on 
the recent advances in clinical and molecular genetic studies of NPS.
Introduction 
Nail patella syndrome (NPS; MIM 161200) is an autosomal dominant condition
affecting tissues of both ectodermal and mesodermal origin, manifested as
symmetrical nail, skeletal, ocular, and renal anomalies. The incidence
approaches 1 in 50,000 live births. The severity of clinical features of this highly
penetrant disorder is extremely variable both within and between families. 
The recent elucidation of the genetic cause of this syndrome has provided
important new insights in the molecular pathways of normal and disturbed 
kidney development. 
The striking resemblance of anomalies of the glomerular basement membrane
(GBM) in NPS and Alport syndrome suggested a common etiopathogenetic 
factor involved in both hereditary glomerulopathies. The identification of the
LMX1B gene (MIM 602575) responsible for NPS1 and the subsequent identifica-
tion of COL4A4 and COL4A3 as the first downstream target genes of Lmx1b,
have shown that Lmx1b regulates type IV collagen expression during GBM deve-
lopment and thus contributes to the maintenance of the glomerular structure 
and function postnatally.2
In this review, the clinical symptoms of NPS and recent insight in the genetic
cause of this syndrome are discussed and three recently identified novel mutations
in the LMX1B gene in NPS patients are presented. In addition, we will emphasize
studies in Lmx1b knockout mice which have provided the basis for the putative
molecular regulation of fetal kidney development by Lmx1b. 
Historical overview
The first report of a patient with congenital anomalies of the nails, elbows,
and knees already dates from 1820.3 The familial and hereditary nature of the
association of patella aplasia or hypoplasia and absent thumbnails, with or
without elbow dysplasia, were first recognised by Pye-Smith4 and Little5 in 1883
and 1897, respectively. Several terms have been proposed for this disorder,
including “Österreicher syndrome”,6 “Turner syndrome”,7 “Turner-Kieser 
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syndrome”,7,8 “arthrodysplasia”,7 “Touraine syndrome”,9 “Fong disease”,10 and
“hereditary osteo-onychodyplasia” (HOOD).11 In 1939, Kieser8 described iliac
horns as part of NPS, although Turner7 had already described in 1933 the 
presence of these bony processes on intravenous pyelography in a NPS patient.
The classical tetrad of anomalies of the nails, elbows and knees, and iliac horns
was described by Mino et al. in 1948.12 In 1936, a cloverleaf dark pigmentation
of the inner margin of the iris, known as Lester’s sign, has been reported as the
first ocular anomaly in NPS patients.13,14 More than 60 years later, Lichter et al.
(1997)15 described cosegregation of primary open-angle glaucoma (POAG) and
NPS in 50% of NPS patients (12/24) from two families and suggested this ocular
anomaly to be a variable feature of NPS. Since 1950, the involvement of renal
pathology in NPS has been recognised14,16,17 and confirmed by the identification
of typical changes of the GBM at the ultrastructural level.18-20 Depression and
anxiety symptoms, epilepsy, peripheral neurological symptoms, and gastroin-
testinal complaints, including irritable bowel syndrome and constipation, have
recently been suggested to be associated with NPS.21-23
Clinical features
Nail and skeletal anomalies
Nail dysplasia and patella aplasia or hypoplasia are essential features for 
the diagnosis of NPS. The presence of triangular nail lunulae is a pathogno-
monic sign for NPS figure 1a. Furthermore, anonychia, hemianonychia, nail
hypoplasia, longitudinal ridging, splitting, and spoon shaped and flaky nails
have been associated with NPS figure 1b. The toenails are rarely involved. Nail 
dysplasia is usually present at birth, but it has been noted to appear after birth.24
Nail anomalies have been found in 95.1% of the NPS patients (235/248) reported
in literature.25-29
Patella aplasia or more frequently patella hypoplasia has been shown in
92.7% of the cases (230/248).25-30 Small and dysplastic patellae accompanied 
by hypoplasia of the lateral femoral condyle may result in recurrent subluxation
or dislocation of the patellae, knee disability, and knee pain complicated by
patellofemoral arthrosis. 
Other skeletal anomalies associated with NPS frequently involve the pelvis,
elbow, and feet. Iliac horns are triangular bony protuberances of the posterior
ilium figure 2.31,32 On physical examination, the iliac bones are frequently palpable
and can be shown as pyramidal processes projecting dorsolaterally from the ilia
on pelvis radiographs from birth. No complaints or effects on gait related to
this skeletal anomaly have been reported in NPS patients.26 Although iliac horns
are pathognomonic for NPS, they have been found in only 70% - 80% of NPS
patients.14,21,22,26,33
Elbow dysplasia has been described in 92.5% of NPS patients (161/174).25,28-30
Hypoplasia of the radial heads and/or capitella with recurrent posterolateral
subluxation or dislocation of the radial heads has been shown in 61% of
patients.26,34,35
Foot deformities have been found less frequently in NPS patients, the most
common being talipes equinovarus and equinovalgus.26, 35 Short stature has
sporadically been described in NPS.26, 35 The incidence of NPS mentioned above
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might be biased by the fact that in many patients, referred to orthopaedic sur-
geons for complaints related to patella aplasia/hypoplasia or other skeletal
anomalies, the diagnosis NPS might simply be overlooked. 
Ocular findings
Various ocular anomalies have sporadically been found in NPS patients,
including microcornea, sclerocornea, congenital cataract, iris processes, 
pigmentation of the inner margin of the iris, and congenital glaucoma.35-37 The
iris pigmentation named Lester’s sign as well as congenital cataract, are known
to be coincidental findings rather than characteristic anomalies of this 
syndrome.17,38 After the first report of cosegregation of POAG and NPS by
Lichter et al. (1997),15 POAG was recognised in 13 families among 33 NPS 
families. Furthermore, they found pigmentary glaucoma and ocular hypertension
with and without pigment dispersion syndrome.15 The latter findings and the
subsequent identification of mutations in the gene underlying NPS in families
in which POAG cosegregated with NPS, provided further evidence that POAG is
a variable feature of this syndrome.39-41 Ocular investigation of 123 NPS patients
revealed ocular hypertension in 7% and glaucoma in 10% of the cases (age
ranged 23 to 78 years).21,22
Renal disease
Nephropathy is the most serious aspect of NPS. There is great variability 
in the incidence of renal disease and the severity of renal symptoms within 
and between NPS families. Early signs of defects of the glomerular basement
membrane (GBM) affecting glomerular filtration are proteinuria and less 
figure 1
Nail dysplasia in (a) a nail patella syndrome
patient aged 34 years showing triangular
lunulae and longitudinal ridging of the thumb
and (b) his affected son aged 25 years demon-
strating ulnar hemianonychia of the thumb.
figure 2
Radiograph of the pelvis showing bilateral 
iliac horns (arrows) that project as bony
outgrowths posterolaterally from the ilium.
a b
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frequently hematuria. In 1990, Meyrier et al.25 studied 123 NPS patients reported
in literature and found that 38% showed no apparent renal involvement. In 62%
of the NPS patients glomerular abnormalities were found, ranging from chronic
benign proteinuria in most patients to end-stage renal disease in 15%.25 In
another cohort of 123 NPS patients, renal disease was found in 25% of the cases,
with an average age of 22 years at the time of detection.21,22 In the latter group,
only 2% of the patients developed renal failure.
Light microscopic examination of renal biopsies in NPS reveals non-specific
findings mostly related to the degree of renal failure, including focal and 
segmental sclerosis, proliferative glomerulonephritis with crescent formation,
and hyalinisation of the glomeruli.25,36,42,43 The only consistent but non-specific
glomerular feature studied by light microscopy is focal thickening of the
GBM.42 Although renal biopsy specimens may not reveal any anomalies on 
light microscopy, characteristic changes of the GBM have been found in all 
NPS patients on electron microscopy.25,36 Ultrastructural examination of the
GBM shows focal or diffuse and irregular thickening containing patchy 
electron-lucent areas giving the GBM a “moth-eaten” appearance with electron-
dense areas in the thickened spaces figure 3a.36 Another highly specific finding of
the NPS kidney is irregular deposition of bundles of fibrillar collagen in the
GBM figure 3b, especially in the lamina densa, and occasionally in the mesangial
matrix, usually accompanied by mesangial cell proliferation. These characteristic
and uniform ultrastructural features of the GBM have been identified in all
biopsied NPS patients and have already been found in young NPS patients. 
The severity of these changes do no seem to correlate well with patient’s age,
the severity of proteinuria, the degree of impaired renal function, and even the
presence of nephropathy.25,36,42,43
Development of glomerular disease to end-stage renal failure is usually 
slow, although rapid progression to terminal renal insufficiency at young age
has been observed in a minority of the cases.25 For example, follow up of renal
symptoms in a sporadic female NPS patient revealed rapid progression to end-
figure 3
Electron microscopy from a nail patella syndrome patient. (a) Irregular shaped fibrils are located in the glomerular
basement membrane (GBM) and the subendothelial space. The GBM shows thickening with electron-lucent areas (FP,
epithelial foot processes), X6,000. (b) On higher magnification (X14,000) the fibrils have the characteristic striated perio-
dicity of collagen (arrow). 
a b
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figure 4
LMX1B mutations identified in nail patella syndrome patients. The diagram on the left represents the LMX1B gene and
the LMX1B protein, comprising eight exons and containing two LIM domains (LIM-A and LIM-B) and a homeodomain,
respectively. The dotted lines in the LMX1B gene show the exon boundaries. The vertical lines link the positions of the 
specific mutations with its description in the table on the right. (PTC, premature termination codon). aNucleotide 
numbering follows GenBank AF057135.
1 71-37del17 71-37del17 Loss of exon 2, fameshift, PTC 66
2 71-2A→G 71-2A→G Loss of exon 2, frameshift, PTC 64
3 71-1G→A 71-1G→A Loss of exon 2, frameshift, PTC 41
4 85del27 85del27 Disrupt Zn-finger 64
5 C36R 106T→C Disrupt Zn-finger 64
6 C36S 107G→C Disrupt Zn-finger 64
7 C36Y 107G→A Disrupt Zn-finger This article
8 115delC 115delC Frameshift, PTC 67
9 R47X 139C→T PTC 67
10 S51X 152C→A PTC 67
11 154del9 154del9 Disrupt Zn-finger 64
12 W53X 159G→A PTC 64
13 H54Y 160C→T Disrupt Zn-finger 64
14 H54N 160C→A Disrupt Zn-finger 67
15 H54L 161A →T Disrupt Zn-finger This article
16 H54Q 162C→R Disrupt Zn-finger 64
17 C57R 169T→C Disrupt Zn-finger 64
18 C57X 170delGinsAA PTC 67
19 L58W 173T→G Disrupt Zn-finger 67
20 Q59X 175C→T PTC 40
21 C60G 178T→G Disrupt Zn-finger 64
22 C60R 178T→C Disrupt Zn-finger 67
23 C60Y 179G→A Disrupt Zn-finger 64
24 C60F 179G→T Disrupt Zn-finger 67
25 C63R 186T→C Disrupt Zn-finger 64
26 187insT 187insT Frameshift, PTC 64
27 187del46 187del46 Frameshift, PTC 64
28 Q64X 190CÆT PTC 29, 64
29 199insTC 199insTC Frameshift, PTC 64
30 200ins57 200ins57 Disrupt Zn-finger 67
31 200del8 200del8 Frameshift, PTC 64
32 233delTG 233delTG Frameshift, PTC 40
33 C80W 239CÆG Disrupt Zn-finger 67
34 D83G 248A→G Disrupt Zn-finger 64
35 Y84X 252C→G PTC 64
36 Q85X 253C→T PTC 67
37 Q86X 256CÆT PTC 67
38 257+2T→C 257+2TC Loss of exon 2, frameshift, PTC 41
39 258-2A→G 258-2A→G Loss of exon 3, frameshift, PTC 64
40 C95Y 284G→A Disrupt Zn-finger 64
41 C95F 284G→T Disrupt Zn-finger 29,40
42 320del G 320delG Frameshift, PTC 41
43 C111X 333C→A PTC 64
44 Y113X 339C→G PTC 64
45 H114Y 340C→T Disrupt Zn-finger 67
46 C117Y 350G→A Disrupt Zn-finger 67
47 C120S 359G→C Disrupt Zn-finger 64
48 C123Y 368G→A Disrupt Zn-finger 64
49 C123F 368G→T Disrupt Zn-finger 64
50 F133X 396insGAAT PTC 64
51 Q139X 415C→T PTC 64
52 C142W 426C→G Disrupt Zn-finger 41
53 Y146X 438CvvA PTC 41
54 485ins8 485insACTCCGGT Frameshift, PTC 41
55 534delG 534delG Frameshift, PTC 41
56 553del3insA 553del3insA Frameshift, PTC 67
57 571delA 571delA Frameshift, PTC 67
58 R198X 592C→T PTC 1, 29, 41
59 R200Q 599G→A DNA binding 29, 41
60 606del6 606del6 DNA binding 67
61 611del7 611del7 Frameshift, PTC 41
62 R208X 622C→T PTC 40, 41
63 A213P 637G→C DNA binding 29, 41
64 E216X 646G→T PTC 41
65 S218del 651del3 DNA binding 67
66 S218P 652T→C DNA binding 41
67 S218X 653C→A PTC 64
68 R223X 667C→T PTC 41, 55
69 672+1G→A 672+1G→A Loss of exon 4, frameshift, PTC 41, 29
70 672+1G→T 672+1G→T Loss of exon 4, frameshift, PTC 41
71 672+2T→A 672+2T→A Loss of exon 4, frameshift, PTC 64
72 672+1G→C 672+1G→C Loss of exon 4, frameshift,PTC 67
73 R226X 676C→T PTC 41
74 676insC 676insC Frameshift,PTC 67
75 R226P 677G→C DNA binding 41
76 L229P 686T→C DNA binding 64
77 A230V 689C→T DNA binding 41
78 694del17 694del17 Frameshift,PTC 67
79 697insA 697insA Frameshift, PTC 1
80 699delG 699delG Frameshift, PTC 64
81 706delAG 706delAG Frameshift, PTC 64
82 708delT 708delT Frameshift, PTC 64
83 V240D 719T→A DNA binding This article
84 Q241X 721C→T PTC 64
85 W243X 728G→A PTC 41, 64
86 W243C 730G→C DNA binding 67
87 Q245X 733C→T PTC 41, 64
88 N246K 738CÆA DNA binding 1, 64
89 A249P 745G→C DNA binding 29
90 750+1G→A 750+1G→A Loss of exon 5 64
No Mutation Nucleotidea Putative effect Reference
LIM-A
LIM-B
Homeodomain
exon 8
exon 7
exon 6
exon 4
exon 5
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No Mutation Nucleotidea Putative effect Reference
1 71-37del17 71-37del17 Loss of exon 2, fameshift, PTC 66
2 71-2A→G 71-2A→G Loss of exon 2, frameshift, PTC 64
3 71-1G→A 71-1G→A Loss of exon 2, frameshift, PTC 41
4 85del27 85del27 Disrupt Zn-finger 64
5 C36R 106T→C Disrupt Zn-finger 64
6 C36S 107G→C Disrupt Zn-finger 64
7 C36Y 107G→A Disrupt Zn-finger This article
8 115delC 115delC Frameshift, PTC 67
9 R47X 139C→T PTC 67
10 S51X 152C→A PTC 67
11 154del9 154del9 Disrupt Zn-finger 64
12 W53X 159G→A PTC 64
13 H54Y 160C→T Disrupt Zn-finger 64
14 H54N 160C→A Disrupt Zn-finger 67
15 H54L 161A →T Disrupt Zn-finger This article
16 H54Q 162C→R Disrupt Zn-finger 64
17 C57R 169T→C Disrupt Zn-finger 64
18 C57X 170delGinsAA PTC 67
19 L58W 173T→G Disrupt Zn-finger 67
20 Q59X 175C→T PTC 40
21 C60G 178T→G Disrupt Zn-finger 64
22 C60R 178T→C Disrupt Zn-finger 67
23 C60Y 179G→A Disrupt Zn-finger 64
24 C60F 179G→T Disrupt Zn-finger 67
25 C63R 186T→C Disrupt Zn-finger 64
26 187insT 187insT Frameshift, PTC 64
27 187del46 187del46 Frameshift, PTC 64
28 Q64X 190CÆT PTC 29, 64
29 199insTC 199insTC Frameshift, PTC 64
30 200ins57 200ins57 Disrupt Zn-finger 67
31 200del8 200del8 Frameshift, PTC 64
32 233delTG 233delTG Frameshift, PTC 40
33 C80W 239CÆG Disrupt Zn-finger 67
34 D83G 248A→G Disrupt Zn-finger 64
35 Y84X 252C→G PTC 64
36 Q85X 253C→T PTC 67
37 Q86X 256CÆT PTC 67
38 257+2T→C 257+2TC Loss of exon 2, frameshift, PTC 41
39 258-2A→G 258-2A→G Loss of exon 3, frameshift, PTC 64
40 C95Y 284G→A Disrupt Zn-finger 64
41 C95F 284G→T Disrupt Zn-finger 29,40
42 320del G 320delG Frameshift, PTC 41
43 C111X 333C→A PTC 64
44 Y113X 339C→G PTC 64
45 H114Y 340C→T Disrupt Zn-finger 67
No Mutation Nucleotidea Putative effect Reference
46 C117Y 350G→A Disrupt Zn-finger 67
47 C120S 359G→C Disrupt Zn-finger 64
48 C123Y 368G→A Disrupt Zn-finger 64
49 C123F 368G→T Disrupt Zn-finger 64
50 F133X 396insGAAT PTC 64
51 Q139X 415C→T PTC 64
52 C142W 426C→G Disrupt Zn-finger 41
53 Y146X 438CvvA PTC 41
54 485ins8 485insACTCCGGTFrameshift, PTC 41
55 534delG 534delG Frameshift, PTC 41
56 553del3insA 553del3insA Frameshift, PTC 67
57 571delA 571delA Frameshift, PTC 67
58 R198X 592C→T PTC 1, 29, 41
59 R200Q 599G→A DNA binding 29, 41
60 606del6 606del6 DNA binding 67
61 611del7 611del7 Frameshift, PTC 41
62 R208X 622C→T PTC 40, 41
63 A213P 637G→C DNA binding 29, 41
64 E216X 646G→T PTC 41
65 S218del 651del3 DNA binding 67
66 S218P 652T→C DNA binding 41
67 S218X 653C→A PTC 64
68 R223X 667C→T PTC 41, 55
69 672+1G→A 672+1G→A Loss of exon 4, frameshift, PTC 41, 29
70 672+1G→T 672+1G→T Loss of exon 4, frameshift, PTC 41
71 672+2T→A 672+2T→A Loss of exon 4, frameshift, PTC 64
72 672+1G→C 672+1G→C Loss of exon 4, frameshift,PTC 67
73 R226X 676C→T PTC 41
74 676insC 676insC Frameshift,PTC 67
75 R226P 677G→C DNA binding 41
76 L229P 686T→C DNA binding 64
77 A230V 689C→T DNA binding 41
78 694del17 694del17 Frameshift,PTC 67
79 697insA 697insA Frameshift, PTC 1
80 699delG 699delG Frameshift, PTC 64
81 706delAG 706delAG Frameshift, PTC 64
82 708delT 708delT Frameshift, PTC 64
83 V240D 719T→A DNA binding This article
84 Q241X 721C→T PTC 64
85 W243X 728G→A PTC 41, 64
86 W243C 730G→C DNA binding 67
87 Q245X 733C→T PTC 41, 64
88 N246K 738CÆA DNA binding 1, 64
89 A249P 745G→C DNA binding 29
90 750+1G→A 750+1G→A Loss of exon 5 64
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stage renal failure during young childhood (G. Landthaler, personal communi-
cation). In this patient proteinuria, present from birth, had progressed to 
persistent nephrotic syndrome by the age of 4 years and end-stage renal disease
by the age of 7 years. The factors responsible for progression to terminal renal
insufficiency in NPS are completely unknown and therefore prognosis is totally
unpredictable. Longitudinal studies on renal function of NPS patients are 
necessary to investigate the age of onset of asymptomatic proteinuria and
microscopic hematuria, its progress, and the diagnostic and clinical value of
regular screening of urine samples. In addition, the contribution of potential
modifying genes and the type and location of LMX1B mutations on renal 
outcome needs further investigation.
Genetics 
Linkage studies and identification of the genetic cause
The determination of genetic linkage of NPS to the ABO blood group locus
and the adenylate kinase 1 gene were among the first successful linkage studies
for human genetic disorders.44,45 Only recently the location of the NPS gene was
significantly refined to a 1-cM interval at chromosome 9q34.1.46-50 Based on the
striking similarity of skeletal and renal dysplasia in NPS and Lmx1b knockout
mice,51 together with the mapping of mouse Lmx1b to a region syntenic to
human 9q34, Dreyer et al. (1998)1 hypothesised that mutations in the human
LMX1B gene cause NPS. Subsequently, they identified the first heterozygous
mutations in the LMX1B gene, which resulted in premature termination of
translation and disruption of sequence-specific DNA binding in three sporadic
patients with classical symptoms of NPS.1 Independently, Iannotti et al. (1997)49
and Vollrath et al. (1998)40 mapped LMX1B within the NPS candidate region. 
LMX1B gene
LMX1B is a member of the LIM-homeodomain family of transcription fac-
tors, which play a fundamental role in pattern formation during vertebrate limb
development and morphogenesis of the kidney.1,51-56 The acronym LIM is derived
from the first letters of the three founder genes, lin-11,57 ISL1,58 and mec-3.59
LMX1B comprises eight exons, encompassing an ∼6−kb transcript after RNA
splicing,1,40 and encodes a highly conserved protein of 379 amino acids con-
taining two cystine-rich zinc-binding motifs (LIM-A and LIM-B domain), a
homeodomain, and a carboxy terminal glutamine-rich and serine-rich domain 
figure 4.56 The amino-terminal LIM domains mediate interactions with other 
transcription factors,56 the homeodomain is involved in DNA-binding, and 
the carboxy terminal motif represents a transcriptional activation domain.55
LMX1B-mediated transactivation is not only regulated by the function of these
domains, but presumably requires interaction with a complex transcriptional
mechanism including the LIM domain-interacting protein, LDB1, and the helix-
loop-helix protein, E47/shPan1 also.60-62
LMX1B mutations in NPS and their putative effect
Since the identification of the LMX1B gene as the molecular basis of NPS, 
87 different heterozygous mutations have been described in NPS patients in 
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the literature (for overview of LMX1B mutations see Clough et al. (1999)63 and
figure 4).this article, 1,29,40,41,63-66 Here, we present three new LMX1B mutations,
including the mutation (V240D) identified in the female patient with rapid pro-
gression of kidney disease described above figure 4. Eleven polymorphisms have
been found in NPS patients available for LMX1B mutation analysis.29,40,49 In
approximately 19% of the NPS patients/families, a LMX1B mutation has not yet
been detected, possibly due to the kind of detection analysis used and/or the
location of the mutation, which might be in the promotor or in the 5’ and 3’
untranslated regions.63 Remarkably, none of the observed LMX1B mutations
have been detected in exon 1, 6, 7, and 8, including the C-terminal transcrip-
tional activation domain. Clough et al. (1999)63 suggested that mutations in this
transcriptional activation domain may have no effect on the function of LMX1B
in skeletal and kidney development or that this domain is not essential for nor-
mal LMX1B function. 
The human LMX1B mutations are concentrated within the LIM domains
(LIM-A 44%, LIM-B 38%) and homeodomains (18%), predominantly in exon 
2 and 4 and to a lesser extent in exon 3, 4 and 5, and include single base sub-
stitutions (missense, splice-site, and nonsense or frameshift mutations), or
deletions/ insertions figure 4.63 The highest rate of recurrent missense mutations
has been found within the homeodomain (R198X, R200Q, R208X, A213P,
R223X) comprising almost 30% of all known LMX1B mutations.1,40,41,66
The putative consequences of the mutations have been predicted from the
nature of mutations, the location in the functional domains of the LMX1B
gene, DNA binding studies of the homeodomain, and structural analysis of the
homeodomain helices and the LIM domains.1,29,63,67 Missense mutations in the
LIM domains presumably disrupt the zinc finger structure and prevent the 
formation of a stable protein. The R200Q substitution located in N-terminal
arm of the homeodomain is supposed to only partially reduce DNA binding 
by disruption of contact to the minor groove of the DNA.1,29,40,41 The A213P
mutation in the first helix of the homeodomain is supposed to completely 
abolish DNA binding by disturbance of the three-dimensional helical structure
of the homeodomain, which is important for direct contact with the third helix
of the homeodomain.29,40,62 Dreyer et al. (2000)62 have shown that missense
mutations in each of the helices of the homeodomain can affect DNA binding
and, ultimately, transactivation of the reporter gene. 
From the identification of putative loss-of-function mutations in LMX1B
in NPS it is hypothesised that this disorder is caused by haploinsufficiency of
LMX1B. A dominant-negative effect in humans, however, cannot be ruled out,
especially since deletions encompassing the entire gene have not yet been
reported.62
Role of LMX1B in limb development
Lmx-1 was first identified in the hamster as a positive regulator of insulin
expression in islet cells.60 The presumption of Dreyer et al. (1998)1 that 
mutations in the human homologue of Lmx-1, LMX1B, might be the underlying
cause of NPS was based on expression and functional studies of orthologues 
of this gene during limb development in chicken and mice, respectively, 
52
together with the localisation of the LMX1B gene on chromosome 9q34.51-53
The vertebrate limb develops along three primary axes: antero-posterior, 
dorso-ventral, and proximo-distal. Lmx1 has been shown to be spatiotemporal
and selectively expressed in the dorsal limb mesenchymal cells during early
chick embryogenesis52 and it has been demonstrated that Lmx1 specifies dorsal
cell fate along the dorso-ventral axis of the developing limb.52,53 The skeletal and
renal dysplasia of Lmx1b homozygous mutant mice has been compared with 
the NPS phenotype by Chen et al. (1998).51 Mice heterozygous for a targeted 
disruption of the Lmx1b gene showed no evident defects, whereas homozygous
mutant embryos revealed absence of dorsal limb structures, including the nails
and the patellae, and duplication of ventral structures. Furthermore, the finding
of strong expression of Lmx1b in precursors of the podocytes during murine
embryogenesis and the remarkable resemblance of ultrastructural changes in the
GBM of Lmx1b-/- mutant mice and in NPS further supported the hypothesis that
LMX1B mutations cause NPS. After the identification of LMX1B mutations 
in NPS patients,1,40,41 Dreyer et al. (2000)62 demonstrated LMX1B expression in 
dorsal mesenchymal precursors of muscles, tendons, joints, patellae, and 
anterior limb structures and suggested that limb defects of NPS not only result
from a disruption of normal dorso-ventral patterning. Hypoplastic scapulae
and iliac horns, and gradual decrease of severity of nail dysplasia from the 
first to the fifth digit and hypoplasia of the radial head are examples of 
abnormal patterning along the proximo-distal and anterio-posterior axes,
respectively. 
The role of Lmx1b in regulating motor axon guidance during embryogenesis
has been demonstrated by studies in mice which revealed that Lmx1b is
required by dorsal limb mesenchymal cells in coordinating the dorso-ventral
axonal trajectories of lateral motor column neurons that innervate limb mus-
cles.54 The involvement of Lmx1b has also been shown in mesencephalic
dopamine system neuron development in mice.68 Neurodegenerative diseases
have not been described in NPS. However, mood symptoms as depression and
anxiety symptoms have been reported in NPS patients and might result from 
dysfunction in the mesencephalic dopaminergic neurons.23
Lmx1b expression in the eye 
The molecular basis underlying ocular defects associated with NPS, 
including glaucoma, has not yet been elucidated. The expression pattern 
of Lmx1b in the neural crest-derived periocular mesenchyme during murine
embryogenesis and subsequently in its derivate tissues in the anterior segment
of the eye, suggests an essential role of Lmx1b in normal anterior segment
development.69 Lmx1b-/- mutant mice show anterior segment dysgenesis,
including iris and ciliary body stromal aplasia/hypoplasia, ultrastructural 
anomalies of corneal collagen fibrils, and a reduction in anterior chamber
depth.69 The extracellular matrix of the trabecular meshwork is supposed 
to play a role in regulating intraocular pressure, and defects in its composition
resulting from LMX1B mutations have been suggested to cause glaucoma 
secondarily.69
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New insights in the pathogenesis of the NPS phenotype 
Role of LMX1B in regulating type IV collagen expression in the glomerular basement
membrane 
Recently, Morello et al. (2001)2 elucidated the putative role of Lmx1b in the
pathway of normal GBM morphogenesis and renal dysplasia of NPS by demon-
strating the transcriptional regulation and dysregulation of type IV collagen
expression by Lmx1b in the kidney of wildtype and Lmx1b-/- mice, respectively.
The glomerular structure and function of the kidney require accurate 
regulation of type IV collagen expression in the extracellular matrix of the
GBM.70 Type IV collagen is the major constituent of the renal GBM. Each type 
IV collagen heterotrimer is composed of three of the six distinct alpha chains of
type IV collagen [α1 to α6 (IV) chains] that are encoded by COL4A1 to COL4A6,
respectively. During embryogenesis only the α1/α2 network of type IV collagen
is essential for normal glomerular development. The adult GBM predominantly
comprises α3 and α4(IV) chains together with the α5(IV) chain. In GBM mor-
phogenesis a developmental switch from the fetal α1/α2 network to the adult
α3/α4/α5 network of type IV collagen is crucially important for long-term 
stability of the GBM and maintenance of glomerular function.70
Mutations in COL4A3 and COL4A4, and COL4A5 and associated type IV 
collagen alterations in the GBM have been identified as the underlying defects
of autosomal recessive and X-linked forms of Alport syndrome, respectively.71-74
In contrast to previous studies,75 Heidet et al. (2000)76 have shown that the
absence of α3(IV) and α4(IV) chains in the GBM of Alport syndrome patients
with COL4A5 mutations is not due to the arrest of transcriptional isoform
switching but to the absence of integration of the chains within the collagen
network: COL4A3 and COL4A4 transcripts are highly expressed by the
podocytes and the α3(IV) chain accumulates within podocytes. The ultrastruc-
tural GBM anomalies in the NPS kidney are strikingly similar to Alport GBM
anomalies. Before the identification of LMX1B mutations in NPS, the COL5A1
gene encoding α1(V) collagen was suggested to cause NPS, based on the resem-
blance of the ultrastructural GBM anomalies in NPS and in Alport syndrome,
together with the chromosomal localisation of COL5A1. However, linkage
analysis excluded the involvement of COL5A1 in NPS.77
Morello et al. (2001)2 performed RNA in situ hybridisation and immunohisto-
chemical investigations of different chains of type IV collagen in renal biopsy
specimens of Lmx1b-/- mice. The GBM of Lmx1b mutant mice showed a signifi-
cant diminished expression of α3(IV) and α4(IV) collagen, whereas the expres-
sion of α1(IV), α2(IV), and α5(IV) chains was unaffected.2,78 Lmx1b mutations
are suggested to contribute to renal pathology by preventing a transcriptional
switch from α1/α2 to an α3/α4/α5 network of type IV collagen during GBM
development and by disrupting maintenance of COL4A3 and COL4A4 expres-
sion, which is important for the long-term structure and function of the GBM.2
LMX1B may regulate COL4A4 and possibly COL4A3 expression by a direct
action on enhancer sequences.2 Investigation of newborn mouse kidneys by
RNA in situ hybridisation and immunohistochemistry has shown that Lmx1b
regulates α3(IV) and α4(IV) collagen expression during normal GBM morpho-
genesis and that Lmx1b mutations cause disruption of type IV collagen expres-
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sion resulting in glomerulopathy in Lmx1b-/- mice.2 It is postulated that persis-
tence of the fetal α1/α2 network predisposes the GBM to proteolytic degradation. 
Furthermore, genetic and immunohistochemical studies have shown 
that the expression of genes which are involved in podocyte differentiation,
including Cd2ap and podocin, is strongly decreased in Lmx1b-/- mice.79,80
Based on these results it is suggested that Lmx1b mutations may also disrupt 
the transcriptional regulation of podocyte differentiation, thus contributing to
nephropathy in NPS.
In contrast to the mouse model for NPS, immunohistochemical investigation
of the kidney of two NPS patients showed normal expression of podocin and
different alpha chains of type IV collagen, including α3(IV) and α4(IV) (M.-C.
Gubler, personal communication). Molecular genetic studies, RNA in situ
hybridisation, and histological and immunohistochemical investigations in
the human NPS kidney are necessary to investigate whether the pathways of
glomerulopathy in the mouse model for NPS are similar in man and to explain the
more severe nephropathy observed in mice homozygous for Lmx1b mutations
compared to NPS patients heterozygous for mutations in the LMX1B gene.
Genotype-phenotype correlations
An orthopaedic scoring system has been developed by Farley et al. (1999)28
in order to evaluate the variable expressivity of skeletal features of NPS by 
quantifying fingernail dysplasia, limited motion of the elbows, aplasia or
hypoplasia and dislocation of the patellae, the presence of palpable iliac horns,
and other major and minor orthopaedic features. No significant correlation
between a specific LMX1B mutation (C95F) and the degree of severity of
orthopaedic symptoms within and between two NPS families was found by
Farley et al. (1999).28 Consistent with the orthopaedic findings, no convincing
genotype-phenotype correlations have been found for the occurrence and 
severity of nephropathy in NPS.29,63 For example, in two NPS families with the
same splice-site mutation (672 + 1G→A) none of the two examined NPS
patients from one family was diagnosed with renal dysfunction, whereas in 
the other family 13 of 30 NPS patients (43%) have clinical symptoms related 
to nephropathy.29,41 In a previously reported monozygotic twins with NPS a 
marked intrafamiliar variability of renal disease has been shown. One twin
developed end-stage renal disease at the age of 16 years, whereas his twin
brother showed no progression to renal failure at the age of 40 years (M.-C.
Gubler, personal communication). We have recently demonstrated a new 
mutation in the LIM-A domain (C36Y) in this twin figure 4. Evidence for a 
correlation between the type and location of LMX1B mutations and the inci-
dence and severity of glaucoma is also lacking.29,41 It is possible that modifying
genes influence the individual manifestation and severity of NPS symptoms 
and the prognosis of renal disease. 
“Nail patella like” nephropathy
Typical ultrastructural changes of the GBM, similar to the glomerular
lesions of NPS, in the absence of nail and osseous anomalies characteristic for
NPS, have been reported in 14 patients81-85 and reviewed by Meyrier et al.
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(1990).25 In 1993, Gubler et al.86 described additional clinical and molecular
studies in eight patients from the latter cohort of patients.85 They suggested that
these cases do not represent a variant of NPS, but a new type of genetic GBM
disease termed “collagen type III glomerulopathy”. This assumption was based on
the occurrence of extrarenal symptoms, including hypertension and haemato-
logical and pulmonary involvement, the finding of type III collagen fibrils within
the lamina rara with a normal distribution of the α3 and α4 chains of type IV
collagen in the GBM, and an autosomal recessive mode of inheritance in seven
families. In addition to the collagen type III glomerulopathy, there is ample 
evidence for an autosomal dominant “nail patella like” syndrome without
extrarenal symptoms. In 20 affected members of a family spanning five 
generations, renal symptoms and ultrastructural GBM anomalies typical for
NPS, but without extrarenal features, have been observed (M.-C. Gubler, 
personal communication). Molecular genetic studies are needed to investigate
whether the GBM disease in these families results from partial expression of
NPS or represents an independent type of hereditary glomerulopathy. 
Conclusions 
In the past few years, the knowledge of normal limb and kidney development
and the specific role of LMX1B in the pathogenesis of renal anomalies associa-
ted with NPS has significantly increased. In contrast, comparatively little is
known on the molecular regulatory mechanisms of the LMX1B gene and its
upstream and downstream target genes. Moreover, the pathways by which 
a loss-of-function mutation in one allele affects the function of the LMX1B
protein and produces a dominant NPS phenotype remains to be determined.
Finally, further detailed molecular studies on candidate modifying genes are
necessary to understand the molecular mechanism underlying intra- and inter-
familial variation in phenotypic severity and to identify the factors involved in
progression to renal insufficiency. 
References
1. Dreyer SD, Zhou G, Baldini A, Winterpacht A, Zabel B, Cole W, Johnson RL, Lee B (1998). Mutations in
LMX1B cause abnormal skeletal patterning and renal dysplasia in nail patella syndrome. Nat Genet 19, 47-50.
2. Morello R, Zhou G, Dreyer SD, Harvey SJ, Ninomiya Y, Thorner PS, Miner JH, Cole W, Winterpacht A,
Zabel B, Oberg KC, Lee B (2001). Regulation of glomerular basement membrane collagen expression 
by LMX1B contributes to renal disease in nail patella syndrome. Nat Genet 27, 205-208.
3. Chatelain (1820) Cited by Tachdijan MO: Paediatric Orthopedics Vol 2, 2nd ed, W B Saunders Company,
Philadelphia-London-Toronto 1990.
4. Pye-Smith (1883). Idiopathic Anaemia. Lancet 2, 993. Cited by Beals and Eckhardt AL (1969). Hereditary
onycho-osteodysplasia (nail-patella syndrome): a report of nine kindreds. J Bone Joint Surg Am 51, 505-516.
5. Little EM (1897). Congenital absence or delayed development of the patella. Lancet 2, 781-784.
6. Österreicher W (1930). Gemeinsame Vererbung von Anonychie, bzw. Ochyatrophie, Patellardefekt und
Luxatio radii. Dominantes Auftreten in 5 Generationen. Z Menschl Vererb Konstitutionsl 15, 465-476.
7. Turner JW (1933). An hereditary arthrodysplasia associated with hereditary dystrophy of the nails. JAMA
100, 882-884.
8. Kieser W (1939). Die Sog. Flughaut beim Menschen. Ihre beziehung zum Status dysraphicus und ihre
Erblichkeit. Z Menschl Vererb Konstitutionsl 23, 594-619.
56
9. Touraine HA (1943). L’onycharthrose héréditaire. Prog Med 71, 7.
10. Fong EE (1946). Iliac horns (symmetrical bilateral central posterior iliac processes): a case report.
Radiology 47, 517-518.
11. Roekerath W (1951). Hereditäre Osteo-onycho-dysplasie. Fortschr Roetgenstra 75, 700-712.
12. Mino RA, Mino VH, Livingstone RG (1948). Osseous dysplasia and dystrophy of the nail: review of 
literature and report of a case. Am J Roentgenol 60, 633-641.
13. Lester AM (1936). A familial dyschondroplasia associated with anonychia and other deformities. Lancet 2,
1519-1521.
14. Carbonara P, Alpert M (1964). Hedereditary osteo-onycho-dysplasia (HOOD). Am J Med Sci 248, 139-151.
15. Lichter PR, Richards JE, Downs CA, Stringham HM, Boehnke M, Farley FA (1997). Cosegregation of
open-angle glaucoma and the nail-patella syndrome. Am J Ophthalmol 124, 506-515.
16. Brixey AM, JR, Burke (1950). Arthro-onychodysplasia; hereditary syndrome involving deformity of
head of radius, absence of patellas, posterior iliac spurs, dystrophy of finger nails. Am J Med 8, 738-744.
17. Hawkins CF, SMITH OE (1950). Renal dysplasia in a family with multiple hereditary abnormalities 
including iliac horns. Lancet 1, 803-808.
18. Silverman ME, Goodman RM, Cuppage FE (1967). The Nail-Patella syndrome. Clinical findings and
ultrastructural observations in the kidney. Arch Intern Med 120, 68-74.
19. Ben Bassat M, Cohen L, Rosenfeld J (1971). The glomerular basement membrane in the nail-patella 
syndrome. Arch Pathol 92, 350-355.
20. Del Pozo E, Lapp H (1970). Ultrastructure of the kidney in the nephropathy of the nail-patella syndrome.
Am J Clin Pathol 54, 845-851.
21. Sweeney E, Fryer AE, Mountford RC, Green AJ, McIntosh I (2001). Nail patella syndrome: expanding 
the clinical phenotype. J Med Genet 38, S1-S17.
22. Sweeney E, Fryer AE, ountford RC, reen AJ, cIntosh I (2001). Nail patella syndrome: a study of 123 patients
from 43 British families and the detection of 16 novel mutations of LMX1B. Am J Hum Genet 69 [Suppl], A72.
23. McIntosh I, Tierney E, Bukelis I, Marsh L (2001). Behavioral phenotype of nail-patella syndrome. Am J
Hum Genet 69 [Suppl], A571.
24. Jameson RJ, Lawler SD, Renwick JH (1956). Nail-patella syndrome: clinical and linkage data on family G.
Ann Hum Genet 20, 348-360.
25. Meyrier A, Rizzo R, Gubler MC (1990). The nail-patella syndrome. A review. J Nephrol 2, 133-140.
26. Guidera KJ, Satterwhite Y, Ogden JA, Pugh L, Ganey T (1991). Nail patella syndrome: a review of 44 
orthopaedic patients. J Pediatr Orthop 11, 737-742.
27. Höger PH, Henschel MG (1997). Skelettanomalien beim Nagel-patella Syndrom: Fallbericht und 
Übersicht. Hautartzt 48, 581-585.
28. Farley FA, Lichter PR, Downs CA, McIntosh I, Vollrath D, Richards JE (1999). An orthopaedic scoring
system for nail-patella syndrome and application to a kindred with variable expressivity and glaucoma. 
J Pediatr Orthop 19, 624-631.
29. Knoers NVAM, Bongers EMHF, van Beersum SE, Lommen EJ, van Bokhoven H, Hol FA (2000). Nail-patella
syndrome: identification of mutations in the LMX1B gene in Dutch families. J Am Soc Nephrol 11, 1762-1766.
30. Zidorn T, Barthel T, Eulert J (1994). Das Nail-Patella Syndrom. Eine Familienstudie. Z Orthop Ihre Grenzgeb
132, 486-490.
31. Darlington D, Hawkins CF (1967). Nail-patella syndrome with iliac horns and hereditary nephropathy.
Necropsy report and anatomical dissection. J Bone Joint Surg Br 49, 164-174.
32. Karabulut N, Ariyurek M, Erol C, Tacal T, Balkanci F (1996). Imaging of “iliac horns” in nail-patella 
syndrome. J Comput Assist Tomogr 20, 530-531.
33. ter Haar BG, van Dam FE (1972). Het nagel-patella syndroom of de herediatire onycho-osteo-artro-
dysplasie. Ned Tijdschr Geneeskd 116, 2218-2227.
C
hapter 2.1
N
ail patella syndrom
e. O
verview
on clinical and m
olecular findings
57
34. Yakish SD, Fu FH (1983). Long-term follow-up of the treatment of a family with nail-patella syndrome. 
J Pediatr Orthop 3, 360-363.
35. Beals RK, Eckhardt AL (1969). Hereditary onycho-osteodysplasia (Nail-Patella syndrome). A report of
nine kindreds. J Bone Joint Surg Am 51, 505-516.
36. Bennett WM, Musgrave JE, Campbell RA, Elliot D, Cox R, Brooks RE, Lovrien EW, Beals RK, Porter GA (1973).
The nephropathy of the nail-patella syndrome. Clinicopathologic analysis of 11 kindred. Am J Med 54, 304-319.
37. Spitalny LA, Fenske HD (1970). Hereditary osteo-onychodysplasia. Am J Ophthalmol 70, 604-608.
38. Flickinger RR, Jr., Spivey BE (1969). Lester’s line in hereditary osteo-onychoysplasia. Arch Ophthalmol 82,
700-703.
39. McIntosh I, Lichter PR, Clough MV, Roig CM, Wong D, Scott C, Downs C, Stringham H, Boehnke M,
Francomano CA, Richards JE (1997). Glaucoma and nail-patella syndrome (NPS) co-segregate: one gene
or two? Am J Hum Genet 61 [Suppl], A58.
40. Vollrath D, Jaramillo-Babb VL, Clough MV, McIntosh I, Scott KM, Lichter PR, Richards JE (1998). Loss-of-
function mutations in the LIM-homeodomain gene, LMX1B, in nail-patella syndrome. Hum Mol Genet 7,
1091-1098.
41. McIntosh I, Dreyer SD, Clough MV, Dunston JA, Eyaid W, Roig CM, Montgomery T, Ala-Mello S, Kaitila I,
Winterpacht A, Zabel B, Frydman M, Cole WG, Francomano CA, Lee B (1998). Mutation analysis of
LMX1B gene in nail-patella syndrome patients. Am J Hum Genet 63, 1651-1658.
42. Hoyer JR, Michael AF, Vernier RL (1972). Renal disease in nail-patella syndrome: clinical and 
morphologic studies. Kidney Int 2, 231-238.
43. Taguchi T, Takebayashi S, Nishimura M, Tsuru N (1988). Nephropathy of nail-patella syndrome.
Ultrastruct Pathol 12, 175-183.
44. Renwick JH, Lawler SD (1955). Genetical linkage between the ABO and nail-patella loci. Ann Hum Genet
19, 312-331.
45. Schleutermann DA, Bias WB, Murdoch JL, McKusick VA (1969). Linkage of the loci for the nail-patella
syndrome and adenylate kinase. Am J Hum Genet 21, 606-630.
46. Campeau E, Watkins D, Rouleau GA, Babul R, Buchanan JA, Meschino W, Der K, V (1995). Linkage 
analysis of the nail-patella syndrome. Am J Hum Genet 56, 243-247.
47. McIntosh I, Clough MV, Schaffer AA, Puffenberger EG, Horton VK, Peters K, Abbott MH, Roig CM,
Cutone S, Ozelius L, Kwiatkowski DJ, Pyeritz RE, Brown LJ, Pauli RM, McCormick MK, Francomano CA
(1997). Fine mapping of the nail-patella syndrome locus at 9q34. Am J Hum Genet 60, 133-142.
48. Eyaid WM, Clough MV, Root H, Scott KM, McCormick MK, Zhang X, Lisitsyn NA, Kearns WG,
Francomano CA, Richards JE, McIntosh I (1998). Physical mapping of the nail patella syndrome interval
at 9q34: ordering of STSs and ESTs. Hum Genet 103, 525-526.
49. Iannotti CA, Inoue H, Bernal E, Aoki M, Liu L, Donis-Keller H, German MS, Permutt MA (1997).
Identification of a human LMX1 (LMX1.1)-related gene, LMX1.2: tissue-specific expression and linkage
mapping on chromosome 9. Genomics 46, 520-524.
50. Silahtaroglu A, Hol FA, Jensen PK, Erdel M, Duba HC, Geurds MP, Knoers NV, Mariman EC, Tumer Z,
Utermann G, Wirth J, Bugge M, Tommerup N (1999). Molecular cytogenetic detection of 9q34 break-
points associated with nail patella syndrome. Eur J Hum Genet 7, 68-76.
51. Chen H, Lun Y, Ovchinnikov D, Kokubo H, Oberg KC, Pepicelli CV, Gan L, Lee B, Johnson RL (1998).
Limb and kidney defects in Lmx1b mutant mice suggest an involvement of LMX1B in human nail patella
syndrome. Nat Genet 19, 51-55.
52. Riddle RD, Ensini M, Nelson C, Tsuchida T, Jessell TM, Tabin C (1995). Induction of the LIM homeobox
gene Lmx1 by WNT7a establishes dorso-ventral pattern in the vertebrate limb. Cell 83, 631-640.
53. Vogel A, Rodriguez C, Warnken W, Izpisua Belmonte JC (1995). Dorsal cell fate specified by chick Lmx1
during vertebrate limb development. Nature 378, 716-720.
58
54. Kania A, Johnson RL, Jessell TM (2000). Coordinate roles for LIM homeobox genes in directing the
dorso-ventral trajectory of motor axons in the vertebrate limb. Cell 102, 161-173.
55. Sanchez-Garcia I, Rabbitts TH (1994). The LIM domain: a new structural motif found in zinc-finger-like
proteins. Trends Genet 10, 315-320.
56. Curtiss J, Heilig JS (1998). DeLIMiting development. Bioessays 20, 58-69.
57. Freyd G, Kim SK, Horvitz HR (1990). Novel cysteine-rich motif and homeodomain in the product of the
Caenorhabditis elegans cell lineage gene lin-11. Nature 344, 876-879.
58. Karlsson O, Thor S, Norberg T, Ohlsson H, Edlund T (1990). Insulin gene enhancer binding protein Isl-1 
is a member of a novel class of proteins containing both a homeo- and a Cys-His domain. Nature 344, 
879-882.
59. Way JC, Chalfie M (1988). mec-3, a homeobox-containing gene that specifies differentiation of the touch
receptor neurons in C. elegans. Cell 54, 5-16.
60. German MS, Wang J, Chadwick RB, Rutter WJ (1992). Synergistic activation of the insulin gene by a LIM-
homeo domain protein and a basic helix-loop-helix protein: building a functional insulin minienhancer
complex. Genes Dev 6, 2165-2176.
61. Johnson JD, Zhang W, Rudnick A, Rutter WJ, German MS (1997). Transcriptional synergy between LIM-
homeodomain proteins and basic helix-loop-helix proteins: the LIM2 domain determines specificity. Mol
Cell Biol 17, 3488-3496.
62. Dreyer SD, Morello R, German MS, Zabel B, Winterpacht A, Lunstrum GP, Horton WA, Oberg KC, Lee B
(2000). LMX1B transactivation and expression in nail-patella syndrome. Hum Mol Genet 9, 1067-1074.
63. Clough MV, Hamlington JD, McIntosh I (1999). Restricted distribution of loss-of-function mutations
within the LMX1B genes of nail-patella syndrome patients. Hum Mutat 14, 459-465.
64. Seri M, Melchionda S, Dreyer S, Marini M, Carella M, Cusano R, Piemontese MR, Caroli F, Silengo M,
Zelante L, Romeo G, Ravazzolo R, Gasparini P, Lee B (1999). Identification of LMX1B gene point muta-
tions in italian patients affected with Nail-Patella syndrome. Int J Mol Med 4, 285-290.
65. Hamlington JD, Clough MV, Dunston JA, McIntosh I (2000). Deletion of a branch-point consensus
sequence in the LMX1B gene causes exon skipping in a family with nail patella syndrome. Eur J Hum Genet
8, 311-314.
66. Hamlington JD, Jones C, McIntosh I (2001). Twenty-two novel LMX1B mutations identified in nail patella
syndrome (NPS) patients. Hum Mutat 18, 458.
67. Gehring WJ, Qian YQ, Billeter M, Furukubo-Tokunaga K, Schier AF, Resendez-Perez D, Affolter M, Otting
G, Wuthrich K (1994). Homeodomain-DNA recognition. Cell 78, 211-223.
68. Smidt MP, Asbreuk CH, Cox JJ, Chen H, Johnson RL, Burbach JP (2000). A second independent pathway
for development of mesencephalic dopaminergic neurons requires Lmx1b. Nat Neurosci 3, 337-341.
69. Pressman CL, Chen H, Johnson RL (2000). LMX1B, a LIM homeodomain class transcription factor, is
necessary for normal development of multiple tissues in the anterior segment of the murine eye. Genesis
26, 15-25.
70. Harvey SJ, Zheng K, Sado Y, Naito I, Ninomiya Y, Jacobs RM, Hudson BG, Thorner PS (1998). Role of
distinct type IV collagen networks in glomerular development and function. Kidney Int 54, 1857-1866.
71. Peissel B, Geng L, Kalluri R, Kashtan C, Rennke HG, Gallo GR, Yoshioka K, Sun MJ, Hudson BG,
Neilson EG, . (1995). Comparative distribution of the alpha 1(IV), alpha 5(IV), and alpha 6(IV) collagen
chains in normal human adult and fetal tissues and in kidneys from X-linked Alport syndrome patients. 
J Clin Invest 96, 1948-1957.
72. Ninomiya Y, Kagawa M, Iyama K, Naito I, Kishiro Y, Seyer JM, Sugimoto M, Oohashi T, Sado Y (1995).
Differential expression of two basement membrane collagen genes, COL4A6 and COL4A5, demonstra-
ted by immunofluorescence staining using peptide-specific monoclonal antibodies. J Cell Biol 130, 1219-
1229.
C
hapter 2.1
N
ail patella syndrom
e. O
verview
on clinical and m
olecular findings
59
73. Kleppel MM, Fan W, Cheong HI, Michael AF (1992). Evidence for separate networks of classical and
novel basement membrane collagen. Characterisation of alpha 3(IV)-alport antigen heterodimer. J Biol
Chem 267, 4137-4142.
74. Yoshioka K, Hino S, Takemura T, Maki S, Wieslander J, Takekoshi Y, Makino H, Kagawa M, Sado Y,
Kashtan CE (1994). Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked
Alport syndrome revealed by monoclonal antibody. Am J Pathol 144, 986-996.
75. Kalluri R, Shield CF, Todd P, Hudson BG, Neilson EG (1997). Isoform switching of type IV collagen is
developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal base-
ment membranes to endoproteolysis. J Clin Invest 99, 2470-2478.
76. Heidet L, Cai Y, Guicharnaud L, Antignac C, Gubler MC (2000). Glomerular expression of type IV 
collagen chains in normal and X-linked Alport syndrome kidneys. Am J Pathol 156, 1901-1910.
77. Greenspan DS, Northrup H, Au KS, McAllister KA, Francomano CA, Wenstrup RJ, Marchuk DA,
Kwiatkowski DJ (1995). COL5A1: fine genetic mapping and exclusion as candidate gene in families with
nail-patella syndrome, tuberous sclerosis 1, hereditary hemorrhagic telangiectasia, and Ehlers-Danlos
Syndrome type II. Genomics 25, 737-739.
78. Morello R, Dreyer SD, Oberg KC, Lee B (1999). Localization of Lmx1b during kidney and limb develop-
ment and pathogenesis of nail patella syndrome. Am J Hum Genet 65S, A77.
79. Morello, R., Miner, J. H., and Lee, B. LMX1B requirement for podocyte differentiation. The eighth inter-
national workshop on developmental nephrology: genes, morphogenesis, and function. International
Paediatric Nephrology Association. 29-31 August. 2001. Victoria, British Coloumbia. 
80. Lee, B. Nail patella syndrome and insight into glomerular morphogenesis. The eighth international
workshop on developmental nephrology: genes, morphogenesis, and function. International Paediatric
Nephrology Association. 29-31 August 2001. Victoria, British Columbia. 
81. Sabnis SG, Antonovych TT, Argy WP, Rakowski TA, Gandy DR, Salcedo JR (1980). Nail-patella syndrome.
Clin Nephrol 14, 148-153.
82. Dombros N, Katz A (1982). Nail patella-like renal lesions in the absence of skeletal abnormalities. 
Am J Kidney Dis 1, 237-240.
83. Salcedo JR (1984). An autosomal recessive disorder with glomerular basement membrane abnormalities
similar to those seen in the nail patella syndrome: report of a kindred. Am J Med Genet 19, 579-584.
84. Ikeda K, Yokoyama H, Tomosugi N, Kida H, Ooshima A, Kobayashi K (1990). Primary glomerular fibrosis:
a new nephropathy caused by diffuse intra-glomerular increase in atypical type III collagen fibers. 
Clin Nephrol 33, 155-159.
85. Gubler MC, Dommergues JP, Furioli J, Foulard M, Bensman A, Boccon-Gibod L, Broyer M, Habib R
(1990). Nail-patella syndrome without extra-renal lesions. A new hereditary glomerular nephropathy. 
Ann Pediatr (Paris) 37, 78-82.
86. Gubler MC, Dommergues JP, Foulard M, Bensman A, Leroy JP, Broyer M, Habib R (1993). Collagen type
III glomerulopathy: a new type of hereditary nephropathy. Pediatr Nephrol 7, 354-360.
60
C
hapter 2.2
N
ail patella syndrom
e: identification ofm
utations in the LM
X1B gene in D
utch fam
ilies 
61
Nail patella syndrome: identification of mutations in the LMX1B gene
in Dutch families 
Nine VAM Knoers1
Ernie MHF Bongers1
Sylvia EC van Beersum1
Ed JP Lommen2
Hans van Bokhoven1
Frans A Hol1
1Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
2Department of Paediatrics, Máxima Medical Centre, Veldhoven, The Netherlands 
J Am Soc Nephrol 2000;11(9):1762-1766
62
Abstract
Nail patella syndrome is an autosomal dominant disorder characterised by
dyplasia of finger nails, skeletal anomalies, and, frequently, renal disease. 
It has recently been shown that this disorder is caused by putative loss-of-
function mutations in a transcription factor (LMX1B) belonging to the LIM-
homeodomain family, members of which are known to be important for pattern
formation during development. A cohort of eight Dutch NPS families were
screened for mutations in the LMX1B gene; seven different mutations, inclu-
ding one novel variant, were identified. Three of the mutations are very likely to
result in truncated LMX1B proteins, three are predicted to influence sequence-
specific DNA binding, and one is presumed to prevent the formation of a stable
protein by abolishing the Zn(II) binding site of the protein. Although there was
a remarkable high incidence of renal disease in one of the families, the
nephropathy was not seen in all affected family members and the severity 
of renal impairment varied significantly among the patients. This indicates 
that the incidence and severity of nephropathy within this family cannot be
attributed to the LMX1B genotype. In addition, evidence of a correlation
between other characteristics of the NPS phenotype and specific mutations has
not been found. 
Introduction
Nail patella syndrome (NPS; MIM 161200), also known as hereditary osteo-onycho-
dysplasia, is a rare autosomal dominant disorder that is characterised by nail
and bone abnormalities and, frequently, renal disease. Well more than 500
cases have been described after the first description of the disorder by Little in
1837.1 Nail hypoplasia or dysplasia and absent or hypoplastic patellae are essential
features for the diagnosis. Other diagnostic signs are deformation or luxation
of the head of the radius, resulting in impaired mobility of the elbow, and iliac
horns, which are pathognomonic but reported to be present in only 70% of
cases. Various other skeletal anomalies, such as pes equinovarus, dislocated
hips, and contractures of major joints, have been described frequently in NPS
but do not contribute to the diagnosis. Approximately 50% of affected individuals
exhibit cloverleaf pigmentation of the inner margin of the iris. Its significance
is unclear. One report described two families in which NPS cosegregated with
open-angle glaucoma,2 suggesting that glaucoma may be another variable 
feature of the syndrome. 
The most serious component of NPS is the nephropathy, but this does not
occur in all patients with the syndrome. In a retrospective study analysing renal
features of 123 observations in the literature, Meyrier et al. (1990)3 discovered
renal involvement in more than 60% of cases. In most cases, the nephropathy
manifests only by chronic benign proteinuria. In approximately 15% of cases,
however, the disease developed towards end-stage renal disease. It is unknown
which factors are responsible for progression to renal insufficiency, and there-
fore renal prognosis is unpredictable. The light microscopy findings of renal
biopsies in NPS are nonspecific. At the ultrastructural level, however, the
glomeruli show a uniform and characteristic picture: irregular thickening of 
the glomerular basement membrane (GBM) with electron-lucent areas giving 
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it a so-called “moth-eaten” appearance. Within the GBM and the mesangium,
fibrillar collagen-like material is found, and finally there is fusion of epithelial
foot processes. Remarkably, these ultrastructural changes have been found in
all biopsied cases, independent of clinical involvement, and therefore do not
seem to correlate with impaired renal function. 
In the late 1960s, the gene for NPS was assigned to the distal end of the long
arm of chromosome 9 by the establishment of linkage of NPS to the ABO blood
group locus and the adenylate kinase 1 gene.4,5 It lasted a few decades, however,
before the localisation of the NPS gene could be significantly refined to a 
genetic interval of 1-cM in region 9q34.1.6-9 
Recently, Dreyer et al. (1998)10 showed that NPS is caused by mutations in the
LMX1B gene. The involvement of this gene in NPS was subsequently confirmed
by others.11,12 Mutations in LMX1B were also found in families with NPS and
glaucoma.11 LMX1B belongs to a family of highly related LIM-homeodomain
transcription factors that are involved in pattern formation during development.
These proteins contain two tandem LIM domains, which are cysteine-rich, 
zinc-binding domains that facilitate the interaction with other transcription
factors: a homeodomain that has DNA-binding activity and a transcriptional
activation domain.13 The identification of the LMX1B gene as being responsible
for NPS was anticipated by investigations of the role of LMX1B homologous
genes in limb development. In the chicken, it had been shown that lmx1 speci-
fies the dorsal cell fate of the limb. Thus, absence of lmx1 expression leads to the
development of biventral limbs.14 Mice with a homozygous deletion of exon 3 
to 7 in the mouse lmx1 homologue, Lmx1b, exhibit nail dysplasia and skeletal
defects similar to those observed in NPS, such as iliac hypoplasia, aplasia of the
Familya No. of affected Nail hypo/ Absent/small Elbow Iliac horns Eye Nephropathy
members dysplasia patellae immobility abnormalitiesb
1 1S 1c/1d 1c/1d 1c/1d 1c/1d 0c/1d 0c/1d
2 5 5/5 5/5 5/5 1/3 2/5 Unknown
3 14 3/3 3/3 3/3 1/1 0/2 0/11
4 8 2/2 2/2 2/2 Unknown 1/1 0/2
5 1S 1/1 1/1 1/1 1/1 0/1 0/1
6 1S 1/1 1/1 1/1 0/1 0/1 Unknown
7 3 3/3 3/3 3/3 1/3 0/3 0/3
8 33 23/24 20/24 20/24 17/23 5/12 13/30
Total 66 39/40 36/40 35/39 22/33 8/26 13/48
table 1
Summary of clinical features of nail patella syndrome patients
a Numbers refer to the families in which mutations in the LMX1B gene are presented in table 3.
b Eye abnormalities include hyperpigmentation of the iris, cataract, and/or glaucoma.
c Number of patients in which symptom is present. 
d Number of patients examined.
S Sporadic.
Unknown, not examined.
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patellae, and joint abnormalities marked by osseous misarticulations. In addition,
ultrastructural examination of the kidneys showed prominent irregular thickening
of the GBM with occasional regions of membrane discontinuity, reminiscent of
the renal findings in NPS.15 
In this report, we present the identification of seven different mutations,
including one novel variant, in the LMX1B gene in eight Dutch families with 
NPS and discuss the presumptive effect of these mutations on the function of
the LMX1B protein, as well as the absence of convincing genotype-phenotype
correlations. 
Materials and methods
Patients
We studied three large families with NPS, two smaller families with NPS, and
three families with sporadic cases of NPS. The clinical phenotype of affected
individuals in the eight families is summarised in table 1. The two largest families
(families 3 and 8) were studied more then 10 years ago, at that time with the
aim of determining the presence or absence of nephropathy.16 Recently, most 
of the patients of family 8 were seen again for molecular genetic analysis and
confirmation of the absence/presence of other major NPS signs. Some patients
that were included in the study of 10 years ago had died, and three additional
patients had received diagnoses. We discovered that one recently identified
patient who was a presumed sporadic patient belongs to family 3. 
We were not able to examine all of the affected individuals of this family again;
therefore, we have the data only on nail, patella, and iliac signs from three patients.
The nephropathy data from families 3 and 8 were taken from the original
paper.16 We also were not able to examine clinically all patients from family 4.
In the families with NPS, we had previously confirmed linkage to the 9q34.1
region, and haplotype analysis in two of the larger families had proved helpful
in narrowing the region encompassing the NPS gene to a 1-cM interval.8,9 
Mutation detection analysis
Genomic DNA was extracted from whole blood according to the procedure
described by Miller et al. (1988).17 To find mutations in the LMX1B gene, we 
performed single-strand conformation polymorphism (SSCP) analysis. The 
different LMX1B exons were amplified by PCR using standard PCR buffer in a
total volume of 25 ul, containing 50 ng of genomic DNA, 15 pmol of each
appropriate primer table 2, 1 U of Taq polymerase (Life Technologies, Breda, 
The Netherlands) and 0.5 mM of each dNTP. Amplifications were performed in
a Thermal Cycler (Perkin Elmer, Norwalk, CT). Samples were denatured at 92°C
for 5 min and then subjected to 35 cycles of amplification: 1 min at 95°C, 1 min
at annealing temperature table 2, 1 min at 72°C. SSCP analysis was performed
using the Genephor Gelsystem (Amersham Pharmacia Biotech, Roosendaal,
The Netherlands). PCR products were loaded on precast, ready-to-use GeneGel
Excel 12.5/24 polyacrylamide gels (Pharmacia). After electrophoresis, gels were
silver stained in an automated gel stainer using the Plus-one DNA Silverstaining
Kit (Pharmacia), according to the protocol of the manufacturer. Samples were
run in duple at 5°C and 15°C, respectively, to increase sensitivity. When a band
C
hapter 2.2
N
ail patella syndrom
e: identification ofm
utations in the LM
X1B
gene in D
utch fam
ilies 
65
shift was detected, the corresponding fragment was bidirectionally sequenced
to reveal the nature of the mutation. In case no mutations were found through
SSCP analysis, all exons were sequenced. Automated DNA sequencing was 
performed on an ABI PRISM 377 (PE Biosystems, Nieuwerkerk a/d Yssel, The
Netherlands) using dye terminator chemistry.
Results
Human genomic DNA from the probands of five families and of three 
sporadic patients was screened for mutations in the LMX1B gene by PCR-SSCP
of exons 2 to 8, followed by sequencing of amplified DNA fragments that had
resulted in SSCP band shifts. We identified mutations in all of them table 3. Two
patients from different families (families 3 and 4) share the same R198X mutation.
The seven different mutations were all single base-pair substitutions, consisting
of four missense mutations, two nonsense mutations, and one splice-site mutation.
One of the identified mutations (A249P) has not been described previously. Of
the remaining six mutations, three (Q64X, C95Y, splice-site mutation) have
been found in one other family, and the other three (R198X, R200Q, A213P) are
more frequently occurring mutations and have been found in five, six, and four
families, respectively.10-12,18 Both nonsense mutations (R198X and Q64X) are
predicted to cause premature termination of translation, resulting in truncation
of the LMX1B protein. The G to C transversion and the G to A transition in exon
4, leading to an A213P and an R200Q missense mutation, respectively, in the
homeodomain of the LMX1B protein, have been shown to have a negative effect
on DNA binding.11 The G to A transition in exon 3, resulting in a C95Y missense
mutation in the second LIM domain, may abolish the Zn(II) binding site and
prevent the formation of a stable protein. The splice-site mutation (672 +1GA)
will probably lead to a shorter LMX1B mRNA as a result of exon skipping.
Because LMX1B-expressing tissue, such as kidney, was not available, we were
not able to confirm this presumed effect of this mutation. In families 2, 3, 4, 7,
and 8, the mutations cosegregate with the NPS phenotype. The seven mutations
were not found in a panel of 100 control chromosomes. In addition to these
putative loss-of-function mutations, five common polymorphisms, two silent
Exon Forward primer Reverse primer Ta (°C)a
2 cgctgacggccgggctttc gctcgagtgccgggcggtg 58
3 ggcaggagtggcctctgb tccaggacaccccagcaac 61
4 gtgtcaacagaggggacagg gtgtgcgggcatcagcctg 61
5 ctaaacccaccatctccccg accgtagtcttctggctgcc 59
6 ggcagccagaagactacgg tctgccccagctcaccctg 55
7 cttcagccagagtggggtb atgctgcctgagccctagg 63
8 gtcagcaggccatcctgtb ggagctctgcatggagtagab 55
table 2
Primers flanking LMX1B exons
a Ta, annealing temperature.
b Primer has previously been reported.11
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mutations (Ser219Ser; Glu124Glu), and three intron polymorphisms (IVS 2, +7
G→C; IVS 4, -49 C→T; IVS 8, -49 C→A) were found in our series. 
Discussion 
In our group of Dutch families with NPS, we identified seven different 
mutations in the LMX1B gene, including one novel variant, which brings the
total number of different mutations identified to 65.10,11,18,19 Approximately 
43% of these 65 mutations are localised in the homeodomain, 40% in the 
LIM1 domain, and the rest in the LIM2 domain. Remarkably, mutations in 
the transcriptional activation domain in the C-terminus of the LMX1B protein 
have not yet been found.
Three of the mutations identified in our study are frequently occurring
mutations. R198X has been found in 4%, R200Q in 5%, and A213P in 3% of all
families tested. Although they did not show their data, McIntosh et al. (1998)12
concluded, on the basis of haplotype analysis with polymorphic microsatellite
markers from the 9q34 region, that these mutations recur in unrelated individuals.
Haplotype analysis in our Dutch cohort has been performed only in the larger
families, at the time when the gene responsible for NPS was not yet identified,
to narrow the chromosomal region encompassing the disease gene. The
patients carrying the R198X, R200Q, and A213P mutations did not belong to
these previously analysed families, either because they were sporadic patients 
or because the family was too small or only a few family members were avai-
lable for study. Therefore, although unlikely, we cannot exclude the possibility
that our patients are related to any of the other families carrying a similar 
mutation. The high rate of recurrence of the R198X and R200Q mutations
might be explained by the fact that these mutations are the result of a transition
at a CpG dinucleotide, which is a mutational hot spot because of the tendency
Mutation Nucleotidea Domain Putative effect Recurrent/ Family numberb
new mutations
Q64X C190T LIM1 PTC Recurrentc 1
C95Y G284A LIM2 Zn (II) binding Recurrentc 2
R198X C592T HD PTC Recurrentd,e 3,4
R200Q G599A HD DNA binding Recurrente 5
A213P G637C HD DNA binding Recurrente 6
A249P G745C HD DNA binding New 7
672+1G→A 672+1G→A HD Loss of exon 4, Recurrente 8
frameshift, PTC
table 3
Mutations identified in NPS patients
HD, homeodomain; PTC, premature termination codon.
a Nucleotide numbering follows GenBank AFO57135.
b Numbers refer to the families presented in table 1.
c Reference 18.
d Reference 10.
e Reference 12.
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for the cytosine to be methylated and subsequently deaminated to thymine. 
The recurrence of the A213P mutation, however, remains unexplained.
On the basis of the nature of the mutations and/or the mutations’ localisation
in functionally important domains of the LMX1B protein, together with the
cosegregation of the mutations with the NPS phenotype within the families 
and the absence of these mutations in 100 control chromosomes, it is very 
likely that these seven mutations are indeed harmful mutations and not 
innocuous polymorphisms. Thus, the two nonsense mutations and the 
splice-site mutation are predicted to result in truncated LMX1B proteins. The
four remaining mutations are missense mutations, and three of these amino-
acid substitutions are localised in the homeodomain of the protein, where they
are likely to have an effect on DNA binding. R200Q and A213P were shown to
reduce and abolish DNA binding, respectively, in in vitro DNA binding studies.12
The homeodomain-DNA interactions of homeobox genes have been intensively
studied in many species (for review, see reference 20). In the course of the 
evolution, the amino-acid sequence of the homeodomain has been conserved to
a high degree, reflecting the importance of this sequence for establishing DNA
binding. Because it is known which amino acids in the homeodomain are
important for DNA-binding specificity, direct DNA-backbone contacts, and 
secondary structure, the putative effects of the identified mutations in the home-
odomain of LMX1B on DNA binding may be predicted. The R200Q substitution
affects a highly conserved amino acid located in the flexible N-terminal arm of the
homeodomain, which is important in establishing contact to the minor groove
of the DNA and as such significantly contributes to the high DNA-binding
affinity of the homeodomain. The alanine substitution in the first helix of the
homeodomain (A213P) is likely to disturb the formation of a three-dimensional
structure that is determined by the folding of the helices I, II, and III into a 
tight globular structure.21 Because this three-dimensional structure of the
homeodomain ensures the positioning of the third (recognition) helix in the
major groove of the DNA, where it establishes contact with both strands of the
DNA, it can be predicted that disturbance of the three-dimensional structure by
the A213P mutation will indirectly disrupt direct DNA contact with the third
helix and therefore DNA binding. The substitution of an alanine in the third
helix of the homeodomain (A249P) is likely to hinder the base-specific contact
with DNA in the major groove and as such the specificity of DNA binding.
From the function and expression studies of lmx-1 in chicken and Lmx1b
in mice, respectively, it can be deduced that the skeletal defects seen in NPS
reflect a disruption of normal dorso-ventral patterning of the limb during 
development.14,15 Although it is known from these animal studies that Lmx1b
is expressed in fetal and adult kidney tissue, the exact role of this gene in the
development of the kidney is much less clear. On the basis of the renal manifes-
tations in NPS, it is likely that Lmx1b has an important role in patterning and
cell differentiations in the kidney also. Recent studies by Morello et al. (1998)22
showed that Lmx1b localises to the glomeruli of E15.5 and newborn wild-type
mice. In addition, these investigators demonstrated absence of α3 (IV) and α4
(IV) collagen expression in Lmx1b-/- mutant kidneys. It is widely known that 
during development, there is a switch from an α1/α2 to an α3/α4 network of
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collagen IV expression in the GBM.23 Therefore, on the basis of the findings in
Lmx1b-/- mutant kidneys, it was postulated that Lmx1b might play an integral role
in this coordinated transcriptional switch.22 For humans with a heterozygous
mutation in LMX1B, however, the situation may be much less clear. Thus, 
previous immunologic studies of the GBM using MCAP1 antibody, which
recognises the NC1 domain of α3 (IV), gave conflicting results: normal
labelling in three patients and no GBM labelling in two others.24,25 
Consistent with the findings of other investigators,11,12,18 we have not 
found convincing evidence of a correlation between the presence and severity 
of certain features of NPS and the type or location of the LMX1B mutation. The
absence of a genotype-phenotype correlation is not surprising given that there
is not only interfamilial but also intrafamilial variability in the expression 
and severity of symptoms. Family 8 is a very good example of intrafamilial 
phenotypic variability. It is intriguing that a large percentage of the patients
within this family have nephropathy. Nevertheless, renal abnormalities are not
present in all affected individuals of this family; in addition, the severity of the
nephropathy varies among the patients, ranging from very mild proteinuria in
nine patients to end-stage renal disease in four of them. Patients from a family
reported by McIntosh et al. (1998),12 who carry the same splice-site mutation
(672 +1G→A) as patients in family 8, do not have nephropathy. Therefore, the
high incidence and the significant difference in severity of nephropathy within
family 8 cannot be attributed to the LMX1B genotype. Recently, Farley et al.
(1999),26 on the basis of genetic studies in a very small family with NPS and
quantified variable expression of orthopaedic symptoms, found support for 
the old hypothesis of Renwick (1956),27 who proposed that the severity of NPS
symptoms is modulated by the allele contributed by the unaffected parent. We
believe that more genetic studies in clinically well characterised large families
with NPS are necessary to evaluate the possible influence of modifying alleles
on phenotypic expression and variability.
GBM abnormalities similar to those seen in NPS have been observed in 
several families without bone or nail abnormalities.28 It will be of interest to
determine, by LMX1B mutation analysis, whether these cases represent partial
expression of NPS or an independent genetic form of GBM disease. In case 
this “NPS like” nephropathy turns out not to be due to LMX1B mutations, the
possibility that genes encoding proteins that interact with LMX1B are involved
should be investigated. We are performing yeast two-hybrid analysis with the
ultimate aim of identifying these genes.
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Abstract
The nail patella syndrome (NPS) is characterised by nail and bone abnormalities,
associated with glomerular involvement in 40% of patients. Typical glomerular
changes consist of fibrillar material in the irregularly thickened glomerular
basement membrane. NPS is inherited as an autosomal dominant trait and
caused by heterozygous loss-of-function mutations in LMX1B, a member of the
LIM homeodomain protein family. Mice with homozygous inactivation of the
gene exhibit nail and skeletal defects, similar to those observed in patients,
associated with glomerular abnormalities. Strong reduction in the glomerular
expression of the α3 and α4 chains of type IV collagen, and of podocin and
CD2AP, two podocyte proteins critical for glomerular function, has been
observed in Lmx1b-/- mice. The expression of these proteins appeared to be
regulated by Lmx1b. To determine whether these changes in podocyte gene
expression are involved in the development of NPS nephropathy, using
immunohistological techniques, we analysed the podocyte phenotype and the
renal distribution of type IV collagen chains in the kidneys of seven NPS
patients with severe glomerular disease. We also examined the nature of the 
fibrillar material present within the glomerular extracellular matrix. The
glomerular basement membrane fibrillar material was specifically labelled 
with anti-type III collagen antibodies, suggesting a possible regulation of type
III collagen expression by LMX1B. The expression of the α3 and α4 chains of
type IV collagen, and of podocin and CD2AP, was found to be normal in the
seven patients. These findings indicate that heterozygous mutations of LMX1B
do not appear to dramatically affect the expression of type IV collagen chains,
podocin, or CD2AP in NPS patients. 
Introduction
The nail patella syndrome (NPS; MIM 161200) is an autosomal dominant 
disease linked to chromosome 9q34. It is characterised by nail and bone 
abnormalities. Since its first description by Little in 1897,1 more than 500 
cases have been reported. Nail dysplasia, hypoplastic or absent patellae, elbow
dysplasia, and iliac horns are highly penetrant features of the disease. They 
are observed in 75 to 90% of patients.2,3 Other skeletal defects are less frequent.
Open-angle glaucoma has recently been recognised as an additional feature of
the disorder.4 Glomerular involvement, which affects 30 to 40% of patients, was
described later.5-7 Persistent and moderate proteinuria, possibly associated with
microscopic hematuria is the revealing symptom. Progression to nephrotic 
syndrome and/or end-stage renal disease occurs in 10% of cases. The prognosis
of NPS depends on the severity of the glomerulopathy, the course of which is
unpredictable, even among members of the same family.2 The ultrastructural
changes of the glomerular basement membrane (GBM) in the NPS are character-
istic. They consist of irregular GBM thickening with electron-lucent areas 
containing bundles of fibrillar material that has the periodicity of interstitial
collagen.8,9 Bundles of fibrils are also present in the mesangial matrix. The
lesions are observed in proteinuric but also, surprisingly, in nonproteinuric 
NPS patients.10-12 Based on these renal changes, it had been initially suggested
that the primary defect in NPS could affect one of the basement membrane
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components. The pathogenic role of fibrin has also been discussed on the finding
of glomerular fibrin deposits in a spontaneously aborted 18-week fetus whose
mother had NPS.13
Two groups found LMX1B mutations associated with NPS.14-16 LMX1B
is a LIM-homeodomain transcription factor playing a key role in limb develop-
ment.17 It establishes dorso-ventral patterning of the limb where it is expressed
in a temporally and spatially restricted manner in the mouse and the chicken.
15,18,19 Mice with homozygous inactivation of the gene die within 24 hours after
birth. They exhibit nail and skeletal defects similar to those observed in the
human cases, defects that are associated with renal abnormalities.15,20-22 More
than 90 LMX1B mutations have now been reported in NPS patients.23-27 They 
are located in the LIM or homeodomain regions and are thought to result in 
a loss-of-function of the mutated protein.24,28 The role of LMX1B in limb 
patterning provides a satisfactory explanation for the occurrence of nail 
and skeletal anomalies in NPS patients. 
The link between LMX1B mutation and GBM alteration was less easy to
understand. However, recent data resulting from the analysis of the expression
and the role of Lmx1b in the mouse kidney shed light on the mechanisms leading
to GBM abnormalities: the gene is only expressed in podocytes from the S-shaped
body stage onwards and persists in postnatal mature podocytes.15,20 Moreover,
genes expressed by podocytes were recently shown to be down-regulated in
Lmx1b-/- mice. Specifically, a reduced expression of Col4a3 and Col4a4 trans-
cripts, with a stronger effect on Col4a4, has been observed in Lmx1b-/- mice,
associated with diminished expression of the α3 and α4 chains of type IV colla-
gen in the GBM.20 These two chains are known to be important for long-term
glomerular filtration as mutations in COL4A3 or COL4A4 cause Alport syn-
drome, a progressive hereditary nephritis in humans.29,30 LMX1B was shown to
bind to a putative enhancer in both human and mouse COL4A4 intron 1.20 On
the other hand, the expression of podocin that is mutated in a subset of chil-
dren with steroid-resistant nephrotic syndrome,31 was found to be severely
reduced in Lmx1b-/- mice, and potentially regulated by LMX1B.21,22 The expres-
sion of CD2AP, a podocyte protein also required for normal glomerular func-
tion,32 was also greatly reduced in Lmx1b-/- mice.22 Globally these findings indi-
cate that LMX1B regulates the expression of several podocyte genes critical for
podocyte differentiation and function. They strongly suggest that defects in
GBM type IV collagen and changes in podocyte phenotype could contribute to
the glomerular disease in NPS. However, whereas in humans, the disease is asso-
ciated with heterozygous LMX1B mutations thought to result in haploinsuffi-
ciency, no renal symptoms, and no morphological abnormalities were found in
Lmx1b+/- mice, even after 1 year of life.21
To determine whether these changes in podocyte gene expression are
involved in the development of glomerular lesions in NPS, we analysed the
podocyte phenotype and the renal distribution of type IV collagen chains in 
the kidneys of NPS patients, most of them suffering from severe glomerular 
disease. In parallel, using light and ultrastructural immunohistology, we 
examined the nature of the fibrillar material present within the glomerular
extracellular matrix. 
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Patients and methods
Patients and kidney tissue specimens table 1
Renal tissue from seven patients (six biopsies and two nephrectomies 
performed at the time of transplantation) were available for this study. All
patients had a typical association of nail dysplasia, abnormal or absent patellae,
elbow dysplasia, and iliac horns. The diagnosis was made at birth in patients 
4 and 6 because of skeletal abnormalities with pseudo-arthogryposis. A family
history for NPS was found in four patients (patients 1, 2, 3, and 7) including
monozygotic twin brothers (patients 2 and 3). No family history was available
in two NPS patients and no information could be obtained about the father 
of patient 5. All patients had renal involvement varying from microscopic 
hematuria, mild proteinuria, nephrotic syndrome, to end-stage renal disease.
Five developed nephrotic syndrome. It was congenital in patient 6 and infantile
in patient 4. Various degrees of severity of glomerular lesions were observed,
from minimal glomerular changes to nearly diffuse glomerulosclerosis. Typical
ultrastructural GBM changes were found in the biopsy specimens from all of
the five patients studied by electron microscopy and in the frozen nephrectomy
specimen from patient 6. However, in patient 4, no GBM changes were detected
at 21 months of age (some fibrillar structures were present in the mesangial
matrix) whereas irregular GBM thickening with fibrillar deposits were seen at 
5 years. No ultrastructural examination was performed on end-stage kidneys
from patient 3. Frozen tissues (four specimens) were used for the immunohis-
tological analysis of podocyte proteins (podocin, nephrin, CD2AP, α3-integrin)
and analysis of the glomerular extracellular matrix. Paraffin-embedded tissues
(seven specimens) were used for immunodetection of type III collagen, and
analysis of podocyte proteins podocin, synaptopodin, GLEPP1, and vimentin,
detectable after fixation and paraffin-embedding. Four normal kidneys (from
Status at the time of kidney examination
Patients Sex Age (y) H Pu/NS Renal function Nail dysplasia
1 F 5.6 - 1 g/24 hours N +
2 M 13.6 + <0.5 g/24 hours N +
3 M 16 + NS ESRD +
4 M 1.6 - NS N +
5 - NS N +
5 F 19 - NS CRF +
6 F 7 - NS ESRD +
7 M 25 - NS N +
table 1
Clinical and morphological features in the seven nail patella syndrome patients
H, hematuria; Pu/NS, proteinuria/nephrotic syndrome; N, normal; LM, light microscopy; EM, electron microscopy;
GBM, glomerular basement membrane; ESRD, end-stage renal disease; CRF, chronic renal failure; MGC, minimal
glomerular changes; ESK, end-stage kidney; FSGS, focal segmental glomerular sclerosis.
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humans 1 to 51 years of age), unsuitable for transplantation because of vascular
problems, were used as controls. In addition, nephrectomy specimens obtained
before renal transplantation from 10 patients affected with various types of
nephropathies (renal hypoplasia, thrombotic microangiopathy, cystinosis,
nephronophthisis) were studied for the comparative analysis of changes in the
glomerular extracellular matrix of sclerotic glomeruli. None of these kidneys
were from patients with Alport syndrome or with steroid-resistant nephrotic
syndrome. Specimens were either immediately snap-frozen in liquid nitrogen
using OCT compound (Miles Laboratories Inc., Naperville, IL) and stored at 
-80°C until use, and/or fixed in 4% formalin or Dubosq-Brazil medium before
embedding. 
Mutation screening 
Two NPS patient DNA samples were available for LMX1B mutation analysis.
Genomic DNA was extracted from whole blood or renal tissue in patients 3 
and 6, respectively, using standard protocols.33 Screening of the LMX1B gene 
for mutations was performed by single-strand conformation polymorphism
analysis, as previously described.26 When a band shift was detected, the 
corresponding fragment was sequenced bidirectionally to identify the nature 
of the mutation. In case no mutations were detected by single-strand confor-
mation polymorphism analysis, all exons were sequenced. Automated DNA
sequencing was performed on an Abi Prism 377 (PE Biosystems, Nieuwerkerk
a/d Yssel, The Netherlands) using dye terminator chemistry. 
Immunohistology
Antibodies table 2
Analysis of the glomerular extracellular matrix was performed using 
antibodies against types I, III, IV, V, and VI collagen; the α1, α2, α3, α4, and 
α5 chains of type IV collagen; fibronectin; laminin α5 and β2 chains; agrin; 
and fibrin. Podocyte proteins were studied using antibodies against GLEPP1,
synaptopodin, nephrin, podocin, CD2AP, α3-integrin, and vimentin. 
Cyanine2 or fluorescein isothiocyanate-conjugated AffiniPure goat or 
Patellae Iliac horns Elbow dysplasia LM EM GBM Renal status at
lesions last follow-up
Absence + + MGC + Pu 13
Hypoplasia + + MGC + Pu 26
Hypoplasia + - ESK ND ESRD 16
+ + + MGC -
+ + + FSGS + ESRD 17
Absence + + FSGS + ESRD 20
Absence + + ESK + ESRD 7
Hypoplasia + + FSGS + ESRD 27
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Antibodies Specificity Dilution Source
A: Anti-collagen antibodies
Rabbit anti-[α1(IV)2 α2(IV)] Type IV collagen 1/60 Novotec, Lyon, France
[α1(IV)2 α2(IV)]
Mouse mAb anti-α1(IV) 1(IV)NC1 1/2 Wieslab AB, Lund, Sweden
Mouse mAb M3F7 Type IV collagen 1/200 Hybridoma Bank, Iowa City, IA
[α1(IV)2 α2(IV)]
Mouse mAb3 α3(IV)NC1 1/40 Wieslab AB, Lund, Sweden
Mouse mAb 85 α4(IV)NC1 1/4 M.M. Kleppel, Minneapolis, MN34
Rat mAb H43 α4(IV)NC1 1/25 Y Sado, Okayama, Japan35
Rat CFT-45325 α2–α5 (IV)NC1 1/1 Shigei Medical Research Institute,
Okayama, Japan
Mouse mAb A7 α5(IV)NC1 1/4 Wieslab AB, Lund, Sweden
Goat anti-collagen I Type I collagen 1/10 Southern Biotechnology, Birmingham, AL
Goat anti-collagen III Type III collagen 1/5 Southern Biotechnology, Birmingham, AL
Goat anti-collagen V Type V collagen 1/10 Southern Biotechnology, Birmingham, AL
Mouse mAb 5C6 Type VI collagen 1/1000 Hybridoma Bank, Iowa City, IA
B: Other antibodies
Rabbit anti-fibronectin Fibronectin 1/80 Novotec, Lyon, France
Rabbit anti-fibrinogen Fibrin/fibrinogen 1/100 Dako AS, Glostrup, Denmark
Mouse mAb 1924 Laminin α5 1/100 Chemicon International, Temecula, CA
Mouse mAb C4 Laminin ß2 1/20 Hybridoma Bank, Iowa City, IA
Mouse mAb 458 Agrin HSPG 1/100 Chemicon International, Temecula, CA
Mouse mAb 5C11 GLEPP1 1/100 BioGenex, San Ramon, CA
Rabbit anti-podocin Podocin 1/1000 Rosselli et al36
Rabbit anti-nephrin Nephrin 1/500 Tryggvason et al37
Mouse mAb G1D4 Synaptopodin 1/10 Progen Biotechnik GMBH, Heidelberg,
Germany
Mouse mAb V9 Vimentin 1/100 Beckman Coulter, Brea, CA
Mouse CD49c Alpha-3 integrin 1/100 Beckman Coulter, Brea, CA
table 2
Characteristics of antibodies used in the study
Cyanine2 or fluorescein isothiocyanate-conjugated AffiniPure goat or donkey anti-rabbit IgG and cyanine3-conjugated
AffiniPure donkey anti-mouse IgG antibodies were from Jackson ImmunoResearch Laboratories (West Grove, PA).
Vectastain Elite ABC kit, avidin-biotin blocking kit, and diamobenzidine were from Vector Laboratories (Burlingame, CA).
- 5C11 (BioGenex, San Ramon, CA) is a monoclonal antibody reacting with human GLEPP1 protein, a transmem-
brane protein tyrosine phosphatase found only in the podocytes.
- G1D4 (Progen Biotechnik GMBH, Heidelberg, Germany) is a monoclonal antibody recognising synaptopodin, an
actin-associated protein in differentiated podocytes and in a subset of telencephalic synapses.
- Vimentin antibody (clone V9) (Beckman Coulter, Villepinte, France) is a monoclonal antibody reacting with the
vimentin 57-kd intermediate filament protein without any cross-reaction with other intermediate filament proteins
such as cytokeratin, desmin, neurofilaments, or glial fibrillary acidic protein.
- Biotinylated horse anti-mouse immunoglobulins, Vectastain Elite ABC kit, diaminobenzide, and VIP substrates
were from Vector Laboratories (Burlingame, CA).
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donkey anti-rabbit IgG and cyanine3-conjugated AffiniPure donkey anti-mouse
IgG antibodies were purchased from Jackson ImmunoResearch Laboratories
(West Grove, PA). The Vectastain Elite ABC kit, avidin-biotin blocking kit, 
and diaminobenzidine were from Vector Laboratories (Burlingame, CA). 
For immunoelectron microscopy, normal human serum adsorbed goat 
anti-rabbit IgG conjugated with 10-nm colloidal gold particles (GAR-gold 10-
nm), staphylococcal protein A conjugated with 15-nm colloidal gold particles
(ptA-gold 15 nm) were obtained from BioCell (Cardiff, UK). Rabbit anti-protein
A was obtained from Sigma (St. Louis, MO). 
Immunofluorescence and immunoperoxidase staining 
Immunofluorescence labelling was performed on 3-µm-thick cryostat 
sections fixed in acetone for 10 minutes and incubated for 20 minutes with
10% normal swine serum in PBST [0.01 mol/L phosphate-buffered saline (PBS)
containing 0.05% Tween-20] for blocking nonspecific binding. After incubation
for 1 hour at room temperature with primary antibodies diluted in the same
buffer, sections were rinsed three times in PBS and incubated for 30 minutes
with conjugated anti-rabbit or anti-mouse antibodies diluted to 1 to 40 to 1 to 80
in PBS. A mounting medium (Fluoprep; BioMérieux, Lyon, France) was used to
delay fluorescence quenching. Labelling was examined with a Leitz Orthoplan
microscope equipped for light, fluorescence, and phase contrast microscopy. 
Before incubation with mouse monoclonal antibodies mAb3, mAb85, and
mAbA7, and rat H43, the slides were pretreated with 0.1 mol/L of glycine and 6
mol/L of urea, pH 3.5, for 10 minutes, to reveal hidden antigenic determinants.38
They were then rinsed with distilled water and processed as described above. 
Immunoperoxidase staining for type III collagen was performed using 
the Vectastain Elite ABC kit and diaminobenzidine substrate as previously
described.39 Three-µm-thick deparaffinised sections were pretreated by
microwave heating in a urea solution (2 x 5 minutes in 0.8 mol/L of urea, pH
6.4). After washing in fresh buffer (0.01 mol/L of PBS, pH 7.4), endogenous
biotin was blocked by the biotin blocking agent, according to the instructions of
the manufacturer. Then sections were incubated for 1 hour at room temperature
in a moist chamber with the primary antibody in PBST. They were washed in
PBS and incubated with biotinylated secondary antibody for 30 minutes. For
quenching the endogenous peroxidase, sections were treated with 3% hydrogen
peroxide in methanol for 5 minutes and then washed in PBS for 20 minutes.
They were then incubated for 30 minutes with Vectastain Elite ABC reagent.
After washing, final staining of the sections by diaminobenzidine was monitored
under the microscope. Tissue sections directly incubated with the secondary
antibodies or incubated with the preimmune rabbit sera served as control
experiments. 
Immunogold electron microscopy
Renal biopsy samples from two patients were fixed in 4% buffered
paraformaldehyde and embedded in LRWhite. The resin was polymerised at 
-10°C. Ultrathin sections were cut, mounted on nickel grids coated with 
collodium and carbon films, and processed for immunocytochemistry. 
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For immunolabelling with polyclonal rabbit anti-collagen I, III, and IV 
antibodies, tissue sections were first incubated on a drop of 0.01 mol/L of PBS,
pH 7.4, containing 0.5% bovine serum albumin (BSA), 0.1% gelatin (G), 
and 0.05% Tween 20 (T) (PBS-BSA-G-T buffer), then transferred to a drop of
primary antibody diluted in the same buffer and incubated at room temperature
for 120 minutes. The grids were rinsed with PBS-BSA-G-T buffer and then 
incubated with goat anti-rabbit IgG (GAR-gold 10 nm). Alternatively, they were
incubated with protein A conjugated with 15-nm colloidal gold particles 
(ptA-gold 15 nm) for 45 minutes at room temperature before incubation 
with anti-protein A, then reincubation with ptA-gold 15-nm for 45 minutes.
Subsequently, they were washed with PBS, postfixed with 2% glutaraldehyde,
and dried. After staining with uranyl acetate and lead citrate, the sections were
examined with a Siemens Elmiskop 101 electron microscope. 
Three normal kidney tissues not used for transplantation were tested as 
controls for evaluation of the normal distribution of the antigens. Incubation 
of the sections with normal rabbit or mouse serum instead of the primary 
antibodies, or direct incubation with secondary antibody or the protein A-gold
alone were performed as control experiments, and no positive results were
obtained. 
Results
Mutations in the LMX1B gene 
Screening of mutations in the LMX1B gene was performed by single-strand
conformation polymorphism analysis and direct sequencing in two NPS
patients. Patient 3, one of the twin brothers, was heterozygous for a T→A tran-
sition in exon 5 that creates a valine to aspartate missense mutation (V240D) in
the homeodomain. Patient 6 was heterozygous for a G→A transversion in exon
2, resulting in a cysteine to tyrosine missense mutation (C36Y) in the first LIM
domain of the protein that may abolish the Zn(II) binding site. 
Immunofluorescence/immunoperoxidase labellings 
Extracellular matrix proteins 
Normal Controls: In the normal kidney, antibodies to the [α1(IV)2 α2(IV)]
molecule, the α1 or the α2 chain of type IV collagen stained all extraglomerular
basement membranes (BMs). Within the glomerular tuft, they strongly labelled
the mesangial matrix and gave a thin linear staining of the GBM figure 1.
Antibodies to the α3 to α5 chains of type IV collagen stained linearly the GBM
and the distal tubule BM. In addition, the α5(IV) chain was expressed in the
Bowman’s capsule and collecting duct BM. Antibodies to type VI collagen and
fibronectin stained the mesangial matrix and faintly labelled the subendothelial
aspect of the GBM. They also stained peritubular capillaries (data not shown).
Types I, III, and V collagen were present in the interstitium and absent from
glomeruli figure 1. Antibodies against α5 and ß2 laminin chains and agrin
heparan sulfate proteoglycan gave a linear staining of the GBM. Bowman’s 
capsules and extraglomerular BM were also stained with antibodies to laminin
chain α5 and agrin, whereas the ß2 chain had a restricted GBM and arterial 
distribution (data not shown). 
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End-stage non-NPS kidneys: Globally the same normal distribution of extra-
cellular matrix proteins was observed in preserved glomeruli of end-stage renal
disease patients not affected with NPS. In sclerotic ones, persistent and strong
labelling of the wrinkled GBM was observed with antibodies against the α3, α4,
and α5 chains of type IV collagen, the α5 and ß2 chains of laminin and agrin.
Decrease or disappearance of mesangial labelling with anti-type IV collagen
[α1(IV)2 α2(IV)] antibodies contrasted with the strong labelling with antibodies
to type VI collagen. Focal and segmental labelling of sclerotic glomeruli could
be observed with antibodies to types I, III, and V collagen (data not shown). 
NPS kidneys: The intensity and distribution of glomerular labelling with
anti-type IV collagen chains (α1, α2, α3, α4, and α5) was similar to that
observed in controls in nonsclerotic and in sclerotic glomeruli figure 1. In particu-
lar the anti-α3, -α4, and -α5 (IV) antibodies gave a strong linear staining of the
figure 1
Immunohistological analysis of the expression of type IV collagen chains (immunofluorescence) and type III collagen
(immunofluorescence and immunoperoxidase) in glomeruli from normal controls and nail-patella syndrome (NPS)
patients. Two stages of glomerular lesions are studied: normal appearing glomeruli (NPS1) and sclerotic glomeruli
(NPS2). No decrease in the level of expression of the α3 to α5 (IV) chains is observed in NPS patients. Thin segmental
labelling of the GBM with anti-type III collagen antibodies is seen in preserved glomeruli. Massive accumulation of
type III collagen is observed in completely sclerotic glomeruli.
Controls NPS1 NPS2
α1 (IV)
α3 (IV)
α4 (IV)
α5 (IV)
COL III
COL III
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GBM and a moderate labelling of distal tubule basement membranes. Labelling
of collecting duct BMs with the anti-α5(IV) antibodies was also normal when
compared to controls. In sclerotic glomeruli, labelling with antibodies to the
α3, α4, and α5 chains of type IV collagen was especially strong, similar to the
one seen in control sclerotic kidneys. In contrast poor labelling of the tuft was
observed with the anti-α1 and anti-α2 antibodies. The distribution of noncol-
lagenous components of the GBM (α5 and ß2 laminin, and agrin) was also pre-
served (data not shown). No significant differences in the glomerular distribu-
tion of types I, V, or VI collagen were observed in sclerotic glomeruli compared
to sclerotic controls (data not shown). 
In contrast, by immunofluorescence and immunoperoxidase, an irregular
and discontinuous labelling of the GBM with anti-type III collagen antibodies
was seen in normal appearing glomeruli figure 1. This labelling varied in extension
and intensity among glomeruli, and within a glomerulus, from one capillary
wall to another. In sclerotic glomeruli large amounts of type III collagen were
focally seen within segments of the tuft figure 1. Within the interstitium, the
intensity and extension of type III collagen labelling paralleled the severity
of interstitial fibrosis.
Fibrin/fibrinogen 
In NPS kidneys, as in controls, no specific labelling of the GBM or of the mesan-
gial matrix was observed with anti-fibrin/fibrinogen antibodies (data not shown). 
Podocyte proteins 
Normal Controls 
In normal mature kidneys, specific podocyte labelling was seen with antibodies
to nephrin, podocin, CD2AP, GLEPP-1, and synaptopodin. Labelling was
observed along the GBM figures 2 and 3. Other renal structures were negative,
except for CD2AP that was expressed in tubular cells. 
Strong labelling of podocyte cytoplasm was observed with anti-vimentin 
antibodies figures 3. It was also seen in other glomerular cells as well as in 
interstitial and vascular, muscular, and endothelial cells. Tubular cells were
vimentin-negative. 
Antibodies against the α3 chain of the integrin α3ß1 gave a strong labelling
of the podocytes along the GBM. It was also expressed, at a lower level, by distal
tubular epithelial cells figure 3. 
End-stage non-NPS kidneys 
Normal labelling of preserved podocytes along sclerotic or nonsclerotic
glomeruli was observed with all antibodies against podocyte proteins. 
NPS kidneys 
Normal podocyte labelling was observed for all antibodies tested figures 2 and 3.
Especially no qualitative or quantitative difference in podocin, CD2AP, or
nephrin labelling was detected between controls and nail patella kidneys figures 2.
In end-stage kidneys with severe glomerular changes, preserved podocytes were
clearly labelled with all antibodies. 
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Electron microscopy
The six renal biopsies from five patients as well as the nephrectomy specimen
from patient 6 were studied by electron microscopy. In patients 5, 6, and 7,
many glomeruli, were completely or partially sclerotic. In less damaged
glomeruli of these patients as well as in glomeruli of patients 1 and 2, which
looked normal by light microscopy, typical ultrastructural abnormalities of the
GBM were observed. They were always focal and their extent varied within 
and between glomeruli. They consisted in irregular thickening of the GBM-
containing electron lucent zones figure 4 or dense fibrillar material distributed in
the lamina densa but also observed in subepithelial or subendothelial location.
Fibrillar bundles and their periodicity were better seen after phosphotungstic
impregnation figure 4. Clusters of fibrils were also present in the mesangial areas.
Along patent capillary lumens, podocytes were usually normal or showed focal
effacement of foot processes; slit diaphragms were otherwise preserved.
Occasionally, the rough endoplasmic reticulum was increased and dilated. 
Most endothelial cells were normal, some of them were slightly swollen with
focal loss of fenestration. 
In patient 4, no GBM changes were detected on the first renal biopsy. Only 
a few fibrillar structures were seen in the slightly increased mesangial matrix.
Focal effacement of foot processes was present but most pedicles and slit
diaphragms were preserved. Severe and diffuse glomerular lesions were 
present on the second biopsy specimen. They consisted in diffuse mesangial
hypercellularity and matrix increase associated with marked thickening of the
capillary wall because of focal double-contours and accumulation of basement
membrane-like material in subendothelial location. Abundant aggregates of
figure 2
Immunohistological analysis of noncollagenous podocyte gene expression in glomeruli from normal controls and 
nail patella syndrome (NPS) patients. Two stages of glomerular lesions are studied: normal appearing glomeruli 
(NPS1) and partially sclerotic glomeruli (NPS2). No difference in the level of expression of nephrin, podocin, or 
CD2AP is observed between control and NPS1 glomeruli. In NPS2 glomeruli, expression of nephrin, podocin,
and CD2AP is seen in preserved podocytes.
Controls NPS1 NPS2
Nephrin
Podocin
CD2AP
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fibrils were seen in the GBM and the mesangial matrix. Podocytes were
enlarged, frequently vacuolised, with focal effacement of foot processes. 
They were rich in rough endoplasmic reticulum. Glomerular and arteriolar
endothelial cells were swollen. 
Electron microscopy: Immunogold labelling 
Type I, III, V, and VI collagen 
In normal control kidneys, using anti-type I, III, or V collagen antibodies,
gold particles were specifically distributed on interstitial bundles of fibrillar 
collagen. No specific labelling was detected in glomeruli. Using anti-type VI
collagen antibodies, gold particles were seen in the glomeruli, on the mesangial
matrix, and faintly along the subendothelial space of the GBM. 
The same distribution was observed in NPS kidneys for types I, V, and VI
antibodies. However, with anti-type III antibodies, in addition to interstitial
labelling, gold particles were observed focally within the GBM and the mesangial
matrix figure 5. They were clearly localised on the fibres or within the clear vacuoles
distributed within the thickness of the GBM or the mesangial matrix figures 5a-c
figure 3
Immunohistological analysis of podocyte gene expression in glomeruli from normal controls and nail patella syndrome
(NPS) patients. The level of expression of synaptopodin, Glepp 1,α3 integrin, and vimentin is similar in controls and
NPS patients.
Controls NPS
Synaptopodin
Glepp 1
α3 integrin
Vimentin
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(after paraformaldehyde fixation without postfixation with osmium tetroxide,
the NPS GBM often have a “moth-eaten” appearance, the fibrillar inclusions
being frequently unstained). No specific labelling of the GBM fibres was
obtained with the other anti-collagen antibodies. 
Discussion
Ultrastructural abnormalities of the GBM are consistently found in NPS
patients, with or without renal symptoms.8-12 The NPS GBM was initially
described as thickened and moth eaten by Del Pozo and colleagues.8 It was 
subsequently shown that the electron-lucent areas contained a dark fibrillar
material, inconsistently stained with uranyl acetate and lead citrate, but always
visible after phosphotungstic acid impregnation. In Alport syndrome glomerulo-
pathy, a hereditary type IV collagen disease, characterised by thickening and
fraying of the GBM, such fibrillar structures are never observed. Fibrils show
the periodicity of interstitial collagen,9 however, their precise nature had not
been determined. It has been suggested that fibrinogen deposition could be the
first step of the lesion because of its finding in glomeruli of a spontaneously
aborted fetus from a NPS mother with platelet defect.13 In our study, as in most
reports,10,40,41 we did not find any fibrin deposit in the GBM. We used antibodies to
types I, III, V, and VI collagen to examine the deposits at the light and electron
microscopic levels. By light microscopy, we showed the presence of type III 
collagen within the GBM, with an irregular focal and segmental distribution. By
electron microscopy, the labelling was seen on the fibrils located in the electron
lucent vacuoles present in the GBM and the mesangial matrix. No labelling of
these structures was observed with antibodies recognising other fibrillar collagens.
These data indicate that the ultrastructural hallmark of NPS is because of the
abnormal distribution of type III collagen within the GBM. 
The presence of type III collagen within the GBM of NPS patients may be
figure 4
Ultrastructural changes in nail patella syndrome
patients. (a) The GBM is markedly thickened and has 
a “moth-eaten” appearance (arrows) (lead citrate and
uranyl acetate staining). (b) The fibrillar material is 
clearly seen after phosphotungstic acid impregnation.
Inset: On higher magnification the fibrils have the 
characteristic striated periodicity of interstitial collagen.
Interestingly, the lesions observed in this patient had a
focal distribution: several GBM segments were strictly
normal. Original magnifications: (a); x17,000 (b); x15,000 
(inset); x27,500 .
a
b
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because of the regulation of type III collagen gene by
LMX1B. Alternatively, it could be secondary to struc-
tural GBM abnormalities. However, the finding of
type III collagen in the GBM of asymptomatic patients
whose glomeruli are normal by light microscopy
strongly suggests that it is a primary lesion.10 For
this reason, we believe that a down-regulation of
COL3A1 by LMX1B, either directly or indirectly, is
likely. Further experiments are required to test this
hypothesis. The pathogenic role of the aberrant
GBM expression of type III collagen known to 
accumulate in nonglomerular fibrotic processes,
remains to be determined because the GBM lesions
have been observed in NPS patients with or without
any renal symptom.10,11,41 Conversely, it was not
detected in one of our patients biopsied at 21
months of age because of severe nephrotic 
syndrome and was not described in mouse models
of NPS that develop a severe glomerular disease 
and die at day 1 with renal abnormalities and diffuse
effacement of foot processes.21,22
Absence of GBM binding of a monoclonal 
antibody directed toward the Goodpasture antigen
[the noncollagenous domain of α3(IV)], was
described in two NPS patients, 40 and 22 years 
old, respectively, with mild proteinuria and normal
renal function.38 The labelling was performed on
formalin-fixed, paraffin-embedded renal biopsies
and the expression of the other type IV collagen
chains was not studied. Likewise, the GBM expression
of the α4 and α3 chains of type IV collagen is
strongly reduced in Lmx1b-/- mice and LMX1B
was shown to bind in vitro regulatory elements in
COL4A4.20 These observations suggest that, similarly
to the findings in recessive Alport syndrome because
of COL4A3 or COL4A4 mutations, dysregulation 
in the podocyte synthesis of α3(IV) and α4(IV) 
collagen chains contributes to GBM changes and
renal pathology in NPS patients. However, at 
variance with murine, canine, or human autosomal recessive Alport syn-
drome,38,42-44 the α5(IV) chain expression is preserved in the GBM of Lmx1b-/-
mice. In the normal GBM, the three chains are strongly co-expressed and form a 
distinct network characterised by loops and super coiled helices that are 
stabilised by disulfide bonds.45,46 The absence of one of these chains in Alport
syndrome, when the corresponding gene is mutated, prevents the assembly of
the two other chains and the organisation of the network, and results in the
absence of all three α3, α4, and α5(IV) chains. In our study, performed on
figure 5
Type III collagen immunogold labelling in NPS
patients. (a) Within the GBM, the dense material
as well as the clear vacuoles are specifically
labelled with the antibody. No gold particles are
seen in the adjacent basement membrane. (b)
Numerous gold particles are seen on the mesan-
gial matrix. The paramesangial basement mem-
brane is not labelled. (c) Higher magnification
underlines the close association between the gold
particles and the fibrillar material. Original magni-
fications: (a); x9000 (b); x12,000 (c); x27,000.
a
b
c
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frozen kidney tissues from NPS patients, heterozygous for LMX1B mutation,
and affected with a severe glomerular disease, the α3, α4, and α5(IV) chains
were strongly expressed in the GBM, without any visible difference with the
expression in controls. In another NPS patient, the occurrence of Goodpasture
syndrome was an indirect demonstration of the presence of the α3(IV) chain 
in the GBM.47 In heterozygous Lmx1b+/- mice, a decreased expression of renal
Col4a3 and Col4a4 mRNAs has been shown by semiquantitative reverse 
transcriptase-polymerase chain reaction20 but these mice did not develop any
renal symptom. Moreover, patients with heterozygous mutations of COL4A3 or
COL4A4, and reduced synthesis but normal distribution of the α3, α4, and
α5(IV) chains frequently show thin GBM.48 Thin GBM was not observed in 
our series of NPS patients and never reported in the literature, perhaps because
of the persistence of more than 50% expression of both chains, as observed in
Lmx1b-/- mice.20 In addition, contrary to the findings in mice, the expression of
podocin and CD2AP, two podocyte proteins important for podocyte function as
demonstrated by the occurrence of early and severe nephrotic syndrome when
they are mutated,31,32 was found to be normal in NPS patients. Again, a slight
reduction of these proteins may escape detection by immunohistochemical
methods, although contributing to progressive renal dysfunction. Such a level
of expression may be sufficient for proper renal development in humans,
whereas kidneys in lmx1b-/- mice show severe developmental defects: they have
small kidneys with smaller than normal glomeruli. The glomerular endothelial
cells are poorly fenestrated and the podocytes have an immature appearance:
they are cuboidal, lack foot processes and slit diaphragms and are connected by
structures resembling adherens junctions.20,21 In NPS patients, in our experience
as in other reported data, the glomerular endothelial cells were normal and
podocytes were large fully differentiated cells with long cytoplasmic expansions
running toward the capillaries and dividing into foot processes. Slit diaphragms
were clearly identified. Effacement of foot processes was observed only focally
along severely affected GBM segments, or in patients with nephrotic syndrome
in association with massive proteinuria. 
Globally, in NPS patients heterozygote for a LMX1B mutation, we show 
that the fibrillar material observed in the thick GBM segments is type III 
collagen. We did not detect any of the GBM or podocyte abnormalities
described in Lmx1b-/- mice: no specific podocyte changes were observed by 
electron microscopy, by immunofluorescence, CD2AP and podocin appeared 
to be normally expressed by the podocytes, and the distribution of type IV 
collagen chains α3 and α4 was similar to that found in normal kidneys.
However, a moderate reduction of expression of several genes playing a role 
in the maintenance of the structure and function of the glomerular filtration
barrier, and escaping detection by immunohistochemical methods, may 
explain the glomerular disease in the humans. But, at variance with hetero-
zygous Lmx1b+/- mice that did not develop any symptom, our seven patients 
with obvious nail and bone abnormalities, had a glomerular disease that 
progressed to end-stage renal disease in five. It may be hypothesised that 
the presence of type III collagen in the glomerular extracellular matrix is 
an additional pathogenic factor involved in kidney disease progression. 
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Abstract
Nail patella syndrome (NPS), an autosomal dominant disorder characterised 
by nail dysplasia, absent or hypoplastic patellae, iliac horns, and often associated
with nephropathy and, less frequently, with open-angle glaucoma, is caused 
by mutations in the LMX1B gene. Interfamilial and intrafamilial phenotypic 
variability raises the question whether modifier genes can be identified to
explain differences in the expression and severity of clinical features of NPS.
Genes encoding proteins that interact with the LMX1B protein are good 
candidates and, therefore, methods to search for interactions can be used to
this purpose. By the yeast two-hybrid screening we detected the CLIM2 gene 
as a LMX1B interactor, confirming previous reports which described the same
interaction by biochemical methods. Sequencing of the CLIM2 coding region 
in seven NPS cases in which no LMX1B mutation had been found, did not
detect any molecular variant in these patients. Moreover, by genotyping a poly-
morphic dinucleotide repeat close to the CLIM2 gene in affected members of a
large Dutch NPS family with high incidence of nephropathy, we were unable to
find a correlation between the presence of a specific allele and the expression of
nephropathy. In conclusion, although the results of this study could not provide
any proof of CLIM2 involvement in the pathogenesis of NPS or in determination
of the clinical phenotype, we suggest that the CLIM2 gene can be considered 
as a good candidate for further studies on normal and disturbed kidney 
development associated with NPS or other hereditary glomerulopathies.
Introduction
Nail patella syndrome (NPS), or hereditary osteo-onychodysplasia, is an auto-
somal dominant condition characterised by nail dysplasia, skeletal anomalies
and, in 48% of the cases, nephropathy.1 Furthermore, in several families with
recurrence of NPS, the association of open-angle glaucoma has been reported.2 
NPS was one of the first disorders in human for which genetic linkage was
established demonstrating linkage of the NPS locus to the ABO and adenylate
kinase loci on human chromosome 9q34.3,4 Only few years ago,5 the LMX1B
gene, encoding a LIM-homeodomain (LIM-HD) protein, was identified as
responsible for NPS and for NPS associated with open-angle glaucoma.6,7 This gene
belongs to a large family of genes encoding transcription factors characterised
by common cysteine-rich zinc binding motifs, called LIM domains, that are
important in mediating protein-protein interactions.8 The LIM-HD proteins
play an important role in cell lineage determination and pattern formation 
during animal development.8 Despite the size of the LIM-HD gene family and
its importance in development, mutations responsible for human genetic 
disorders have been found only in a few genes belonging to this family, 
including LMX1B. 9,10
Extensive mutation analysis of different NPS families by differents groups
failed to demonstrate any correlation between disease severity and type or 
location of the LMX1B mutation.5,11 Moreover, although only part (56%) of 
the patients we have analysed carried mutations in the coding sequence of the
LMX1B gene, linkage studies carried out in the remaining NPS families did not
reveal genetic heterogeneity for the syndrome.12 Other authors have also reported
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that approximately in 19% of the NPS cases the causative gene defect has not 
yet been identified.13 It is possible that causative mutations are located in the
promoter, within introns, or in the 3’ untranslated regions or that a significant
number of patients carry small deletions inside the gene. In addition, although
unlikely because of previous linkage results, we cannot exclude that other genes
are involved in sporadic cases of NPS. 
While the biological importance of LMX1B during embryonic development
has been subject of several investigations, only initial information is available
about its gene targets and the molecular mechanisms by which it functions. 
To better understand the pathogenetic mechanisms and variable expressivity 
in NPS, in particular the presence of nephropathy, we performed a study to
identify proteins interacting with the LMX1B gene product. To perform these
studies, we utilised the yeast two-hybrid technology. 
Materials and methods
Two-hybrid system
We used the Matchmarker (Clontech) two-hybrid system, in which interaction
between the bait protein (fused to the Gal4 DNA-BD) and a library-encoded
protein (fused to the Gal4 AD) creates a novel transcriptional activator with
binding affinity for a GAL4-responsive UAS. The system utilises two reporter
genes (His3 and LacZ) under the control of the GAL4-responsive UAS.
The long isoform of LMX1B cDNA12 was cloned in the pGBT9 vector, 
containing the Gal4 DNA-binding domain (DBD) and the Trp nutritional gene.
To identify interacting gene products, we have used a commercial human fetal
kidney library (Clontech), cloned in the pACT2 vector, that contains the Gal4
activation domain (AD) and the Leu2 nutritional gene. The Trp, Leu and His
nutritional genes allow yeast auxotrophs to grow on limiting synthetic media.
Approximately, 3x106 cotransformants were screened, 45 of which grew in 
histidine lacking medium and 5 of the 45 were lacZ-positive when tested by a 
β-galactosidase assay. Plasmid DNA was isolated from the 5 lacZ-positive 
co-transformants and retransformed into yeast with the LMX1B bait plasmid.
Only a single clone was able to activate the His and LacZ reporter genes upon
re-transformation, and this clone was used to transform E. coli cells and to 
perform sequence analysis. 
Screening of the CLIM2 gene
The complete coding sequence of CLIM2 was divided in five regions, and 
five pairs of primers were used. The primer sequences and the conditions 
of amplification are reported in table 1. 
Purified PCR products (100 ng) were directly cycle-sequenced using the dye 
terminator chemistry (3100 ABI PRISM Perkin Elmer). The samples were 
electrophoresed in an ABI 3100 automated sequencer and analysed by the 
analysis software.
Genotyping
Thirteen patients of a large Dutch NPS family with variable expression of
nephropathy11,14 were presently investigated for clinical symptoms of nephropa-
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thy and genotyped for known polymorphisms, reported in the SNP database
and located in the coding region and in the promoter of the CLIM2 gene. The
analysed intronic polymorphisms were studied by PCR and direct sequencing. 
A nucleotide repeat in the promoter region and a nucleotide repeat outside the
gene were amplified with fluorescent primers and PCR products were loaded in
an automated sequencer ABI mod 3100 and allele size defined using the
Genescan software. Subsequently, we analysed the following polymorphisms
(the numbers refer to the ATG start codon considered as +1): a TG repeat in the
5’ upstream region at –4485; 6 SNPs in the first intron -3145 A→T, -3118 A→T,
-2795 G→T, -2707 T→G, -2254 C→T, -1716 G→T; an SNP in the fourth intron
316 A→G; an synonimous SNP in the fourth exon 402 A→G; a TA repeat, loca-
ted 34 kb downstream of the gene 3’. 
Results
To better understand the pathogenetic mechanisms leading to variable expres-
sivity in NPS, as well as LMX1B function during renal development, we under-
took a study to identify proteins interacting with LMX1B using the yeast two-
hybrid method. The LMX1B cDNA, with the exclusion of the first exon, was
used as a bait and a human fetal kidney library used for the yeast two-hybrid
screening. After two subsequent rounds of screening, we found a positive clone
containing the CLIM2 gene. The interaction between the LMX1B and the CLIM2
proteins had already been described in the literature15 by using other methods,
therefore our finding represents a strong confirmation of previous results.
Moreover, it suggests that CLIM2 can be considered a good candidate either as 
a causative gene in cases where no mutations in the LMX1B gene were found or
as a modifier gene which could explain some aspects of phenotype variability. 
A A f: aggctgcccattttagatgc
Ex 11 A r:ctctggtgttcttcagtagg
530 pb Ta 53°C, Mg 1.5 mM, DMSO 5°C
B B f: aactgtctttgcttctacgc
Ex 10-9-8 B r: tctcaggagtgtcacaatgc
850 pb Ta 55°C, Mg 2 mM
C C f: tctgtctaagtagtcagtcg
Ex 7 C r: ccagatttaatgtgcaggtg
348 pb Ta 55°C, Mg 2 mM
D D f: gtgagtatacactgggagag
Ex 5-6 D r: acacatgacacccgttacc
550 pb Ta 53°C, Mg 1.5 mM, DMSO 5°C
E E f: gtaacgggtgttcatgtgtc
Ex 2-3-4 E r: ttcctcaaagtcattcaagc
549 pb Ta 55°C, Mg 1.5 mM
table 1
Primer sequences and conditions of amplification
f, forward primer; r, reverse primer; Ta, temperature of annealing; bp, basepair.
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To test the first hypothesis, we carried out a mutation screening in the 
coding region of the CLIM2 gene in our seven NPS cases in which no LMX1B
mutation had been found. No molecular variants were found in all analysed
patients, thus making it unlikely that CLIM2 is a causative gene, at least in 
the above group of patients.
After CLIM2 mutation analysis, we carried out a study of different polymor-
phisms (see Materials and methods) in the CLIM2 gene in order to study its role
as a modifer gene. Genotyping was performed on 13 affected members of a
large family with recurrence of NPS and variable expression of associated
nephropathy.
All polymorphisms in the 5’ upstream region, in the gene introns and fourth
exon were not informative in our family, whereas the TA repeat, located 34 kb
downstream of the gene 3’ end was informative. We assessed the segregation
pattern related to the presence of nephropathy, but we could not observe any
correlation between the presence of a specific allele and the expression of
nephropathy, as shown in figure 1. 
Discussion
In this study, undertaken in the attempt to gain more insight into the pathogenesis
of NPS and into the mechanisms underlying variable expression of the clinical
phenotype, we identified the CLIM2 protein, able to interact with LMX1B, the
protein that was found mutated in NPS patients. The interaction between
CLIM2 and LMX1B gene products was previously described in the literature as
the result of expression and immunoprecipitation experiments in transfected
mammalian cells.15 Our result confirms the previous observation and stimulates
further questions about the biological role of the CLIM2/LMX1B interaction
and a possible pathogenetic role in NPS.
CLIM2 belongs to a superfamily of proteins, called CLIM, cofactors of LIM
homeodomain proteins, that act as transcriptional activators associated with
the LIM homeoproteins and cooperate in transcriptional regulation, although it
was reported that the association of the CLIM cofactors with LIM domains does
not improve the DNA-binding ability of LIM homeodomain proteins. Both the
LIM homeoproteins and CLIMs are involved in a variety of developmental
processes.16 The human CLIM2 cDNA has been reported and the chromosome
location at 10q24-q25 has been obtained using a human-rodent monochromo-
somal hybrid cell panel and a radiation hybrid mapping panel.17 The CLIM2
protein is composed of 375 amino acids with a 98.7% amino acid identity to his
mouse counterpart. The human CLIM2 is 76% identical to another member of
this gene family, CLIM1. Northern blot analysis showed that the CLIM2/LDB1
gene is ubiquitously expressed, although at different levels, with high levels in
peripheral blood leukocytes, lymph node, bone marrow, thyroid gland, ovary,
kidney, testis, and prostate and lower expression in small intestine, lung, 
skeletal muscle, and liver.18 Two differential transcripts were observed at 
different ratios in different tissues, with higher abundance of the smaller 
size transcript in heart and equal amounts in liver.
The analysis we carried out both on NPS patients showing no LMX1B muta-
tion in the coding sequence and patients belonging to a large Dutch NPS family
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with high incidence of renal involvement, failed to establish a direct association
between a specific CLIM2 sequence variant and NPS phenotype. However, given
the limited knowledge of the effect of the LMX1B and CLIM2 protein interaction,
we cannot exclude that, by a yet unknown mechanism at the level of tissue and
organ development, it could be involved either in NPS pathogenesis or in deter-
mining the variable expression and clinical phenotype of NPS. Additional studies
are needed to further investigate a possible role of CLIM2 in normal and 
disturbed kidney development associated with NPS or other hereditary
glomerulopathies.
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Abstract
Nail patella syndrome (NPS) is characterised by developmental defects of 
dorsal limb structures, nephropathy, and glaucoma and is caused by heterozy-
gous mutations in the LIM homeodomain transcription factor LMX1B. In order
to identify possible genotype-phenotype correlations, we performed LMX1B
mutation analysis and comprehensive investigations of limb, renal, ocular, and
audiological characteristics in 106 subjects from 32 NPS families. Remarkable
phenotypic variability at the individual, intrafamilial, and interfamilial level was
observed for different NPS manifestations. Quantitative urinanalysis revealed
proteinuria in 21.3% of individuals. Microalbuminuria was detected in 21.7% 
of subjects without overt proteinuria. Interestingly, nephropathy appeared 
significantly more frequent in females. A significant association was established
between the presence of clinically relevant renal involvement in an NPS patient
and a positive family history of nephropathy. We identified normal-tension
glaucoma (NTG) and sensorineural hearing impairment as new symptoms
associated with NPS. Sequencing of LMX1B revealed 18 different mutations,
including six novel variants, in 28 families. Individuals with an LMX1B muta-
tion located in the homeodomain showed significantly more frequent and high-
er values of proteinuria compared to subjects carrying mutations in the LIM
domains. No clear genotype-phenotype association was apparent for extrarenal
manifestations. This is the first study indicating that family history of nephro-
pathy and mutation location might be important in precipitating individual
risks for developing NPS renal disease. We suggest that the NPS phenotype is
broader than previously described and that NTG and hearing impairment are
part of NPS. Further studies on modifier factors are needed to understand the
mechanisms underlying phenotypic heterogeneity. 
Introduction
Nail patella syndrome (NPS; MIM 161200) is an autosomal dominant disorder
characterised by developmental defects of dorsal limb structures, the kidney,
and the eye, manifested by nail dysplasia, patellar abnormalities, elbow dysplasia,
iliac horns, nephropathy, and glaucoma, respectively. NPS is caused by hetero-
zygous mutations in the gene encoding the LIM-homeodomain transcription
factor LMX1B.1,2 Studies in Lmx1b-/- mice have shown that Lmx1b plays a crucial
role in dorso-ventral patterning of the limb, patterning of the skull, morpho-
genesis and function of the podocytes and the glomerular basement membrane
(GBM), and development of the anterior segment of the eye, 3-8 In the central
nervous system, Lmx1b is involved in developing dopaminergic and serotonergic
neurons of the hindbrain and the midbrain, and dorsal interneurons of the
spinal cord.9-12
Nephropathy and glaucoma are the most relevant clinical manifestations in
human NPS.13,14 NPS nephropathy is a disease of both the podocytes and the
GBM, with irregular thickening and electron lucent areas as consistent ultra-
structural hallmarks of the GBM.7,15,16 Interestingly, abnormal collagen expres-
sion has been observed in human NPS renal biopsy specimens15 and in Lmx1b-/-
murine kidneys5 and corneal stroma.6 The molecular mechanisms underlying
the phenotypic aspects of this disorder, however, are as yet unclear. Recent
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studies, including an excellent review by Sweeney et al. (2003),17 have shown
remarkable phenotypic heterogeneity of NPS, but no statistical analysis of the
LMX1B genotype with respect to detailed multidisciplinary clinical studies has
been performed. 
Here, we performed comprehensive clinical investigations and LMX1B
mutation analysis in a large cohort of NPS patients. The aim of the study 
was three-fold: a). To define the complete phenotype of NPS based on the
knowledge of the Lmx1b expression and function figure 1; b). To compare the 
presence and severity of renal and extrarenal manifestations at the individual,
intrafamilial, and interfamilial level; and c). To evaluate the NPS characteristics in
the view of the LMX1B genotype in order to identify possible genotype-pheno-
type associations. 
Patients and methods
Patients 
The study population comprised 106 subjects with NPS, 50 males and 56
females. The total of 32 families included 96 individuals from 22 unrelated 
families and 10 sporadic subjects. In total, 21 families were recruited from
Human Genetics Departments, five from Orthopaedic Surgery Departments,
one from a Paediatric department, and two from patient contact groups. Three
families contacted us through the media. The series of families included one 
of the first NPS families (family 1) in which linkage of NPS to the ABO blood
figure 1
Schematic presentation of putative pathogenic pathways underlying the phenotype of nail patella syndrome. 
The hypothesised molecular bases underlying ocular anomalies and hearing impairment and clinical findings of
possible hearing impairment and psychological symptoms are indicated by dotted arrows. GBM, glomerular 
basement membrane. 
kidney
Nephropathy Glaucoma Hearing loss
Nail dysplasia
Patella a/hypoplasia
Psychological symptoms
(depression, mood symptoms)
Peripheral sensory
symptoms1;2
(diminished pain and
temperature sensation)
podocytes GBM
basement membrane
trabecular meshwork
and/or lamina cribrosa
basement
membrane
inner ear
dorsal
structures
dopaminergic
and serotonergic
neurons
dorsal
interneurons
eye ear limb brain spinal cord
Genotype
Disrupted basement
membrane developement
(changes in collagen expression)
Disrupted morphogenesis
and function
Disrupted dorsoventral
patterning
Disrupted development
of the central and peripheral
nervous system
Pathogenetic
   mechanism
Organ system
Organ structure
Phenotype
LMX1B mutations
100
group was shown in 195718 and a five generation family (family 26) with 
high prevalence of nephropathy originally described in 1988.19 The study was
approved by the local medical ethics committee and written informed consent
was obtained from all participants or their parents. All patients were examined
at the Radboud University Nijmegen Medical Centre.
Examination of limbs and pelvis
Radiographic series of both knees of individuals aged >6 years, included an
antero-posterior view, a true lateral view, and an axial view. For assessment of
patella aplasia or hypoplasia in subjects aged <6 years, ultrasonography of both
knees was performed. A lateral view of the elbows and an antero-posterior view
of the pelvis was taken in all subjects. To quantify the nail, patellar and elbow
anomalies, iliac horns, and additional major and minor orthopaedic mani-
festations of NPS, the clinical scoring system developed by Farley et al. (1999)20
was used. However, for objective determination of patellar anomalies and iliac
horns, the radiographic findings were included instead of palpation. Major
orthopaedic diagnosis included club feet and/or hip dysplasia.20 Minor
orthopaedic diagnosis comprised tendon contractures in hands and feet and/or
foot deformities 20. The severity score was categorised as mild, moderate, or
severe according to Farley et al. (1999).20
Nephrological examination
Nephrological investigations could be performed in 81 patients from 28 families,
35 males and 46 females with a mean age of 38.6 years (range 0.5-81.8 years) at
the time of examination. Blood pressures (BP) were measured in supine position
by Dynamap (Criticon, Tampa, FL, USA). The determination of protein and
albumin excretion and microscopic examination of urine sediment were 
performed in a random and a first morning urine specimen. Serum creatinine,
albumin, and cholesterol were measured by standard chemical procedures.
Proteinuria was defined as total urinary protein >0.1 g/l accompanied by a 
protein-creatinine ratio >0.2 g per 10 mM of creatinine. Microalbuminuria 
was defined as an albumin-creatinine ratio (ACR; mg of albumin per 10 mM 
of creatinine) between 20 and 300 in males and between 30 and 300 in females
and macroalbuminuria as an ACR >300. Hypertension was defined as systolic
BP >140 mmHg and/or diastolic BP >90 mmHg for adults and age-related BP 
reference values were used for children.21 Individuals using antihypertensive
therapy were also considered as being hypertensive. Glomerular filtration rate
(GFR) was estimated by endogenous creatinine clearance (CrC), calculated 
by Cockcroft-Gault formula and adjusted for body surface area.22,23 To investi-
gate possible characteristics related to the renal phenotype, individuals 
were subdivided according to the presence or absence of nephropathy. For 
comparing urine and serum analysis and blood pressure between proteinuric
and nonproteinuric subjects, the female patient with end-stage renal disease
(ESRD) was excluded. For identifying possible renal-extrarenal phenotype 
associations, the patient with ESRD was included in the group of individuals 
with nephropathy.
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Ophthalmologic investigation
Ophthalmologic investigation could be performed in 51 subjects from 16 families,
21 males and 30 females with a mean age of 39.7 years (range 6-74 years) at the
time of evaluation. Ocular examination included visual acuity assessment, intra-
ocular pressure (IOP) measurement with Goldmann applanation tonometry,
slit-lamp biomicroscopy, gonioscopy, ophthalmoscopy, and visual field investi-
gation by Humphrey visual field analysis (central 30-2) and glaucoma hemifield
testing. Subjects using intraocular hypotensive medication interrupted medical
therapy four days before examination until completion of ocular examination.
Ocular hypertension was defined by an IOP >21 mmHg on two separate 
occasions. Glaucomatous optic disk alteration was defined by a cup-disk ratio
of >0.7 or a difference in the cup-disk ratios of at least 0.2 between both eyes
accompanied by notching of the rim and/or peripapillary haemorrhages of
the optic rim.24 Primary open-angle glaucoma (POAG) was defined by 
glaucomatous cupping of the optic disk, glaucomatous visual field defects, 
an IOP >21 mmHg on two separate occasions, and open anterior chamber
angle. Normal-tension glaucoma (NTG) was defined as POAG with the
exception of an IOP <21 mmHg at the first ocular examination and confirmed
by diurnal phasing 6-12 months later. 
figure 2
(a) Triangular lunula pathognomonic for nail patella syndrome, longitudinal ridging of
the nail, and absent skin creases on the dorsal aspect of the distal interphalangeal joint
of the index finger. (b) Lower muscle volume of the dorsal muscle group (triceps brachii)
compared to the ventral counterpart (biceps brachii). c) Audiogram of a female NPS 
patient aged 59 years from family 26, showing significant bilateral hearing impairment.
The circles and solid bold line indicate the pure tone thresholds of the right ear; the
crosses and broken bold line of the left ear; the solid line denote the P95 of presbyacusis;
the dotted line the P78.
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figure 3
Pedigrees of families 5 and 26 showing clinical variability of nephropathy, glaucoma, hearing impairment, and nail and
orthopaedic findings within and between families and high prevalence or nephropathy in family 26. MILD, MOD, SEV
denote mild, moderate, and severe nail and orthopaedic scores according to Farley et al. (1999),20 respectively. Asterisks
indicate individuals excluded for audiometry due noise trauma or age >70 years since no age related reference values
are available beyond 70 years.
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Audiometric evaluation
Based on the remarkable similarities between nephropathy in NPS and Alport
syndrome, a type IV collagen kidney disease associated with sensorineural 
hearing loss, we questioned whether hearing loss may accompany NPS figure 1.
Otoscopy and pure tone audiometry were performed in 28 subjects from six
families, nine males and 19 females with a mean age of 46.2 years (range 11-
75 years) at the time of examination. Individual binaural mean pure tone
thresholds (dB hearing loss, air conduction level) at 0.25, 0.5, 1, 2, 4, and 8 kHz
were compared with the International Organization for Standardization (ISO)
standard 7029 presbyacusis thresholds of otologically normal subjects matched
by age and gender.25 For genotype-phenotype studies, an individual severity
score for threshold progression beyond the 95th percentile (P95) presbyacusis
was assessed. Hearing impairment was designated significant when >2 out of 6
thresholds at the frequencies 0.25-8 kHz were >P95 presbyacusis matched by age
and gender for each ear separately, bilaterally tested with p<0.05 and unilateral-
ly with p<0.095.25 Additionally, individual monaural thresholds were compared
with different percentiles (P70 –P95) of presbyacusis to find the best-fitting 
percentile of the ISO 7029 threshold distribution. Four patients were excluded
for audiometric analysis, one individual due to noise trauma and three patients
aged >70 years since no age-related reference values are available beyond 70 years. 
Psychological and health state measures
To investigate psychological symptoms and health status, individuals aged >16
years were asked to complete the Dutch version of standardised self-report
questionnaires, including:
1). Psychopathology using the Symptom Checklist (SCL-90).26
2). Depression using the Beck Depression Inventory, diagnosed from a score of 16.27
3). State and trait anxiety using the Spielberger Trait Anxiety Inventory.28
4). Five personality dimensions using the Revised NEO Five-Factor Inventory.29
To compute an overall “health-related quality of life” figure, five health state
dimensions were assessed using the EuroQol–5D inventory.30 Additionally, valu-
ation of health status using a visual analogue scale (VAS) with a score from 0 to
100, representing the lowest to the highest possible health status was requested. 
Mutational and FISH analysis
Direct sequencing of the eight coding exons and flanking introns of LMX1B
was performed on DNA extracted from peripheral blood lymphocytes as
described already.31 In subjects in which no LMX1B mutation could be identi-
fied, fluorescence in situ hybridisation (FISH) studies were carried out on
metaphases derived from peripheral blood lymphocytes. For FISH analysis,
biotin labelled PAC clones 830-M14 and 1195-M2 located in the LMX1B region
were used according to standard procedures.32
Statistics
Clinical and molecular findings were analysed using linear and logistic 
regression models. Since age and gender are known covariates in developing
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renal, ocular, audiological, and psychological anomalies, multivariate analysis
of these symptoms was adjusted for age and gender. For the comparison
between clinical and molecular data within and between families, analysis 
of covariance was performed. For all statistics, P-values are two-tailed and 
present unadjusted values concerning multiplicity. Significance was set at the
5% probability level.
Results
Limb and pelvis malformations
The results of examination of the limbs and pelvis are summarised in table 1.
Fingernail anomalies were observed in all subjects table 1, figure 2a. On physical
examination, an abnormal volume distribution of the proximal musculature 
of the upper limb was recognised in some NPS patients, with a lower muscle
volume of the dorsal muscle groups (triceps brachii) compared to the ventral
counterparts (biceps brachii) figure 2b. In the lower limb, such evident differences
between dorsal (quadriceps femoris) and ventral (hamstrings) proximal 
musculature volume were not observed. The severity of nail and orthopaedic
features, scored according to Farley et al.(1999)20 was mild in 13.4% (11/82) of
individuals, moderate in 52.4% (43/82), and severe in 34.2% (28/82) and was
highly variable both within and between families figure 3. The complete tetralogy
of nail, patellar, elbow, and pelvis anomalies classified according to Farley et al.
(1999)20 was found in 50.6% (41/81) of individuals. 
Nephropathy
The results of nephrological investigations are summarised in table 2.
Proteinuria was identified in 13 individuals from six unrelated families and in four
sporadic cases by quantitative urinanalysis of a random urine specimen (17/80)
table 2, figure 3. Isolated proteinuria was detected in 14.5% (11/76) of individuals,
both proteinuria and hematuria in 6.6% (5/76), and isolated microscopic hema-
turia in 11.8% (9/76). ESRD was found in only one subject of NPS patients overall
(1/106). The mean age of individuals with proteinuria (48.1 years, range 8.7-76.2
years) was significantly higher compared to nonproteinuric individuals (36.0
years, range 0.5-81.8 years). Protein-creatinine ratio was 1.6±2.1 g/10 mM
(range 0.26-7.47 g/10 mM) in proteinuric subjects. GFR was below 60
mL/min/1.73m2 in 5.3% (4/76) of subjects overall and between 60 and 90
mL/min/1.73m2 in 34.2% (26/76). Proteinuric patients had a significantly 
lower GFR compared to nonproteinuric patients table 2. Patients with isolated
microscopic hematuria had normal GFR table 2. Serum creatinine, albumin and
cholesterol, and mean arterial blood pressure did not differ between proteinuric
and nonproteinuric subjects. Urinanalysis of first morning specimens demon-
strated microalbuminuria in 27.5% (14/51) of an unselected series of NPS
patients and macroalbuminuria in 3.6% (2/51) (data not shown). In the series 
of nonproteinuric subjects, 21.7% (10/46) had microalbuminuria detected in 
the same morning urine specimen. In microalbuminuric subjects, ACR was
85.3±58.3 g/10 mM. Proteinuria was found significantly more frequent in
females (33.3%; 15/45) than in males (5.7%; 2/35), adjusted for age table 2. 
The same was true for microalbuminuria, 29.6% (8/27) of females versus 16.7%
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(4/24) of males, although statistically not significant (P=0.28). We performed 
a follow-up study of family 26, which has been extensively reported with high
prevalence (43.4%; 10/23) of nephropathy 16 years ago.19,31 Previous investigations
demonstrated proteinuria in 33.3% (5/15) of subjects, with a mean age of 48
years (range 33-61 years) of proteinuric subjects at the time of examination.
Present studies of the same subjects revealed proteinuria in 40.0% (6/15) with 
a mean age of 62 years (49-77 years) of proteinuric individuals at the time of
examination and progression of proteinuria compared to earlier studies in three
out of five subjects figure 3. One patient from this family had undergone kidney
transplantation at the age of 24 years. Previous ultrastructural studies of renal
biopsy specimens of the latter patient demonstrated typical GBM anomalies
characteristic for NPS.33 None of the unaffected relatives of NPS family 26 were
reported to have nephropathy. 
Frequency (%)a
Thumbnail and/or fingernail anomalies 100
Nail hypoplasia, splitting, ridging 46.1
Nail aplasia 20.2
Triangular lunulae 79.8
Toenail dysplasia and/or dystrophia (mainly comprised of small and brittle nails) 52.5
Swan-neck deformity of fingers 76.5
Absence of ≥ 1 creases on the dorsal aspect of the distal interphalangeal joints of the fingers 82.5
Pterygia elbow 5.0
Scoliosis 34.5
Patellofemoral joint anomaliesb
Patella aplasia 6.1
Patella hypoplasia 81.0
Underdeveloped lateral femoral condyles 78.3
Prominent medial femoral condyles 76.7
Genu valgum 61.2
Elbow anomaliesb
Radial head hypoplasia 45.2
Radial head dislocation 45.1
Capitellum hypoplasia 21.7
Cubitus valgus 12.0
Pelvis anomalies
Iliac horns 78.4
Iliac bone hypoplasia 75.5
Iliac bone flaring 76.6
table 1
Limb and pelvis anomalies in 32 nail patella syndrome families
a Findings of physical and radiographic investigation and inventories were available from series ranging from 87 
to 106 individuals.
b The skeletal anomalies were separately evaluated for the left and right patellofemoral joint and elbow, and the 
frequency of these anomalies represent the sum of these findings, respectively. 
106
Ophthalmologic involvement
Glaucoma, isolated glaucomatous alteration of the optic disk, and ocular hyper-
tension were found in 35.3% (17/51) of individuals from five out of 16 families
table 3. Glaucoma was diagnosed in 11.8% (6/51) of subjects: POAG in 3.9% (2/51)
or NTG in 7.8% (4/51) table 3. Isolated glaucomatous alteration of the optic disk
was found in 23.3% (10/43) of subjects with normal IOP not using IOP lowering
treatment (data not shown). Ocular hypertension was shown in 3.9% (2/51) of
cases. The mean age at which glaucoma or ocular hypertension had been
detected was 63.4 years (range 55-72 years). Under the age of 40 years, one case
(1/23) showed glaucomatous optic disk excavation and one subject had ocular
hypertension. Between 40 and 50 years, 30.8% (4/13) had glaucomatous alter-
ation of the optic disk. Over 50 years, 13.3% (2/15) had POAG, 26.7% (4/15)
NTG, 33.3% (5/15) glaucomatous optic disk alterations, and 6.7% (1/15) ocular
hypertension. Mean IOP was 15.5 mmHg (range 10-30 mmHg), respectively. No
association between excavation of optic disk and IOP could be demonstrated,
suggesting that pathological cupping of the optic disk in NPS can occur without
elevated IOP. Cataract was found in 7.8% (4/51) of subjects, including congenital
cataract in two siblings (family 32). Additional anomalies of the anterior segment
included corneal abnormalities, iris pigmentation, and pigment dispersion 
syndrome. The frequency of ocular findings did not differ significantly between
males (6/21) and females (12/30).
Hearing impairment
Otoscopy revealed no pathological findings. Sensorineural hearing impairment
was observed in 45.8% (11/24) of NPS subjects from four out of six families
examined table 3. It was diagnosed bilaterally in 36.4% (4/11) of individuals and
unilaterally in 63.6% (7/11) and equally distributed across the various frequencies
(0.25-8 kHz). The mean age at the time of detection was 46.7 years (range 17.5-
69.2 years). Unaffected family members had normal hearing. 
In family 26 with high prevalence of nephropathy, bilateral hearing impairment
was found in a statistical significant proportion of individuals with NPS
(P<0.02), whereas in the group of randomly selected NPS patients, unilateral
hearing impairment was detected significantly frequent (P<0.02).table 3, figure 3
However, detailed evaluation of the audiograms of individuals diagnosed with
unilateral hearing impairment showed fairly symmetrical thresholds suggesting
bilateral involvement, although significant scores for both ears were lacking.
No significant differences were found in the frequency of hearing impairment
in females (7/16) compared to that in males (4/9).
The NPS individual pure tone threshold data were comparable to the 78th
percentile of presbyacusis figure 2c.25 In total, 52% of the individual thresholds were
>P78 at all frequencies. Whether the audiometric results can be interpreted as
mildly accentuated presbyacusis or, alternatively, as the development of a normal
degree of presbyacusis at an earlier age than is normal cannot be elucidated as yet.
Psychological and health state findings 
Response rate of self-report questionnaires on psychological symptoms was
88.2% (75/85). Signs of psychopathology, depression, anxiety, and personality
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dimensions were comparable to those of the general population. Depression
was diagnosed in four subjects (5.3%; 4/75) from four unrelated families. 
Two out of four individuals with depressive symptoms used antidepressive med-
ication. In total, six subjects used antidepressive medication and one patient
used anxiolytics at the time of investigation. The response rate of the health
state inventory was 96.4% (81/84). Findings of health status valuations, includ-
ing mobility, self-care, usual activities, pain/discomfort, and anxiety/depression
were also similar to those of the general population. 34
LMX1B mutations and FISH results
By mutational screening, 18 different heterozygous LMX1B mutations were 
identified in 28 unrelated families, including six novel variants table 3. In four
families in which no LMX1B mutation could be detected, FISH analysis revealed
no deletions of the entire LMX1B gene. All four families showed the cardinal
findings of NPS. Additionally, two siblings from one of these families (family
32) are known with mild mental retardation and congenital cataract. These
Proteinuric subjectsa Nonproteinuric subjectsa P-value
n=17 (21.3%) n=63 (78.7%)
Female gender 88.2% (15/17) 47.6% (30/63) 0.003*
Mean age (yr) 48.1 ± 21.8 36.0 ± 18.9 0.034*
Number of subjects aged 0-15 yr 11.8% (2/17) 14.3% (9/63)
Number of subjects aged 16-40 yr 23.5% (4/17) 46.0% (29/63)
Number of subjects aged >40 yr 64.7% (11/17) 39.7% (25/63)
Protein-creatinine ratio (g/10 mM) 1.55 ± 2.08 0.19 ± 0.19 <0.001*
Microscopic hematuria 31.3% (5/16) 14.5% (9/62) 0.14
Urinary creatinine (mmol/l) 9.3 ± 5.2 8.8 ± 4.9 0.85
Serum creatinine (µmmol/l)
Males 90.0 (n=1) 75.3 ± 15.0
Females 74.5 ± 11.1 68.4 ± 6.3 0.04*
GFR (ml/min/1.73m2)
Hematuric subjects 74.1 ± 10.2 100.3 ± 14.7 0.008*
Nonhematuric subjects 79.9 ± 24.6 100.8 ± 20.12 0.02*
Serum albumin (g/L) 42.4 ± 2.4 44.1 ± 2.8 0.04*
Serum cholesterol (mmol/L) 5.4 ± 1.0 4.7 ± 1.1 0.02*
Mean arterial pressure, supine (mmHg) 99.3 ± 13.8 96.7 ± 13.1 0.61
table 2
Nephrological examinations in 80 individuals from 27 families with nail patella syndrome
GFR, glomerular filtration rate; yr, years.
a Proteinuria was defined as total urinary protein >0.1 g/l and protein-creatinine ratio >0.2 g/10 mM. 
The female patient with end-stage renal disease was excluded from this series of 80 subjects.
* Significant P-values.
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Family Total  Gender Nephropathya POAG NTG Glaucomatous Hearing Hearing Nail 
No No of (M/F) optic disk impairment impairment dysplasia
patients anomalies unilateralb bilateralc
1 3 3/0 0/1 NA NA NA NA NA 3/3
2 1 0/1 NA NA NA NA NA NA 1/1
3 4 3/1 1/3 0/2 0/2 0/2 NA NA 4/4
4 8 5/3 0/8 0/1 0/1 0/1 NA NA 8/8
5 14 2/12 1/13 2/7 0/7 3/5 3/4 0/4 14/14
6 2 1/1 NA 0/1 0/1 0/1 NA NA 2/2
7 2 1/1 0/2 0/2 0/2 0/2 1/2 0/2 2/2
8, Spor 1 1/0 0/1 NA NA NA NA NA 1/1
9 5 1/4 0/4 0/5 1/5 0/1 0/3 0/3 5/5
10 8 6/2 1/6 NA NA NA NA NA 8/8
11 5 5/0 0/2 0/2 0/2 0/2 NA NA 5/5
12 3 3/0 0/3 0/1 0/1 0/1 NA NA 3/3
13 2 1/1 0/2 NA NA NA NA NA 2/2
14, Spor 1 0/1 1/1 0/1 0/1 0/1 NA NA 1/1
15, Spor 1 1/0 NA NA NA NA NA NA 1/1
16, Spor 1 1/0 0/1 NA NA NA NA NA 1/1
17 5 2/3 1/3 NA NA NA NA NA 5/5
18 2 1/1 0/2 NA NA NA NA NA 2/2
19 2 0/2 0/2 NA NA NA NA NA 2/2
20 2 1/1 0/1 0/2 0/2 1/2 0/2 0/2 2/2
21, Spor 1 1/0 1/1 NA NA NA NA NA 1/1
22, Spor 1 0/1 1/1 NA NA NA NA NA 1/1
23, Spor 1 1/0 0/1 0/1 0/1 1/1 NA NA 1/1
24, Spor 1 1/0 0/1 NA NA NA NA NA 1/1
25, Spor 1 0/1 1/1 NA NA NA NA NA 1/1
26 18 4/14 8/15 0/18 3/18 4/15 3/12 3/12 18/18
27 2 1/1 NA 0/1 0/1 0/1 0/1 1/1 2/2
28 3 1/2 2/3 0/3 0/3 1/3 NA NA 3/2
29 2 2/0 NA 0/2 0/2 0/2 NA NA 2/2
30 1 0/1 0/1 NA NA NA NA NA 1/1
31, Spor 1 0/1 0/1 NA NA NA NA NA 1/1
32 2 1/1 0/1 0/2 0/2 0/2 NA NA 2/2
Total 106 50/56 22.2% 3.9% 7.8% 23.3% 29.2% 16.7% 100%
(18/81) (2/51) (4/51) (10/43) (7/24) (4/24) (106/106)
table 3
Summary of clinical features and LMX1B mutations in 32 nail patella syndrome families 
NA, not available; NTG, normal-tension glaucoma; POAG, primary open-angle glaucoma; PTC, premature termination
codon; Spor, sporadic.
a Nephropathy was defined as urinary total protein >0.1 g/l accompanied by a protein-creatinine ratio >0.2 g/10 mM
in a random urine specimen or end-stage renal disease.
b Hearing impairment was diagnosed when ≥ 2 out of 6 frequencies (0.25-8 kHz) were >P95 presbyacusis, unilaterally. 
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Elbow Patella a/ Iliac Mutation DNA Protein Putative Novel/
dysplasia hypoplasia horns location changed effect effect reported
3/3 2/3 3/3 LIM-A c.152C→A p.S51X PTC 48
1/1 0/1 1/1 LIM-A c.152C→A p.S51X PTC 48
2/4 3/4 3/4 LIM-A c.166G→T p.E56X PTC Novel
7/8 6/8 4/8 LIM-A c.169T→A p.C57S Disrupt Zn-finger Novel
12/13 12/12 10/11 LIM-A c.187T→G p.C63G Disrupt Zn-finger Novel
1/2 0/0 1/2 LIM-A c.190C→T p.Q64X PTC 31,49
2/2 2/2 0/2 LIM-A c.213C→G p.C71W Disrupt Zn-finger 50
1/1 1/1 0/1 LIM-A c.234-235delGT PT Frameshift, PTC 2
4/5 5/5 4/5 LIM-B c.284G→A p.C95Y Disrupt Zn-finger 49
4/7 5/5 6/8 LIM-B c.359G→A p.C120Y Disrupt Zn-finger Novel
3/3 2/2 2/3 HD c.592C→T p.R198X PTC 1,31,43
2/3 3/3 3/3 HD c.592C→T p.R198X PTC 1,31,43
2/2 2/2 2/2 HD c.599G→A p.R200Q DNA binding 31,43
0/1 1/1 1/1 HD c.599G→A p.R200Q DNA binding 31,43
0/1 0/1 1/1 HD c.599G→A p.R200Q DNA binding 31,43
0/1 1/1 1/1 HD c.603^604insC PT Frameshift, PTC Novel
4/5 5/5 5/5 HD c.622C→T p.R208X PTC 2,43
2/2 2/2 1/2 HD c.622C→T p.R208X PTC 2,43
2/2 2/2 1/2 HD c.622C→T p.R208X PTC 2,43
1/2 2/2 0/1 HD c.622C→T p.R208X PTC 2,43
1/1 1/1 1/1 HD c.622C→T p.R208X PTC 2,43
1/1 1/1 1/1 HD c.637G→C p.A213P DNA binding 31,43
1/1 1/1 1/1 HD c.637G→C p.A213P DNA binding 31,43
1/1 1/1 1/1 HD c.667C→T p.R223X PTC 43,51
1/1 1/1 1/1 HD c.599G→A p.R223X PTC 43,51
18/18 15/18 13/17 HD c.672+1G→A Abnormal Loss of exon 4, 31,43
splicing frameshift, PTC
1/2 1/1 1/1 HD c.676C→G p.R226G DNA binding Novel
3/3 3/3 3/3 HD c.745G→C p.A249P DNA binding 31
2/2 1/1 1/1 Unknown Unknown Unknown Unknown -
1/1 0/1 1/1 Unknown Unknown Unknown Unknown -
1/1 1/1 1/1 Unknown Unknown Unknown Unknown -
2/2 2/2 2/2 Unknown Unknown Unknown Unknown -
84.3% 89.4% 78.4%
(86/102) (84/94) (76/97)
c Hearing impairment was diagnosed when ≥ 2 out of 6 frequencies (0.25-8 kHz) were >P95 presbyacusis,
bilaterally. Four out of 28 patients were excluded from audiologic evaluation.
d Nucleotide positions are based on GenBank sequence accession number NM_002316.
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families were too small for genetic linkage studies. DNA CGH-microarray
analysis is presently being performed to identify possible microdeletions/
duplications, including the region encompassing LMX1B. 
Genotype-phenotype relationships 
No statistical significant differences between 18 different LMX1B mutations
could be established concerning the presence and severity of the diverse renal
and extrarenal manifestations (data not shown). However, family 26 (with
LMX1B mutation 672+1G→A) demonstrated a high prevalence (53.3%; 8/15) 
of nephropathy compared to family 4 ((C57S), 0%; 0/8), family 5 ((C63G),
7.6%; 1/13) and NPS patients overall (22.2%; 18/81) table 3, figure 3. Comparison of
phenotypic manifestations with LMX1B mutation locations (LIM-A and LIM-B
domains versus homeodomain (HD)) demonstrated a significant higher frequen-
cy of nephropathy (15/40) and higher level of total urinary protein and albumin
excretion in individuals with mutations in the HD than in those with mutations
in the LIM domains (3/38), adjusted for age, gender, and family (P=0.046).
Analysis of the different putative effects of identified LMX1B mutations (prema-
ture truncation of protein, disrupted Zn-finger, or DNA-binding) in relation 
to the phenotype observed in patients carrying these mutations revealed no 
statistically significant relationships concerning any of the NPS characteristics.
A significant association was identified between the presence of renal
involvement in NPS patients and a positive family history of nephropathy. 
In total, 53% of the variance in proteinuria measured in a random urine sample
could be attributed to the family to which an individual is belonging, while the
LMX1B genotype explained only 30% of the variance. 
The presence and severity of different NPS manifestations showed high 
variability at the individual, intrafamilial, and interfamilial level (data not shown).
Comparison of extrarenal NPS characteristics between individuals with and
without nephropathy is summarised in table 4 figure 3. A statistically significant
association was identified between radial head hypoplasia and proteinuria
(P<0.01). In contrast to earlier reports35,36 but consistent with recent observations,
17 no relation could be demonstrated between elbow pterygia (5%; 5/100) and
nephropathy (data not shown). Although statistically not significant, glauco-
matous anomalies or ocular hypertension were observed more frequently in
individuals with renal symptoms (63.6%; 7/11) than subjects without nephropathy
(35.7%; 10/28) (P=0.11). No significant differences were found with respect to
hearing impairment, nail dysplasia, orthopaedic manifestations, and various
skeletal anomalies between individuals with and without nephropathy table 4. 
Discussion
In this study, new clinical and molecular aspects of NPS were identified, 
establishing that: a). LMX1B mutations located in the homeodomain and
female gender may be associated with a higher risk for developing nephropathy;
b). The family history of nephropathy is important in precipitating the individual
risk for developing renal disease; and that c). NTG and sensorineural hearing
impairment expand the NPS phenotypic spectrum.
The prevalence of proteinurian (21.3%) detected by quantitative analysis of 
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a random urine sample is comparable to the frequency (22.3%) demonstrated 
by dipstick analysis by Sweeney et al. (2003).17 The present finding of a female
predominance for both proteinuria and microalbuminuria is in contrast 
with the findings in the general population, where the prevalence of micro-
albuminuria is about twofold higher in males.37 The reason for this observation
is unclear and needs to be determined. Nephropathy is known to occur during
pregnancy only.17 However, none of the present 16 females with nephropathy
was pregnant at the time of investigation and six of them had not been pregnant.
Moreover, we have to keep in mind that half of the female patients with
nephropathy belong to family 26 with a relatively high prevalence of nephropathy
and that less males than females were available for investigation from this family.
Microalbuminuria, as the earliest clinically measurable finding of changes in
Nephropathya (n=18) (22.2%) No nephropathy (n=63) (77.8%) P-value
Female gender 88.9% (16/18) 47.6% (30/63) 0.002*
Ophthalmologic anomalies 63.6% (7/11) 35.7% (10/28) 0.11
POAG 0% (0/11) 7.1% (2/28)
NTG 27.2% (3/11) 3.6% (1/28)
Ocular hypertension 0% (0/11) 7.1% (2/28)
Isolated optic disk excavation 36.4% (4/11) 17.9% (5/28)
Hearing impairment 60.0% (3/5) 40.0% (6/15) 0.44
Orthopaedic score 0.96
Mild 11.8% (2/17) 14.0% (7/50)
Moderate 53.0% (9/17) 54.0% (27/50)
Severe 35.3% (6/17) 32.0% (16/50)
Patella aplasia/hypoplasia 88.9% (16/18) 93.2% (55/59) 0.55
Radial head hypoplasia 72.2% (13/18) 37.3% (22/59) 0.009*
Iliac horns 87.5% (14/16) 75.0% (45/60) 0.53
LMX1B mutation locationb 0.002*,b
LIM-A or LIM-B domain 16.7% (3/18) 58.3% (35/60c)
Homeodomain 83.3% (15/18) 41.7% (25/60c)
table 4
Comparison of extrarenal features and LMX1B mutation location between nail patella syndrome patients with and 
without nephropathy
a Nephropathy included subjects with proteinuria or end-stage renal disease.
b By excluding family 26 with high prevalence of nephropathy, the P-value (0.033) for LMX1B mutation location
remained significant. 
c In three out of 63 nonproteinuric patients (from families 30, 31, and 32, respectively), no LMX1B mutation could 
be identified.
* Significant P-values.
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glomerular permeability may be an important diagnostic tool, since it repre-
sents an early phase in the spectrum of NPS renal disease. Additionally, micro-
albuminuria is known to play a role in the progression of kidney damage and
cardiovascular disease.38 Since GFR was significantly lower in proteinuric indi-
viduals compared to nonproteinuric cases, we also recommend annual screening
of CrC for detecting changes in glomerular filtration in proteinuric patients. In
addition to the NPS podocyte disease,7, the severely impaired development of
the glomerular capillary network with less fenestrated glomerular endothelial
cells as seen in Lmx1b-/- mice16 may contribute to a decreased GFR in NPS. 
The prevalence of NTG (7.8%) in the present NPS patients is significantly 
higher than in the general population (0.6%).39 Based on the finding of POAG,
NTG, and isolated glaucomatous optic disk alterations in NPS, we hypothesise
that primary structural changes in the membranes of the lamina cribrosa and the
trabecular meshwork40 may play a role in NPS glaucomatous optic nerve damage
and may result from disrupted collagen expression and/or an irregular arrange-
ment or deposition of collagen fibrils similar to glomerular changes in NPS. 
Hearing impairment has previously been described in two out of six subjects
from one NPS family, but no additional familial hearing impairment has been
reported in NPS.41 We found sensorineural hearing impairment in almost half of
the examined NPS individuals. Cosegregation of hearing impairment and NPS
and absence of audiological anomalies in unaffected family members further
suggest that hearing impairment is another aspect of the NPS phenotype.
Recently, it has been suggested that disrupted midbrain dopamine neuron
development and function observed in Lmx1b-/- mice may result in psychologi-
cal symptoms in human NPS.11,42 Previous psychological evaluation of self-
report questionnaires revealed depression in five out of 10 cases and anxiety symp-
toms in five out of eight subjects, respectively.42 In the present psychological
assessment of 75 individuals, however, we found no evidence for psychological
symptoms such as depression and mood symptoms associated with NPS. 
Since nephropathy is important for prognosis and possibly indicative for the
occurrence of associated NPS manifestations, we performed comprehensive
nephrological examinations and compared extrarenal NPS manifestations
between the subgroups of individuals with and without nephropathy. A statistically
significant association was only identified between nephropathy and radial head
hypoplasia, but no common pathogenic mechanism could be proposed for 
this finding. No association was found between the presence and severity of
nail and patella dysplasia and iliac horns at the individual and familial level, sug-
gesting that NPS manifestations of disrupted dorso-ventral patterning are not
necessarily associated. Different spatiotemporal effects of LMX1B mutations or
modifier factors may be involved in the highly variable clinical expression of dor-
sal NPS features. 
A significant association was identified between the presence of nephropathy
in NPS patients and a positive family history of renal involvement. These findings
indicate a higher degree of interfamilial than intrafamilial variability for
nephropathy. Individuals within a specific family do not only share the same
LMX1B genotype, but also possible environmental aspects and endogenous risk
cofactors predisposing to nephropathy, such as blood pressure and modifier
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genes. However, no relationship could be established between mean arterial
pressure and protein excretion table 4. The influence of other predisposing risk
factors will be the subject of future studies.
Individuals with mutations located in the HD of LMX1B showed significant
higher frequency of nephropathy and higher values of proteinuria than indi-
viduals with mutations located in the LIM domains. This is in contrast with 
a previous compilation of LMX1B mutations in NPS, which revealed no such
relationship: nephropathy was reported in 55.2% (16/29) of individuals from 
20 families with mutations identified in the HD of LMX1B and in 55.6% (5/9) 
of subjects from four families mutations located within LIM-A or LIM-B
domains.43 However, in the latter study, phenotypic information was provided by
anamnestic history and/or based on qualitative urinanalysis, and no definition
of nephropathy was mentioned. Two other patients with the same mutation
have been reported, both are without nephropathy.43 In two other familial cases
with a similar LMX1B mutation (672+1G→T), one patient had nephropathy.43
In the current study, the high prevalence of nephropathy in patients with HD
mutations is mainly attributable to the large family 26 with a mutation
672+1G→A (8/15 nephropathy). However, if we exclude family 26 from 
statistical analysis, the relationship between nephropathy and the location 
of the LMX1B mutation is still significant, emphasizing the presence of this
association in additional NPS families tables 3 and 4. 
Although haploinsufficiency has been hypothesised as the main molecular
mechanism of NPS, dominant negative and/or gain-of-function effects cannot be
excluded as yet. In fact, the clustering of mutations in the LIM and HD domains,
including many that predict premature truncation codons (PTCs), provide
strong genetic support for such dominant effects. More insight is needed in the
molecular functions of LMX1B to resolve the effects of individual mutations and to
elucidate the mechanism that underlies the distinct nephrological phenotypes.
The present inventory indicates that both LMX1B genotype and modifier fac-
tors shared among family members may contribute to the development of
nephropathy. A possible role of modifier genes in NPS had already been put for-
ward in 1956 by the assumption that the NPS phenotype is modulated by the
wild-type LMX1B allele.44 Although haplotype analysis and quantification of the
severity of orthopaedic anomalies have given some support to this hypothesis,20
recent single-nucleotide polymorphism (SNP) analyses across the LMX1B gene
suggest a relationship between the haplotype of the mutant allele and the severity
of nail anomalies.45 Previous studies on the candidate modifier gene CLIM2,
encoding a transcriptional activator interacting with LMX1B, revealed no corre-
lation between different CLIM2 polymorphisms and the renal phenotype in our
family 26 (LMX1B mutation 672+1G>A) with high prevalence of nephropathy.46 A
previous observation15, 47 of ESRD in one, and absence of renal symptoms in the
other half of identical male twins with NPS emphasizes a role of external and/or
endogenous cofactors in development and progression of renal disease. In the
present study, no association could be identified between the LMX1B genotype
and severity scores of various extrarenal NPS characteristics, indicating that 
different modifier factors may also be involved in extrarenal NPS features.
Further studies on candidate modifier genes are necessary to understand the
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molecular mechanisms underlying inter- and intrafamilial phenotypic variation
and to identify cofactors involved in the progression to glaucoma and terminal
renal insufficiency in NPS. Pyrosequencing and whole-genome microarray 
techniques offer comprehensive genotyping solutions for detecting individual
genetic variations, including SNPs, insertion/deletion polymorphisms, and
mutations in genetic modifiers. Gene expression profiling of urinary podo-
cytes from NPS patients with and without renal symptoms is presently being
performed.
The first indication that hearing impairment and NTG are part of the NPS
phenotype and the finding that LMX1B mutation location, family history, and
female gender may be associated with the NPS renal phenotype requires confir-
mation in additional families before applying into counselling. Further investi-
gation and follow-up of additional large LMX1B mutation and clinically well-
characterised NPS pedigrees, will be of enormous value to finally elucidate the co-
factors underlying the phenotypic variability and the complete phenotype of NPS.
In agreement with the recommendations for clinical management proposed
by Sweeney et al. (2003),17 we stress the necessity of annual measurement of
albumin/creatinine ratio in a first morning specimen starting from birth and
additionally annual ophthalmologic screening, including investigation of 
glaucomatous optic disk alterations from late childhood. NPS patients carrying
mutations in the HD of LMX1B, especially from families with a positive family
history of nephropathy, require comprehensive renal studies.
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Chapter 3 Small patella syndrome and isolated patella 
aplasia-hypoplasia
3.1 The small patella syndrome: description of five cases from
three families and examination of possible allelism with 
familial patella aplasia-hypoplasia and nail patella syndrome
3.2 Mutations in the human tbx4 gene cause small patella 
syndrome
3.3 Evidence for genetic heterogeneity in familial isolated 
patella aplasia-hypoplasia
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The small patella syndrome (SPS; MIM 147891), also known as “ischiopatellar
dysplasia”, “coxo-podo patellar syndrome”, or “Scott-Taor syndrome”, is a 
rare autosomal dominant disorder, characterised by aplasia/hypoplasia of the
patellae and various anomalies of the pelvis and feet. This syndrome was first
described by Scott and Taor1 in 1979 in a large family with bilateral small or
absent patellae accompanied by anomalies of the pelvis girdle and upper femora
in most of the affected subjects. To our knowledge, 42 patients have been
reported with this disorder,1-9 comprising 35 cases from five families and 
seven sporadic cases. This bone dysplasia is characterised by patella
aplasia/hypoplasia and pelvis anomalies, including bilateral absent or delayed
ossification of the ischiopubic junction and infra-acetabular axe cut notches.
Other major signs are a wide gap between the first and second toes, short
fourth and fifth rays of the feet, and pes planus. Various other skeletal 
anomalies have been reported, such as elongated femoral necks, flattened and
widened proximal femoral epiphyses, hypoplasia of the lesser trochanter, and
tarsal anomalies. SPS should be clinically differentiated from disorders with
aplastic/hypoplastic patellae, in particular the autosomal dominant disorders
isolated familial patella aplasia-hypoplasia (PTLAH)10 and the more severe nail
patella syndrome (NPS).11 The latter is caused by mutations of the LMX1B gene
on chromosome 9q34. Recently, a locus for PTLAH has been identified on 
chromosome 17q21-22. As yet, it is unknown whether SPS and PTLAH are 
allelic disorders. Here we report on five cases from three families with SPS,
compare their clinical and radiological anomalies with those of previously
reported cases, and propose minimal diagnostic criteria for SPS. Given the 
clinical overlap between SPS, PTLAH, and NPS, we have studied the possible
involvement of candidate regions of these syndromes on chromosome 17q21-22
and 9q34, respectively, by linkage analysis. 
Family A,
case 1 
This male patient, aged 9 years and 10 months at the time of examination, was
referred because of bilateral absence of the patellae. He is the third child of
non-consanguineous Dutch parents. He was born at 37 weeks’ gestation after
an uneventful pregnancy. Birth weight was 2750 g (10th-25th centile). At birth,
talipes equinovarus was noted. Motor milestones were delayed; he sat at 13
months and walked at 24 months. Mental development was normal. At the age
of 6 and 8 years, surgery for flat feet was performed, but without success. At the
time of examination he complained of unstable knees, muscle weakness of the
lower extremities, fatigue on moderate exertion, and inability to run or to stand
up from sitting without support. At the age of 9 years and 10 months, weight
was 30.2 kg (10th-25th centile), height 146.5 cm (50th-90th centile), and head
circumference 51.5 cm (10th-50th centile). The ears were low set and posteriorly
angulated. He had a wide gap between the first and second toes bilaterally,
short fourth and fifth rays of the feet figure 1a, and pes planus . The patellae were
not palpable. Normal nails and normal joint mobility were found. Radiographs
of the knees confirmed the absence of the patellae and showed dysplasia of the
epiphyses of the proximal fibulae figure 1b. Radiographs of the pelvis showed
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figure 1
(a) Anterior view of the feet of the proband of family A (case 1) showing an increased space between the first and 
second toes and short fourth and fifth rays. (b) Radiograph of the knee at the age of 12 years and 11 months. Note the
absence of the patellae and dysplasia of the epiphyses of the proximal fibula. (c) Radiograph of the pelvis at the age of
12 years and 11 months showing the absent ossification of the ischiopubic junction (white arrows), infra-acetabular axe
cut notches (black arrows), and elongated femoral necks.
figure 2
Radiograph of the pelvis of case 2 at the age of 535 years showing irregular ossification of the ischiopubic junction
and infra-acetabular axe cut notches (arrows).
c
ba
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delayed ossification of the ischia and inferior pubic rami, infra-acetabular axe
cut notches, and elongated femoral necks figure 1c. Short fourth and fifth rays of
the feet and pes planus were confirmed on radiographs of the feet. 
Family A,
case 2 
This male patient, aged 49 years, the father of case 1, was known to lack both
patellae and to have flat feet. In addition to these abnormalities, physical exami-
nation demonstrated a wide gap between the first and second toes, and short
fourth and fifth rays of the feet. Radiographs showed patella hypoplasia, irregular
ossification of the ischiopubic junction, and infra-acetabular axe cut notches figure 2.
No abnormalities of other joints or nails were found. Chromosome analysis
showed a normal male karyotype. His oldest son, daughter, and 10 siblings
showed no anomalies of their elbows, knees, or feet on physical examination,
figure 3
(a) Radiograph of the knees of the proband 
of family B (case 3) at the age of 9 years and 
2 months showing smaller medial femoral 
and tibial condyles compared to lateral 
femoral and tibial condyles. (b) Note the
hypoplastic and dislocated patellae with two ossification centres on the left side, and flattened fossa intercondylares. 
(c) Radiograph of the pelvis at the age of 75 years showing bilaterally hypoplastic ossification of the ischia and inferior
pubic rami for his age (white arrows) and infra-acetabular axe cut notches (black arrows). (d ) Radiograph of the foot
showing hypertrophy of the neck of the talus.
a b
c
d
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figure 4
Pedigrees with the results of haplotype analysis of chromosome 9 and 17 of the family of case 1 (case II.3) and 2 
(case I.1) (Family A), and case 3 (case III.1) and 4 (case II.2) (Family B). Black symbols denote affected subjects who 
had been clinically and radiographically investigated.
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except for short fourth rays of the feet in one sib. Radiological examination of this
relative showed short fourth metatarsals, but because anomalies of the patellae
and pelvis were not seen, he was considered not to have SPS. His parents had
died. According to the patient they did not have any complaints or congenital
anomalies of knees and feet.
Family B,
case 3 
This male patient, aged 9 years and 2 months, was referred because of bilateral
small patellae and knee pain. He is the first child of non-consanguineous Dutch
parents. He was born at term after an uneventful pregnancy. Birth weight was
3500 g (50th centile) and length 52 cm (50th-75th centile). Psychomotor develop-
ment has been normal except for an abnormal gait and weakness of the lower
extremities. He had surgery for cryptorchidism at the age of 75 years. At the
same age, a traumatic pelvis fracture occurred with subsequent recurrent luxations
of the left patella. As a consequence, running was impossible and riding a bicycle
very difficult. At the age of 9 years and 2 months weight was 35.1 kg (90th centile),
height 148.5 cm (>97th centile), and head circumference 53 cm (2nd centile).
The face was unremarkable. The space between the first and second toes was
increased, and bilateral short fourth and fifth rays of the feet were noted. There
were no contractures, hypermobility of other joints, or nail anomalies. Radiographs
of the knees showed small patellae and a dislocated patella on the left side,
composed of two ossification centres figures 3a and 3b. Radiographs of the pelvis
showed bilateral hypoplasia of the ischia and inferior pubic rami, infra-acetabular
axe cut notches, flattened and widened capital femoral epiphyses, elongated
femoral necks, and hypoplasia of the lesser trochanter figure 3c. The medial femoral
and tibial condyles were smaller than the lateral femoral and tibial condyles.
The fossae intercondylares were flattened. Hypertrophy of the neck of the talus
and pes planus were seen on radiographs of the feet figure 3d. Radiographs of the
hands were normal. Chromosome analysis revealed a 47, XXY karyotype. 
Family B,
case 4
This female patient, aged 35 years, the mother of case 3, suffered from 
discomfort of the knees in early childhood. On physical examination, she had
bilateral small patellae and an increased space between the first and second toes
bilaterally. The other joints and nails were normal. Radiographs demonstrated
bilateral small patellae, absent ossification of the ischiopubic junction bilaterally,
and infra-acetabular axe cut notches. The medial femoral and tibial condyles
were smaller than the lateral femoral and tibial condyles and the fossa inter-
condylares were flattened. Radiographs of the feet showed hypertrophy of the
neck of the talus and pes planus bilaterally. Radiographs of the hands were 
normal. The family history was unremarkable. Physical examination and radio-
graphs of the knees of her father, mother, brother, and youngest son showed 
no abnormalities. Furthermore, radiographs of the pelvis of her youngest son 
at the age of 8 years and 1 month showed normal ossification of the ischiopubic
junction and absence of infra-acetabular axe cut notches.
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Family C,
case 5
This female patient, aged 20 years, is the first child of non-consanguineous
Belgian parents. She has one healthy brother. She was born at 41 weeks’ gestation.
Birth weight was 2500 g (<3rd centile) and length 42 cm (<3rd centile). She had
surgery of the knees for recurrent luxations of the patellae in infancy. She was
referred on suspicion of Marfan syndrome because of general hyperlaxity of
joints and poor wound healing at the age of 20 years. At that age, weight was
105.2 kg (>97th centile), height 174 cm (50th-90th centile), and head circumference
55.1 cm (50th centile). She had high nasal bridge, high arched palate, and
micrognathia. Furthermore, clinodactyly of the fifth fingers, short fifth fingers,
bilateral small patellae, flat feet, a wide gap between the first and second toes
bilaterally, short fourth and fifth toes, and joint hyperlaxity were noted. The
other joints and nails were normal. Radiographs showed hypoplastic patellae,
absent ossification of the ischiopubic joint bilaterally, infra-acetabular axe cut
notches, and small medial femoral and tibial condyles as compared to the lateral
femoral and tibial condyles. Radiographs of the skull, thorax, vertebral column,
upper limbs, wrists, hands, and feet showed no abnormalities, except for pes
planus. Echocardiography and ophthalmological examination were normal,
excluding Marfan syndrome. Chromosome analysis showed a
46,XX,t(1;X)(q12;q27) karyotype which was also found in her mother. Her
mother was said to be healthy and was not known to have had knee and foot
anomalies. Her father was known to have had scoliosis and pes planus and he
had surgery of his knees. Her paternal grandmother was also known to have
had knee complaints. Both her father and her mother were unavailable for
examination and further clinical or radiological information could not be
obtained.
Informed consent for molecular genetic investigation was obtained from two
affected and three unaffected members of family A, and two affected and five
unaffected members of family B. Genomic DNA was extracted from peripheral
blood lymphocytes by a salt extraction procedure.12 The DNA concentration was
measured by optical density (OD260) and purity checked by determining the
OD260/OD280 ratio. Manual genotyping of microsatellite markers on chromosome
9q34 and 17q21-22 was carried out as described elsewhere.13 Microsatellite
markers were chosen from the final Généthon linkage map.14 Four patients with
SPS from two families were investigated figures 1-3. Given the overlap of the clinical
features of these families with PTLAH10 and NPS,11 microsatellite markers from
the relevant chromosomal regions were tested for possible linkage in family A
and family B. The results of haplotype analysis in these two families are shown
in figure 4. Linkage to chromosome region 9q34 was excluded in family A and
B. Both families A and B are compatible with linkage to the PTLAH critical
region on chromosome 17q21-22,10 assuming a de novo mutation in case 4
(family B, case II:2, figure 4 ).
Since the first description of a family with 12 affected cases of SPS by Scott and
Taor1 in 1979, 30 patients have been described with this condition.2-9
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Additionally, several possible cases of SPS have been reported. In 1970,
Goeminne and Dujardin15 described a family with three affected members 
with bilateral patella aplasia, bilateral congenital hip dysplasia, hypoplasia of
the descending part of the pubic arches, and absent ischiopubic synostosis,
accompanied by pes planus, tarsal synostosis, short stature, and oligodactyly 
of the feet in one subject. Habboub and Thneibat16 reported a sporadic case with
aplastic patellae and bilateral absence of the ischiopubic rami, and suggested
the name ischiopubic-patella hypoplasia for a possible new syndrome. The 
clinical and radiological features of the patients described in both reports15,16 
are strikingly similar to those of SPS. Therefore, we believe that these cases 
do not represent new syndromes but are further examples of SPS. Thus, a 
total of 51 cases with SPS have currently been described, including the cases 
of Goeminne and Dujardin,15 Habboub and Thneibat, 16 and the present cases.
The clinical and radiographic anomalies of the five patients presented here and
previously reported cases are summarised in table 1. Patella aplasia/hypoplasia/
dysplasia has been found in all cases, except for one familial case with patella
Family A Family B Family C
Previously Frequency (%) Case 1 Case 2 Case 3 Case 4 Case 5
reported casesa
Radiological/clinical anomalies 45/45b 100
of the patella
Patella aplasia 14/45 32 + - - - -
Patella hypoplasia 31/45 69 - + + + +
Radiological/clinical anomalies 34/35c 97
of the pelvis
Absence/hypoplasia/irregularity 24/27d 89 + + + + +
of the ischiopubic junction
Infra-acetabular axe-cut notches 8/9 89 + + + + +
Radiological anomalies of the femora
Hypoplasia of the lesser trochanter 3/6 50 - - + + -
Elongated femoral necks/flattened and 8/15 53 + - + + -
widened proximal femoral epiphyses 
Radiological/clinical anomalies of the feet
Pes planus 9/15 60 + + + + +
Short fourth and fifth rays of feet 10/15 67 + + + + +
Clinical anomalies of the feet
Wide gap between first 13/17 76 + + + + +
and second toes
table 1
Clinical and radiological features of previously published cases1-9,15,16 and present cases with small patella syndrome
a References 1-9,15,16.
b In 45 of the 46 previously reported cases, patella aplasia/hypoplasia was mentioned.
c Thirty five of the 46 previously reported cases had radiological examination of the pelvis.
d Anomalies of the ischiopubic junction were specified in 27 of the 35 previously reported cases with pelvis anomalies.
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dislocation in which radiological examination was not mentioned.9 Complaints
and symptoms varied from pain resulting from gonarthrosis in elderly subjects,
to recurrent luxations from infancy, knee pain, and inability to run and ride a
bicycle. In some cases, however, there were no symptoms. In this report, all
cases had absent, delayed, or irregular ossification of the ischiopubic joint
accompanied by infra-acetabular axe cut notches, but no related complaints 
or additional clinical features were noted. In family B, the medial femoral and
tibial condyles were small compared to the lateral femoral and tibial condyles.
These features have also been mentioned by Vanek et al. (1981)2 and can also 
be seen on radiographs from other reports.3-5 Hypoplasia of the lesser
trochanter, elongated femoral necks, and flattened and widened epiphyses 
of the proximal femora were found in most of the present patients, but have
been reported in only a minority of the previously reported cases. The main
clinical features of the feet, comprising an increased space between the first 
and second toes, short fourth and fifth rays, and pes planus, were found in 
all our patients, and in a majority of the previously reported cases. Furthermore,
hypertrophy of the neck of the talus, short fourth metatarsals, tarsal coalition
or synostosis, winging or an abnormal shape of the scapulae, short fourth and
fifth metacarpals, coxa valga, coxa vara, and genu valgum have been described
in a minority of the previously reported cases. 
Additional anomalies have only been found in five cases. One of the present
cases (case 5) showed a high nasal bridge, micrognathia, and a high arched
palate. One of the two sporadic cases described by Kozlowski and Nelson6
had synophrys, epicanthic folds, a broad nasal bridge, apparently low set, 
posteriorly angulated ears, anteverted nares, long philtrum, high palate, 
prominent lower lip and micrognathia, and the other case had a flattened 
nose and a prominent forehead. Subsequently, Azouz and Kozlowski9
described another sporadic case with macrocephaly and cleft palate. As yet, 
it is not possible to establish whether these anomalies are variable features 
of SPS. Clinical examination of additional cases and the elucidation of the
causative gene defect are required to delineate the phenotypic variability 
of SPS. 
Diagnostic radiographic characteristics of SPS have already been mentioned 
by Kozlowski and Nelson.6 Here, a review of the clinical and radiological 
features of the cases with SPS shows that all the radiological examined cases
have patella aplasia/hypoplasia as well as pelvis anomalies table 1. Based on these
findings we propose aplasia/hypoplasia of the patellae and absent/delayed/
irregular ossification of the ischiopubic junctions or infra-acetabular axe cut
notches as minimal criteria for the diagnosis of SPS. In only one child could
pelvis anomalies not be excluded because she was too young at the time of 
radiological pelvis examination.15 Additional major signs comprise an increased
space between the first and second toes and short fourth and fifth rays of the
feet accompanied by flat feet. Various other skeletal anomalies have been
described but do not contribute to the diagnosis.
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This syndrome should be differentiated from disorders with a/hypoplastic
patellae, including NPS and isolated familial PTLAH. In NPS, patella
aplasia/hypoplasia is associated with nail anomalies, deformation or luxation 
of the head of the radius resulting in impaired mobility of the elbow, iliac horns
and, frequently, nephropathy. Nail aplasia/hypoplasia/dysplasia and absent or
hypoplastic patellae are essential features for the diagnosis. Posterior iliac
horns are pathognomonic for NPS, but reported to be present in only 70% of
cases. Various other skeletal anomalies, including pes equinovarus, dislocated
hips, and contractures of major joints have been described in NPS but do not
contribute to the diagnosis. This skeletal dysplasia results from mutations 
in the LMX1B gene.11 In patients with PTLAH, patella aplasia/hypoplasia is an
isolated anomaly without additional radiological or clinical features. Pelvis
anomalies, including anomalies of the ischiopubic joint or infra-acetabular
notches have never been mentioned in PTLAH.10,17-19 Radiological examination
of the pelvis and feet should be performed in all patients with aplasia/hypoplasia
of the patellae in order to differentiate SPS from PTLAH, and to further evaluate
the diagnostic value of pelvis and feet anomalies in SPS.
In conclusion, given the clinical overlap between SPS, PTLAH, and NPS we
hypothesised that SPS might be allelic to either of these disorders, which map
to the chromosomal regions 17q21-22 and 9q34, respectively. Linkage studies
excluded allelism with NPS in two of the present families that were available for
molecular analysis. Allelism with PTLAH cannot be excluded in our families at
the moment. Further linkage studies in other families with SPS are needed 
to confirm linkage to chromosome 17q21-22 and to examine whether SPS is
genetically homogeneous. In view of the small size of most families, only the
elucidation of the genetic defect will provide the final answer for allelism of 
SPS and PTLAH. 
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Abstract
Small patella syndrome (SPS) is an autosomal dominant skeletal dysplasia 
characterised by patella aplasia or hypoplasia and by anomalies of the pelvis 
and feet, including disrupted ossification of the ischia and inferior pubic rami.
We identified an SPS critical region of 5.6 cM on chromosome 17q22 by 
haplotype analysis. Putative loss-of-function mutations were found in a 
positional gene encoding T-box protein 4 (TBX4) in six families with SPS. 
TBX4 encodes a transcription factor with a strongly conserved DNA-binding 
T-box domain that is known to play a crucial role in lower limb development in
chickens and mice. The present identification of heterozygous TBX4 mutations
in SPS patients, together with the similar skeletal phenotype of animals lacking
Tbx4, establish the importance of TBX4 in the developmental pathways of the
lower limbs and pelvis in humans.
Small patella syndrome (SPS; MIM 147891), also referred to as “Scott-Taor 
syndrome”, “ischio-pubic-patellar syndrome”, “coxo-podo patellar syndrome”,
or “ischiopatellar dysplasia”, is a rare autosomal dominant disorder affecting
skeletal structures of the lower limb and the pelvis.1-5 Essential features for the
clinical diagnosis of SPS are patella aplasia or hypoplasia, associated with
absent, delayed, or irregular ossification of the ischiopubic junctions and/
or infra-acetabular axe cut notches figures 1a-c.6 In addition, femur and foot 
anomalies - including a wide space between the first and second toes, short
fourth and fifth rays of the feet figure 1d, and pes planus - may accompany SPS.
Craniofacial dysmorphisms have been described in reports of four sporadic
individuals with SPS and one familial case of SPS including micrognathia
and/or cleft palate.6-10 Offiah et al. (2002)11 proposed that “ischio-pubic-patellar
syndrome” and SPS should be distinguished clinically, because the former 
condition presents with a more severe skeletal phenotype and facial features
that are not seen in SPS. SPS is clearly clinically different from autosomal 
dominant familial patella aplasia hypoplasia (PTLAH; MIM 168860).12,13 In
PTLAH, congenital aplasia or hypoplasia of the patellae are the only clinical 
features. PTLAH is genetically heterogeneous with one locus mapped to an ∼12-cM
region on chromosome 17q22.13,14 Elsewhere, we found possible linkage of SPS
with this PTLAH locus on chromosome 17q22 in two SPS families, suggesting
that one single gene may be involved in both disorders families A and B in figures 2 and 3a.6
Recently, patella and pelvis anomalies similar to those of SPS and facial features
as micrognathia/retrognathia and high or cleft palate were recognised in indi-
viduals with surviving campomelic dysplasia (MIM 114290) caused by mutations
in the SOX9 gene, located at chromosome 17q24.3.15 Here, we demonstrate that
mutations in the TBX4 gene underlie SPS.
After informed consent and approval were obtained from the human research
ethics committee of the corresponding institutions, blood samples were
obtained from two sporadic Swiss patients (families E and G)16, figure 2 (Pedigree G
not shown); from 15 patients who were part of five families with SPS, comprising
two Dutch families reported elsewhere (families A and B),6 one newly identified
Dutch family (family C), one Belgian family (family D),6 and one Czech family
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(family F);2 and from unaffected family members (figure 2 [family G not shown]).
The proband of the newly identified Dutch family pedigree C in figure 2, aged 29 years
at the time of examination, was referred because of dislocation of the patellae
and familial occurrence of knee complaints. At physical examination, small
patellae, an increased space between the first and second toes, and short fourth
and fifth rays were found bilaterally. She had no facial dysmorphisms. Radio-
graphic examination of her knees confirmed patella hypoplasia, and radiographs
of the pelvis showed irregular ossification of the ischiopubic junction. Physical
figure 1
Characteristic features of the pelvis and the lower limb in individuals with SPS. (a) Radiograph of the pelvis of family A’s
proband at the age of 12 years and 11 months, showing bilaterally absent ossification of the ischiopubic junction
(unblackened arrows), infra-acetabular axe cut notches (blackened arrows), and elongated femoral necks. (b) Radiograph of
the pelvis of family C’s proband at age of 19 years and 7 months. Note that the irregular ossification of the ischiopubic
junction (unblackened arrows) and infra-acetabular axe cut notches (blackened arrows) are less severe, as compared to the
pelvis anomalies seen in the proband of family A. (c) Radiograph of the knee of family C’s proband at the age of 19 
years and 7 months, demonstrating a small patella. (d ) Feet of an affected male from family C at age 14 years and 8
months, showing short fourth and fifth rays and an increased space between the first and second toes. (Radiograph 
a is reproduced from the work of Bongers et al. (2001)6 with permission from the BMJ Publishing Group.)
a b
dc
134
and radiographic examination of her affected family members demonstrated
small patellae associated with pelvis and feet anomalies characteristic of SPS in
all cases figures 1b-d and 2. All patients included in this study had the classical SPS 
phenotype and fulfilled the essential diagnostic criteria for SPS, comprised of
patella and characteristic pelvis anomalies.6 The phenotype of the individuals
with SPS in this study ranged from small patellae, associated with irregular
ossification of the ischiopubic junctions and/or infra-acetabular axe cut notches, 
to absent patellae, severe pelvis and femur anomalies, and more obvious foot
anomalies. The skeletal findings varied both within and between SPS families,
except for one family (C), in which all affected individuals had patella hypoplasia
and only minor skeletal anomalies of the pelvis. A distinctive facial appearance,
including a high nasal bridge, micrognathia, and a high arched palate were
found in one female patient with SPS (family D).6 None of the other patients
showed facial dysmorphisms. Extensive clinical details and photographs of
families A, B, and D-G have been published elsewhere.2,6,16 Control DNA 
samples were obtained from 50 anonymous, unrelated Dutch individuals.
Genomic DNA was extracted from peripheral lymphocytes by use of standard
techniques.17
Previous studies in families A and B showed possible linkage of SPS with a
locus on chromosome 17q22 figure 3a.6 The SOX9 gene is located in this wider SPS
linkage interval (data not shown). To investigate whether SOX9 mutations could
figure 2
Pedigrees of six unrelated kindreds with SPS. Blackened symbols denote individuals with SPS, and unblackened 
symbols denote unaffected individuals. TBX4 mutation analysis was performed in all individuals indicated by an 
asterisk (*). The proband of the newly identified Dutch family is indicated by an arrow.
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* **
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be responsible for SPS, we first performed sequence analysis of the SOX9 gene
(exons 1-3). No pathogenic SOX9 aberrations were found in these two families
with SPS (data not shown; primers and PCR conditions are available on request).
Subsequently, two additional SPS families became available for molecular
investigations. We directed our study to show evidence for linkage of SPS with
the elsewhere reported candidate locus on chromosome 17q22, in a new family
(family C) and in a previously described family (family F).2 Manual genotyping
of microsatellite markers from chromosome 17q22 was performed as described
elsewhere.18 Haplotype analysis demonstrated linkage of SPS with the chromosome
17q22 disease locus in both families with SPS families C and F in figure 3a. We refined
the 18.8-cM candidate-gene interval to a critical region of 5.6 cM between
microsatellite marker D17S957, centromerically, and D17S1874, telomerically,
with a 2.2-cM overlap with the PTLAH candidate region figure 3a. The SOX9 gene 
is located 6 Mb distal from the telomeric flanking marker, D17S1874, of this
critical interval.
Inspection of genes in the SPS critical region revealed the TBX2 and TBX4
genes as positional candidates figures 3a and 3b. TBX2 and TBX4 belong to the T-box
gene family, encoding transcription factors characterised by a strongly conserved
DNA-binding motif (T-box domain).19 Tbx2 is involved in forelimb and
hindlimb development and in the specification of posterior digit identity in
chickens.20,21 Studies in mice and chickens have revealed a crucial role for Tbx4
figure 3
Summary of the linkage analysis and identification of positional candidate genes. (a) Linkage analysis of four families
with SPS and one family with PTLAH. Microsatellite markers (below the line) span an interval of 24.8 cM at chromosome
17q22. The SPS critical region (D17S957 and D17S1874) is boxed. Linkage analysis of families A and B and the clinical
phenotype of family A, B, and F were described elsewhere.2,6 Previous linkage studies revealed a PTLAH candidate
region at chromosome 17q22.13 (b) Localisation and schematic genomic structure of candidate genes TBX2 and TBX4
(not drawn to scale) (UCSC Genome Bioinformatics). 
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figure 4
Molecular analysis of TBX4. (a) Distribution of TBX4 gene mutations identified by sequencing. Exon boundaries are
identified by arrowheads and dotted lines, and the DNA-binding motif (T-box domain) is coloured red. (b) Sequence
homology analysis of amino acids 248 and 531 and flanking residues. The strongly conserved amino acids of the T-box
domain and the C-terminal domain are indicated in red and green colours, respectively. The amino acids that directly
contact the DNA are depicted in blue. Glycine 248 and glutamine 531 (amino acids underlined with an arrow) are strongly
conserved. (c) Segregation of G248V mutation in SPS pedigree A.6 The mutations are present in affected individuals
(blackened symbols, G248V) and absent in their healthy siblings (unblackened symbols, +/+). Haplotypes are defined by
markers D17S1604, D17S948, and D17S1874 and are encoded by numbers. Blackened bars indicate the risk allele. 
Note from the mutation and haplotype analysis that the mutation has occurred de novo in the germline of one of
the grandparents. (d ) Segregation of exon 7 skipping in SPS pedigree F2 detected by RT-PCR analysis of the fragment
encompassing exons 5-8 of the TBX4 coding region, showing an aberrant sized transcript of 172 bp in the affected 
individuals on agarose gel. The RT-PCR experiment was performed in all individuals indicated by an asterisk (*).
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in the development of the lower limbs.22-24 In chickens, it has been shown that
misexpression of dominant-negative Tbx4 results in legless phenotypes and in a
deformed and hypoplastic pelvis, including absent pubis.24 In Tbx4-/- mice, the
initial patterning of the hindlimb bud appears normal, but further hindlimb
development and outgrowth does not occur.23 These Tbx4 animal models clearly
resemble the phenotype of individuals with SPS. On the basis of these findings,
we hypothesised that mutations in the human homologue of Tbx4 result in SPS.
We sequenced TBX4 (exons 1-8) in the four families mapping to 17q22, in one
familial case, and in the two unrelated sporadic individuals with SPS (primers
and PCR conditions are available on request). We identified six different 
heterozygous mutations in the TBX4 gene in five families and in one sporadic
individual with SPS figures 4a and 4d. These include one nonsense, two missense,
one frameshift, and one splice-site mutation and the skipping of exon 7 of the
TBX4 gene; all of these mutations were absent in 100 control chromosomes. 
In family A, a G→T transversion at nucleotide 743 that predicts a G248V substi-
tution in the T-box domain was found figure 4a. Glycine 248 is evolutionarily
strongly conserved among the T-box genes of many species figure 4b. A structural
model of the T-box predicts that substitution of the small glycine 248 by a valine
will create steric hindrance that impairs DNA binding by the neighbouring
lysine 247 figure 5. The G248V mutation is also present in the affected son but not
in any of the healthy relatives figure 4c. Haplotype analysis revealed that G248V is a
de novo mutation pedigree A in figure 4c, which is compelling evidence for the G248V
mutation being causative for SPS in this family. In family B, a C→T transition 
at nucleotide 184 was found. This mutation is predicted to result in premature
termination of the protein (Q62X) with abolition of the T-box domain figure 4a.
This mutation occurred de novo in the germline of one of the healthy grand-
parents and cosegregates with the disease in the affected offspring. In one 
new family with SPS, a 1592A→G transition in exon 8 that predicts a missense
mutation (Q531R), which cosegregates with the disease, was identified family C in
figure 4a. Glutamine 531 is strictly conserved between T-box genes of various
species figure 4b, strongly suggesting its causative role in the disease. In a familial
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case with SPS, an insertion-deletion (Indel) consisting of an deletion of an 18-nt
deletion (13 nt from intron 2 and 5 nt from exon 3) and an AGC triplet insertion
was found at the 3’ splice site of intron 2 family D in figure 4a. Finally, one of the two
sporadic individuals with SPS carried an insertion 1112_1113C in intron 8, which
is predicted to result in a truncated protein lacking 75 amino acids family E in figure 4.
Seven different polymorphisms were identified in seven SPS kindreds and 
100 control chromosomes table 1. These sequence variants were considered non-
pathogenic for SPS, since they were identified in both affected and unaffected
individuals from multiple families, in 100 control individuals, and in addition 
to clear pathogenic mutations in SPS patients. Moreover, some of the sequence
variants are within introns or result in synonymous substitutions. In family F, in
which SPS is linked to chromosome 17q22 figure 3a, and in one sporadic indivi-
dual with SPS (a member of family G), sequence analysis of the TBX4 exons and
intron-exon boundaries did not reveal any pathogenic mutation. The possibility
of a causative deletion of the entire TBX4 gene was excluded in family F by the
identification of heterozygous polymorphisms within this gene table 1. To identify
small deletions or alternatively spliced exons, we performed an RT-PCR of TBX4
in families F and G. Total RNA was prepared from EBV-transformed lympho-
blastoid cell lines of families F and G by use of the Rneasy Midi kit (Qiagen)
according to the manufacturers’ conditions. In the examined affected individuals
of family F, RT-PCR analysis of the fragment encompassing the coding
sequences of exons 5-8 showed an aberrantly sized fragment of 172 bp, which
figure 5
Protein model of the T-box domain of TBX4, created with the help of the modelling methods described by Chinea et al.
(1995)33 and the resolved structure of TBX3 as template34. The T-box domains of TBX3 and TBX4 show a high degree of
homology (80%) and identity (64%), which ensures a faithful prediction of the TBX4 structure. The 310 helical axis of the
T-box domains of TBX3 and TBX4 are 100% identical. The residues of the DNA is represented as a purple stick model.
Protein is shown as a ribbon model with red strands, blue helices, and green/turquoise turns and loops. The protein-
DNA complex is viewed along the T-box. (a) A T-box dimer binding to a DNA consensus sequence. Residue G248 (yellow)
is located in the C-terminal 310 helix that interacts with the DNA in the minor groove. (b) View along the 310 helical axis
of the T-box domain. The G248V mutation leads to the introduction of a hydrophobic side chain (yellow atoms in ball dis-
play) that is normally absent. This likely displaces water molecules that stabilise the protein-DNA interaction through 
hydrogen bonding. Therefore, the G248V mutation is predicted to destabilise the TBX4-DNA interaction. Other 
highlighted amino acids include F245, K247, and F249 (stick representations).
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was absent in the unaffected members of this family F figure 4d. Sequencing of the
latter fragment demonstrated skipping of exon 7, resulting in the absence of
230 nt. This leads to a shift in the reading frame that is predicted to create a
truncated protein of 307 amino acids, of which the 44 C-terminal residues are
generated from the incorrect reading frame. It is possible that a small deletion
encompassing exon 7 is responsible for this abnormal TBX4 transcript, as
sequencing of genomic DNA showed no mutations in the splice sites and
introns flanking exon 7. Alternatively, disruption of splice-enhancer sequences,
buried further into an intron of the TBX4 gene, could be causative for the exon 7
skipping. In the sporadic individual in which no mutation was identified, muta-
tions in regulatory elements, introns, alternatively spliced exons, or small 
deletions (exons 1-4) within TBX4 may underlie SPS. A more tempting explana-
tion is that mutations in the positional candidate gene TBX2 may be responsible
for the SPS phenotype, as TBX2 expression seems to be partly regulated by
TBX4.23 However, TBX2 sequence analysis revealed no pathogenic mutations 
in family G (primers and PCR conditions are available on request). 
The precise pathogenic mechanism by which TBX4 mutations cause 
dominant SPS remains to be elucidated. Haploinsufficiency appears to be
responsible for dominantly inherited SPS in at least some of the families. It 
Presence of change 
DNA changea Predicted effect Location SPS familyb Control chromosomesc
Likely pathogenic mutations:
184C→T Q62X Exon 1 B
IVS2-13_285del18insAGC Abnormal splicing Intron 2, Exon3 D
743G→T G248V Exon 6 A
Not detectedd Skipping exon 7 Exon 7 F
1112_1113insC Frameshift Exon 8 E
1592A→G Q531R Exon 8 C
Likely nonpathogenic polymorphisms:
17G→C G6A Exon 1 A, E, F +
104C→T A35V Exon 1 +
276T→G A92A Exon 2 A, E, F
IVS3-8G→A None Intron 4 D
IVS6-18T→C None Intron 7 E
1224C→T D408D Exon 8 +
1446C→T V482V Exon 8 A, B, D, F +
table 1
Sequence anomalies and small deletions found in the TBX4 gene in SPS families and control chromosomes
a Nucleotide positions are based on GenBank sequence (accession number AF188703).
b No mutation had been identified in family G.
c A plus sign (+) indicates that the polymorphism was found in the control chromosomes.
d The genomic basis of exon 7 skipping remains undefined because the splice sites and intronic sequences flanking
exon 7 were normal.
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is highly likely that the Q62X and the Indel mutation will create null alleles.
Furthermore, protein modelling predicts that the G248V mutation partially or
completely disrupts DNA binding activity. Mice embryos homozygous for the
Tbx4 null allele die because of failure of chorioallantoic fusion, whereas hetero-
zygous mutants appear to have a normal phenotype.23 The observation that the
human heterozygous phenotype resembles the phenotype of Tbx4-/- mice may
reflect differences in dosage sensitivity for this gene in the two species. On the
other hand, dominant-negative effects for some of the other TBX4 mutations
cannot be excluded. 
The identification of TBX4 mutations and exclusion of SOX9 mutations in 
the present SPS families indicate that SPS and surviving campomelic dysplasia
are genetically heterogeneous disorders. We found that TBX4 mutations
account for both an SPS familial case with a distinctive facial appearance and SPS
families without facial features. The sporadic reports on minor facial features in
individuals with skeletal features of SPS do not allow any conclusions on the
previous suggestion that “ischio-pubic-patellar syndrome” and SPS are clinical-
ly heterogeneous disorders.11 Intrafamilial variability of patellar, pelvis, and foot
anomalies was found in all SPS families investigated in this study. At present,
evidence for a genotype-phenotype correlation is lacking. Molecular analysis 
of additional individuals with SPS will facilitate further delineation of the pheno-
typic spectrum of SPS and will finally contribute to the question as to whether
craniofacial anomalies are part of the syndrome. 
Our studies render a role for TBX4 in PTLAH highly unlikely. First, the TBX4
gene is located outside the PTLAH critical region: D17S1838 is >80 kb proximal
to TBX4. Second, we could not identify a causative TBX4 mutation in one
PTLAH family (data not shown). However, disruption of long-range TBX4 regu-
latory elements in PTLAH cannot be formally excluded as yet, and we have to
keep in mind that PTLAH is genetically heterogeneous.14
Mutations in several T-box genes are associated with human developmental
disorders, including TBX1 with DiGeorge syndrome, TBX22 with isolated cleft
palate, TBX3 with ulnar-mammary syndrome (UMS; MIM 181450), and TBX5
with Holt-Oram syndrome (HOS; MIM 142900).25-27 In both UMS and HOS,
mutated TBX genes cause disrupted upper limb development.28,29 Critical stage-
dependent roles of Tbx4 in lower-limb initiation and outgrowth were shown by
misexpression studies of dominant-negative Tbx4 in chickens. A legless pheno-
type was seen after early disruption of development, and truncated legs and
hypomorphic distal structures were seen during Tbx4 misexpression at later
developmental stages.24 Pelvis anomalies were also observed upon late misex-
pression of Tbx4. The SPS phenotype suggests that human TBX4 mutations do
not affect early steps in limb development, such as limb-bud initiation, but do
have a profound effect at later stages. The late effect of TBX4 mutations is 
manifested by patella aplasia/hypoplasia and anomalies of the posterior 
structures of the foot, such as short fourth and fifth rays. Completion of
ischiopubic formation is another very late process in human development that
is disrupted in individuals with SPS. The type and location of TBX4 mutations
reported here is comparable to those of heterozygous mutations in TBX3 and
TBX5, found in UMS and HOS, respectively. UMS and HOS are characterised 
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by severe upper limb anomalies, including phocomelia, as well as several other
developmental defects. The relative mild limb phenotype and the absence of
other developmental anomalies in SPS suggest a higher degree of redundancy
for TBX4 in comparison to TBX3 and TBX5. 
Our data provide the first evidence for a crucial role of human TBX4 in 
the skeletal development of the patella, pelvis, and feet. Genes underlying 
syndromes characterised by patella aplasia or hypoplasia appear to be involved
in a common regulatory pathway of the patterning of dorsal structures of the
lower limb. Heterozygous mutations in the LIM-homeodomain transcription
factor LMX1B are responsible for nail-patella syndrome (MIM 161200). LMX1B
cooperates with specific downstream PTX genes.30,31 Pitx1, in turn, encodes a
transcription factor that acts upstream of Tbx4 in hindlimb development.32
Mutations in two genes from this signaling cascade, LMX1B and TBX4, lead to
abnormal patella formation. Therefore, it is very possible that other genetic 
disorders with patellar anomalies, such as PTLAH and Meier-Gorlin syndrome
(also named “ear, patella, short stature syndrome”; MIM 224690) are caused 
by a molecular defect in the same PTX/TBX signalling cascade.23,24
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Congenital patella aplasia or hypoplasia (PTLAH; MIM 168860) without associated
clinical or radiological anomalies is a very rare autosomal dominant disorder
which has been reported in one sporadic case1 and four families in the litera-
ture.2-5 Isolated PTLAH should be differentiated from small patella syndrome,6
Meier-Gorlin syndrome,7 and nail patella syndrome (NPS),8 in which patella
aplasia/hypoplasia as an essential feature is accompanied by other characteristics.
The latter bone dysplasia is caused by mutations in the LMX1B gene located on
chromosome 9q34.8 A gene for PTLAH has been localised to chromosome
17q21-22 in a large family with four affected generations.5 Here, we report on
three patients from a three-generation family with isolated PTLAH in which
linkage with chromosome 9q34 and chromosome 17q21-22 was excluded.
These findings suggest that familial isolated PTLAH is a genetically hetero-
geneous disorder. 
The proband (III.I), aged 28 years at the time of examination, was referred
because of bilateral small patellae. She is the first child of nonconsanguineous
English parents. She complained of instability and dislocation of the patellae
since the age of seven years. Surgery for patella dislocation was performed at
the age of 13 and 14 years. At physical examination, no anomalies of the height,
ears, nails, elbow mobility, or foot were found. Hypoplasia of the patellae was
confirmed by radiographs of the knees. Radiographs of the pelvis showed no
iliac horns and no absent/irregular ossification of the ischiopubic junction or
infra-acetabular axe cut notches, which are characteristic for NPS and small
patella syndrome, respectively. Furthermore, radiological examination of the
foot showed no short fourth and fifth rays, and no tarsal anomalies associated
with small patella syndrome. Her father and paternal grandmother were known
to have similar complaints of the knees since childhood. All the family members
included in the linkage studies have been examined clinically for patella
aplasia/hypoplasia. Patellar anomalies were only observed in the proband,
father, and paternal grandmother at physical examination. No other clinical 
features of NPS, such as nail dysplasia or impaired elbow mobility, were found
in the affected and unaffected family members. Unfortunately, no permission
for radiographic studies was obtained from them. The proband and her father
both have PTLAH and hereditary motor and sensory neuropathy type 1A
(HMSN1A), due to peripheral myelin protein 22 gene (PMP22) duplication 
on chromosome 17p11.2.9 The paternal grandmother of the proband had no
clinical characteristics of HMSN1A, which was confirmed by a normal PMP22
status, and other family members with HMSN1A have no PTLAH. Therefore,
HMSN1A is not co-segregating with PTLAH in this family.
Informed consent for molecular genetic investigation was obtained from three
affected and three unaffected family members. Genomic DNA from peripheral
blood lymphocytes was used for manual genotyping of microsatellite markers
on chromosome 9q34 and chromosome 17q21-22. The NPS gene has been mapped
within a 1-2 cM interval between D9S60 and the adenylate kinase 1 gene (AK1) on
chromosome 9q3410 and a PTLAH gene has been localised within a 12-cM inter-
val on chromosome 17q21-22, most likely between D17S787 and D17S1604.5
In the present family, no evidence was found for linkage with chromosome
9q34 and chromosome 17q21-22, excluding allelism with NPS and isolated
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PTLAH caused by a locus on chromosome 17q21-22,5 respectively figure 1.
Exclusion of linkage with the candidate region on chromosome 17q21-22 
provides evidence that PTLAH is a genetically heterogeneous disorder. Further
linkage studies in additional families are needed to identify the other locus or
loci in isolated PTLAH.
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Abstract
The Meier-Gorlin syndrome or “ear, patella, short stature syndrome” (MIM
224690) is a rare autosomal recessive disorder, characterised by the association
of bilateral microtia, aplasia/hypoplasia of the patellae, and severe pre- and
postnatal growth retardation. Twenty-one cases have been reported in literature
thus far. Here we report on eight patients from seven families and compare
them with previously described cases. One of the present cases had previously
undescribed genital anomalies. There is a difference in facial characteristics
between patients reported in early infancy and those described at older age; 
follow-up of patients is needed to substantiate this changing facial phenotype.
We recommend radiographic survey of the patellae in patients at older age to
investigate the weight of absent or hypoplastic patellae in the diagnosis of the
syndrome.
Introduction
In 1959, Meier et al.1 described a patient with microtia, micrognathia, arthrogry-
posis of the joints of the lower limbs, absent patellae, and cryptorchidism.
Subsequently, Gorlin et al. (1975)2,3 presented a patient with similar symptoms
accompanied by short stature. After these two initial case reports, 19 additional
cases with the triad of bilateral small ears, aplasia/hypoplasia of the patellae,
and short stature were reported in the literature.4-13 In 1991, Cohen et al.5 pro-
posed this syndrome to be termed the “ear, patella, short stature syndrome”.
Boles et al. (1994)6 suggested the eponym Meier-Gorlin syndrome (MGS).
Additional clinical findings include anomalies of cranial sutures, microcephaly,
apparently low set and simple ears, microstomia, full lips, highly arched or cleft
palate, micrognathia, genitourinary tract anomalies, and various skeletal ano-
malies. The most serious aspects of MGS are feeding and respiratory problems
in early infancy, especially in the neonatal period. 
MGS is inherited as an autosomal recessive trait based on the occurrence of
this syndrome in five sib pairs, equal numbers of affected males and females,
and parental consanguinity reported in three cases. 
Here, we describe six female and two male patients from seven families,
compare their clinical findings with those of previously reported patients, and
postulate a change in facial appearance with age.
Clinical reports
Patient 1
This female patient is the second child of healthy nonconsanguineous English
parents. Her parents and her brother have normal height. Delivery was at 34
weeks of gestation by elective caesarean section because of intrauterine growth
retardation. Birth weight was 1,060 g (below the third centile). Initially she had
respiratory distress syndrome. At 2 months, she was referred because of poor
weight gain and abnormal appearance, including bilateral microtia, alternating
strabismus, slightly deep-set eyes, long eyelashes, microstomia, full lips, and
micrognathia figure 1. Physical examination showed hypermobility of the major
joints and absence of the patellae. A skeletal survey, cranial ultrasonography,
blood chromosome analysis, endocrinological examinations, and brainstem
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auditory evoked responses all gave normal results. At 4 years and 5 months of
age, short stature had become more obvious (weight 6.5 kg, height 78 cm, head
circumference 38 cm [all below the third centile]). At that age, an ultrasound
scan of knees confirmed absent patellae, and a complete skeletal survey showed
slender long bones, slender ribs, and metaphyseal abnormalities of the humeri.
Bone age was 18 months at a chronological age of 34 months. Psychomotor
development has been satisfactory apart from some delay in speech development.
Patient 2
This male patient is the third child of healthy Turkish parents. The parents are
not known to be consanguineous, but originate from the same small village.
His parents and sibs have normal height. Pregnancy was complicated by
intrauterine growth retardation and breech position. Birth was at 382/7 gesta-
tional weeks. Birth weight was 1,900 g, length 40 cm, and head circumference
30.5 cm (all below the third centile). He had severe respiratory and feeding
problems during infancy, with an extremely poor weight gain. Despite extensive
examinations, the cause of the respiratory and poor weight gain remained
uncertain. From the second week of life he had recurrent infections of the uri-
nary tract. External genitalia showed a shawl scrotum. Urologic examination
showed hypoplasia of the corpora cavernosa and hypoplasia of the medial 
segment of the urethra, the latter necessitating vesicotomy. Ultrasonography
showed thickening of the urinary bladder wall, but no hydronephrosis was
found. At 17 weeks, he was referred because of multiple physical anomalies.
figure 1
(a) Frontal view of patient 1 at 4 years and 7 months showing full lips, microstomia, and micrognathia. (b) Lateral view at
2 years and 2 months illustrating micrognathia and microtia.
a b
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Frontal bossing, small anterior fontanel, long eyelashes, short palpebral 
fissures, small mouth, full lips, micrognathia, bilateral very small and simple
ears, and bilateral small external auditory canals were noted figure 2. The skin 
was thin and prominent veins were visible over the nose and forehead. He 
had small hands, partial cutaneous syndactyly of the second and third toes, 
and limited extension of the knees, whereas other joints showed hypermobility.
Ultrasonography and radiography confirmed the absence of the patellae noticed
on physical examination. A skeletal survey performed at the age of 1 year and 7
months showed slender long bones and ribs, absence of the left twelfth rib, 
and absence of ossification centres of the epiphyses of the distal humeri, the
proximal and distal radius, and the proximal ulna. Furthermore, flattening and
widening of the distal femora and proximal tibiae, small epiphyses of the distal
femora, absence of the ossification centre of the epiphysis of the right proximal
tibia, small epiphysis of the left proximal tibia figure 3, and a bone age of less 
than 3 months at the age of 1 year and 7 months were found. Audiometric
examinations showed normal binaural hearing levels. Motor milestones 
were mildly delayed. He is very alert and has a happy personality. Cytogenetic
analysis showed a normal 46,XY karyotype. 
figure 2
(a) Patient 2 at 4 months. Frontal view showing full lips, microstomia, micrognathia, and prominent veins over the nose.
(b) Lateral view illustrating small and simple folded ears.
a b
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Patient 3
This male patient is the first child of healthy
nonconsanguineous Gypsy parents from France.
His parents and brother have normal height. 
The pregnancy of their third male child was 
terminated at 14 weeks of gestation because of
an occipital meningocele. The child was born at
term after a pregnancy complicated by intrauterine
growth retardation. Weight at birth was 2,260 g,
length 42.5 cm, and head circumference 31 cm
(all below the third centile). Bilateral microtia, 
a small triangular face, and a submucous cleft
palate were immediately noted. He had gastro-
oesophageal reflux and feeding problems in the
first year of life. At the age of 4 years, height was
88.5 cm, weight was 9.1 kg, and head circum-
ference was 47 cm (all below the third centile).
Additional craniofacial anomalies included a
prominent metopic suture, long philtrum, full
lips, small teeth, micrognathia, bilateral absent
helices, hypoplastic lobules, and small external
ear canals figure 4. Computed tomography scan of
the inner ear showed a normal structure. He had
a micropenis and cryptorchidism. The limbs
showed convex nails of the thumbs, clinodactyly
of the fifth fingers and fifth toes, and hypermo-
bility of the fingers, elbows, shoulders, and
knees. The absence of the patellae was confirmed
by radiographic and ultrasound examination. 
A skeletal survey showed hypoplastic and irregu-
lar epiphyses of the femora and tibiae, elbow 
dislocation, and a bone age of 25 years at a
chronological age of 44 years. Psychomotor
development was slightly retarded. Cytogenetic
analysis showed a normal 46,XY karyotype.
Patient 4
This female patient is the first child of healthy
nonconsanguineous Dutch parents. Her parents have normal height. She was
born at 39 weeks of gestation by normal delivery after an uneventful pregnancy.
Weight at birth was 2,544 g (below the third centile). During the neonatal period,
she had severe feeding and respiratory problems. At 11 months, her weight was
5,520 g and her height was 64 cm (both below the third centile). On physical
examination, a small anterior fontanel, full lips, mandibular hypoplasia, bilateral
malformed small and apparently low-set external ears, and very small auditory
canals were noted figure 5. The external genitalia showed small and hypoplastic
labia minora but no clitoromegaly. Other manifestations included convex nails,
figure 3
Radiograph of the lower limbs of patient 2 at 1 year 
and 7 months showing small epiphyses of the distal 
femora, flattening and widening of the distal femora
and proximal tibiae, absence of the ossification centre 
of the epiphysis of the right proximal tibia, small 
epiphyses of the left proximal tibia, slender long 
bones, and asymmetric delayed skeletal maturation.
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clinodactyly of the fifth toes, and hypermobility of the knees and elbows, but no
radiologic anomalies of the radial heads were found. A skeletal survey displayed
slender long bones and hook-shaped clavicles. Bone age was 15 years at a
chronological age of 2 years and 2 months. The patellae were absent by palpa-
tion and on ultrasonography. Psychomotor development was slightly delayed.
Cytogenetic analysis showed a normal 46,XX karyotype.
Patient 5 and 6
These female patients are monozygotic twins of healthy consanguineous
American parents of Acadian/French Creole ancestry. Their parents have normal
height. An ultrasound study revealed small-for-gestational-age twins at 8 weeks
of gestation. Delivery was at 38 weeks of gestation by elective acesarean section
because of intrauterine growth retardation and a velamentuous cord insertion
of twin B. The placenta was monochorionic/diamniotic. Genotyping for zygosity
confirmed the monozygotic nature of the twinning. Weight at birth of twin A
was 412 g, length was 43 cm, and head circumference was 30.5 cm (all below
the third centile). The birth weight of twin B was 450 g and length was 43 cm
(both below the third centile). Head circumference of twin B at birth is
unknown, but she was known to have microcephaly. During the first 4 and 6
months, respectively, both twins had apnoea. Gastroesophageal reflux was
diagnosed at 10 weeks and disappeared by 9 months in twin B.
Endocrinological examination of both patients showed normal results at the
age of 4 months. Growth hormone therapy was started in both twins at the age
of 18 months and 24 months, respectively, and resulted in a slight improvement
figure 4
(a) Facial appearance of patient 3 at 44 years. Note the full lips and micrognathia on the frontal view. (b) Lateral view
showing micrognathia and microtia. 
a b
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of growth in twin B. Magnetic resonance imaging of 
the brain showed a small anterior lobe of the pituitary
gland. At the age of 54 years, the height of twin A and
B was 94 and 94.5 cm, respectively (both below third
centile), weight was 11.3 and 11.4 kg, respectively (both
below the third centile), and head circumference was
48.1 and 47 cm, respectively (both on the third centile).
On physical examination at the same age, dolicho-
cephaly, mild micrognathia, a flat philtrum with a small
mouth, slight hypoplasia of the alae of the nose, and
microtia was found in both girls figure 6. They had 
simple ears and the external auditory meatuses were 
relatively small. In both patients, the clitoris appeared
prominent, probably because of the mild hypoplasia 
of the labia majora. They had a distal interphalangeal
camptodactyly of the second, third and fourth fingers,
and on the fifth fingers there was proximal interpha-
langeal camptodactyly. Joints were hyperextensible,
especially elbows and knees. The patellae were present
and appeared to be of normal size. Radiographs
demonstrated a left hemivertebra at L3 resulting in a
mild lower thoracolumbar right concave 
scoliosis in twin B. Psychomotor development was 
normal. They had a high-pitched voice with articulate speech and alert and
happy personalities. Cytogenetic analysis showed a normal 46,XX karyotype in
both patients. Uniparental disomy for chromosomes 2, 7, or 16 was excluded. 
Patient 7
This female patient is the first child of nonconsanguineous American parents.
Both parents are healthy except for asthma and allergies. The height of the
father is 2.11 m (above 97th centile). The mother and younger sister have normal
height. She was born at term by normal delivery after an uneventful pregnancy.
Birth weight was 1,472 g (below the third centile). She was hospitalised for 6
weeks for weight gain requiring initial nasogastric feedings. Since then she has
been healthy except for frequent ear infections. At the age of 8 years, she had
bilateral strabismus surgery. Laboratory investigations showed no abnormalities
at the age of 9 years (somatomedin C 169 ng/dl, exercise growth hormone level
1.5 ng/dl). At the age of 10 years, her height was 109 cm, weight 13.5 kg, and
head circumference was 48 cm (all below third centile). On physical examination
at the same age, a prominent forehead, downslant of palpebral fissures, a slight
beaked nose, highly arched and narrow palate, crowded teeth, micrognathia,
and bilateral microtia was found. Furthermore, she had widely spaced nipples,
short fifth fingers, campodactyly of the fifth fingers and the left second finger,
and bilateral femoral anteversion. A skeletal survey at the age of 10 years and 6
months confirmed the latter anomalies and showed severe hypoplasia of the
middle phalanges of the fifth fingers with generally short middle phalanges and
disproportionately long and slender distal phalanges, cone-shaped epiphysis 
figure 5
Facial appearance of patient 4 at 11 months 
showing microstomia and full lips. 
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of the middle phalanges of the second fingers, and fusion of the right lunate
triquetrum. On radiographic examination of the knees, the patellae were not
ossified, but probably present. Furthermore, she had grossly abnormal, flat, 
laterally tilted epiphyses of the tibiae, almost bipartite epiphyses of the distal
tibiae, generally overtubulated long bones, relatively small vertebrae, and 
hook-shaped clavicles. Bone age was 5 years 9 months to 6 years 10 months 
at a chronological age of 105 years. Psychomotor development was normal. 
Patient 8
This female patient is the first child of consanguineous American parents. 
The mother required special education. Both parents had normal height. The
patient was born at 38 weeks’ gestation. Birth weight was 2,495 g, length 48
cm, and head circumference 32 cm (all below the third centile). There were
feeding difficulties and severe gastroesophageal reflux necessitating gastrostomy
until the age of 3 years and 8 months. She had a low-volume, hoarse cry.
Furthermore, she had respiratory infections, diarrhoea, and weight loss at the
age of 4 months. Cranial and renal ultrasound showed no abnormalities. At the
age of 15 years a restrictive persistent ductus arteriosis with small left to right
shunt was surgically corrected. She had surgery for a scalp hamartoma with
meningothelial element at the age of 2 years and 3 months. Long bone osseous
survey showed a mild delay in skeletal maturation at the age of 11 months. At
the age of 5 years and 5 months, height was 95 cm, weight was 11.2 kg, and
head circumference was 46.5 cm (all below third centile). On physical examination
at the same age, she had shallow supraorbital ridges with sloping of the fore-
figure 6
Facial appearance of patients 5 and 6 at 5 years and 5 months.
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head, small external auditory canals bilaterally, long eyelashes, a beaked nose,
full lips, micrognathia, and microtia figure 7. The external genitalia showed
hypoplastic labia majora and hypoplastic praeputium clitoris, but no clitoromegaly.
The extremities showed bridged transverse palm creases bilaterally, adducted
thumbs at the metacarpal phalangeal joint, but fully extenuated otherwise, and
genu recurvatum. At the age of 5 years and 5 months, radiographs of the knees
showed no patellar ossification centres yet. A skeletal survey showed slender
long bones and slender ribs. Motor milestones were slightly delayed. According
to Denver II, there was no delay of personal-social, fine motor-adaptive, or 
language sectors. Speech was noted to show poor intelligibility, although 
not representing a delay. Cytogenetic analysis revealed a normal 46,XX karyotype.
Discussion
All of our patients share the triad of bilateral small ears, patella aplasia/
hypoplasia, and short stature consistent with the diagnosis of MGS, except 
for the monozygotic twins, who appeared to have normal patellae on physical
examination. The additional clinical findings in the present eight patients are
summarised in table 1 and compared with 21 previously described patients. 
Pre- and postnatal growth retardation is well recognised. Three adolescent
and four adult patients with MGS have been described.3,7,10,13 Although a catch-up
of growth during adolescence was seen in two siblings, their height was still
below the third percentile.10 The children have a small appetite and like a limited
range of foods. Growth hormone investigations, reported in 17 patients,
showed a broad range of subnormal, normal, and elevated levels. Therefore, it
is unlikely that short stature is only related to growth hormone deficiency in MGS. 
The facial appearance of our patients shows striking similarities to the facial
characteristics of the cases described by Hurst et al. [1988, case B],4 Boles et al.
[1994, case 1 and 2],6 and Buebel et al. [1996, case 1].8 Although Loeys et al.
(1999)11 recently proposed to have found two additional cases of MGS, we
believe that the facial features of the siblings they described are not very charac-
figure 7
Frontal and lateral view of patient 8 at 5 years.
a b c
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Previously Patient 1 Patient 2
reported patientsa
Sex M 9 M
F 12 F
Anthropometric Weigth <3rd centile 15/19 + +
data at birth Length <3rd centile 10/15 ? +
OFC <3rd centile 10/17 ? +
Short stature Proportionate 13/16 + +
Disproportionate 2/16 - -
Failure to thrive Early feeding problems 10/11 + +
Respiratory problems 7/9 - +
Craniofacial Early closure of sutures 8/15 - +
Microcephaly 12/14 + +
Microtia 21/21 + +
Low-set ears 6/7 + +
Abnormally formed ears 7/12 + +
Atretic/small external auditory canal  3/4 ? +
Small mouth 14/14 - +
Full lips 3/5 + +
Maxillary hypoplasia 6/8 - -
Mandibular hypoplasia 19/20 + +
High arched palate 7/10 ? +
Cleft palate 3/8 - -
Skeletal Absent patellae 11/16 + +
Hypoplastic patellae 3/16 - -
Delayed bone age 13/13 + +
Slender long bones 12/12 + +
Abnormal/flattened epiphyses 7/9 - +
Abnormal glenoid fossae 5/10 - -
Hook-shaped clavicles 5/10 - -
Gaps in ribs 2/8 - +
Narrow, short ribs 3/14 + -
Other thoracic abnormalities 11/14 - +
Dislocated radial heads 4/8 - -
Limbs Camptodactyly of hands 5/10 - -
Clinodactyly of fifth fingers 8/9 - -
Joint abnormalities 11/12 + +
table 1
Clinical findings of previously published patients1-8,10-13 and present patients with Meier-Gorlin syndrome 
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Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Frequencyb
M 38%
F F F F F 62%
+ + + + + - 81%
+ ? + + ? + 75%
+ ? + + ? + 68%
+ + + + + + 88%
- - - - - - 13%
+ + + + + + 95%
- + + + + + 76%
- + - - ? - 45%
+ + + + + + 91%
+ + + + + + 100%
? + - - + - 71%
+ + + + + - 74%
+ + + + + + 91%
- + + + + - 86%
+ + - - + + 69%
+ - - - - + 50%
+ + + + + + 96%
- - + + + - 65%
+ - - - - - 25%
+ + - - - - 63%
- - - - + + 21%
+ + + + + + 100%
+ + + + + + 100%
+ - + + + - 71%
- - + + - - 39%
- + + + + - 50%
? - - - - - 20%
? - - - - - 19%
? - - - - + 62%
- - - - - - 25%
- - + + + - 44%
- - - - - - 47%
+ + + + + + 95%
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teristic for the syndrome at young age. The typical facial characteristics noted in
early infancy, including micrognathia, microstomia, and full lips, differ from
the facial appearance in adolescence and adulthood: at older age, a high vertical
forehead, a narrow nose, and a high nasal bridge are the most prominent signs
[Lacombe et al., 1994, case 4 and 5; Fryns, 1998].7,10 We favour follow-up of
facial signs from birth to adulthood, to substantiate this possible changing 
phenotype, and to allow recognition of the entity at an older age. 
Skeletal anomalies are important manifestations of the syndrome, the most
common one being patella aplasia or hypoplasia table 1. Ultrasonography in early
infancy and adulthood, or radiographic survey of the patellae at an older age
should be performed to discriminate between genuine aplasia or delayed ossifi-
cation of the patellae. These investigations will also give clues as to whether
absent/hypoplastic patellae is indeed a distinct cardinal feature or only a 
manifestation of a more general skeletal development defect.
A summary of various other skeletal and limb anomalies is provided in table 1.
Thoracic defects include absent, hypoplastic, slender and short ribs; lack of
sternum ossification; pectus carinatum; and chest asymmetry. In some cases
brachydactyly, cutaneous syndactyly of the second and third, and/or fourth and
fifth toes were found. Joint anomalies vary from hypermobility to contractures
of major joints, elbow dislocation, talipes equinovarus, genu valgum and
varum, and coxa valga and vara.
Respiratory problems are most severe during the neonatal period and
improve with age. Of all of the previously described cases with respiratory 
problems, only two had thoracic anomalies, and thoracic abnormalities have
Previously Patient 1 Patient 2
reported patientsa
Genitourinary Cryptorchidism 6/6 N/A -
abnormalities Hypospadias 2/9 N/A -
Micropenis 1/10 N/A -
Hypoplasia of the corpora cavernosa - N/A +
Hypoplasia of the urethra - - +
Appearance of clitoromegaly 6/11 ? N/A
Hypoplastic labia majora/minora 2/10 ? N/A
Mammary glands Hypoplasia 3/12 T N/A
Skin, nails Prominent veins over nose and forehead 3/3 - +
Thin skin 3/3 ? +
Hyperconvex nails 5/8 ? -
Development Mental retardation 6/17 - -
Delayed motor milestones 5/17 - +
a References 1-8,10-13. 
b Total frequency of clinical findings of previously published patients 1-8,10-13 and present patients.
+, Present; -, absent; ?, not recorded; N/A, not available; T, too young to ascertain; OFC, occipital-frontal circumference.
table 1
Clinical findings of previously published patients1-8,10-13 and present patients with Meier-Gorlin syndrome 
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also been found in patients without respiratory problems [Lacombe et al., 1994,
case 3; Verhallen et al., 1999].7,12 In our series, two patients had severe respiratory
problems, one with thoracic anomalies. Therefore, the assumption that such
respiratory tract problems as dyspnoea are caused by thoracic deformity, which
both improve with age, is certainly not true for all cases.7
In one of our male cases, hypoplasia of the corpora cavernosa and the 
medial segment of the urethra have been found. These anomalies have not been
reported previously in MGS, and illustrate the wide spectrum of abnormalities
resulting from developmental defects of the genital tubercle and urogenital
sinus found in this syndrome. 
Intelligence is variable in MGS, ranging from normal in most cases to 
moderately retarded in a few patients table 1. Expressive language ability was 
significantly delayed for mental age in some cases and was found to be secon-
dary to hearing loss in only a minority [Cohen et al., 1991, case 1 and 2; Buebel
et al, 1996, case 1 and 2; Loeys et al., 1999; this article, cases 1 and 2].5,8,11 The
personality of these patients is often characterised as cheerful and friendly.
MGS should be differentiated from several well-known syndromes with 
proportionate short stature and small ears table 2. Disorders characterised by
aplasia/hypoplasia of the patellae accompanied by short stature are RAPADILI-
NO14 and Coffin Siris syndrome,15 but microtia has never been observed in these
syndromes. Aplasia/hypoplasia of the patellae in association with pelvis anomalies
are cardinal manifestations of the small patella syndrome,16,17 and nail patella
syndrome,18 the latter being accompanied by hypoplastic/dysplastic nails and
nephropathy. Nail anomalies and renal anomalies are absent in the MGS.
Aplasia/hypoplasia of the patellae without other skeletal anomalies has been
found in autosomal dominant isolated patella aplasia-hypoplasia.19 
Based on the striking similarities of specific morphological skeletal findings,
Lacombe et al. (1994)7 suggested that the MGS might be a human equivalent to
Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Frequencyb
+ N/A N/A N/A N/A N/A 88%
- N/A N/A N/A N/A N/A 18%
+ N/A N/A N/A N/A N/A 17%
- N/A N/A N/A N/A N/A
- - - - - -
N/A - + + - + 56%
N/A + + + + + 47%
N/A T T T T T 25%
- - - - ? + 50%
- - - - - - 36%
+ + - - - - 47%
+ - - - - - 28%
- + - - - + 32%
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the short ear (se) murine disorder. The murine se phenotype is caused by
homozygous mutations in the short ear locus, which contains a member of the
transforming growth factor β superfamily called bone morphogenetic protein 5
(BMP5).20,21 This secreting signalling molecule has a role in antero-posterior
limb axis formation including initiation of bone and cartilage formation in 
specific body regions and differentiation of soft tissues, involving mesen-
chymal-epithelial interactions. The interactions between mesenchyme and 
overlying epithelial structures are crucially important for the early development
of many vertebrate organs including the external ears, mammary glands, 
external genitalia, and limbs. We suggest that other genes that are involved in
the BMP signalling pathway, such as homeobox genes, might be also involved
in MGS. Molecular genetic studies including testing of candidate genes in MGS
are presently being performed.
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At the start of the research described in this thesis (2000), only one gene 
encoding a LIM-homeodomain transcriptor (LMX1B) essential for patella 
development had been identified.1,2 Four years later, we discovered that another
transcription factor encoding gene, TBX4, plays a pivotal role in the formation
of the patellae by studying the small patella syndrome (SPS) chapter 3.2. The
involvement of a third key molecular player in patellar development, the 
RECQL4 helicase gene, evolved from the identification of RECQL4 mutations 
in RAPADILINO syndrome patients by Siitonen et al. (2003).3
Phenotype studies in patients with human syndromes caused by mutations
in these genes and studies of animal models of these syndromes indicate that
LMX1B, TBX4, and RECQL4 are not only essential for patella patterning, but
are required for a wide range of developmental processes. Thus, initial studies
of the nail patella syndrome (NPS) phenotype caused by LMX1B mutations and
Lmx1b-/- mice indicated a clear role for LMX1B in limb, kidney, and eye ano-
malies.4-6 Subsequently, advanced studies in NPS patients, including our own
comprehensive examination of a large Dutch NPS cohort chapter 2.5 and studies 
of mice models revealed additional roles of LMX1B in the inner ear and the
central and peripheral nervous system.7-11 TBX4 is also essential for develop-
ment of pelvis and foot bone structures during late stages of skeletal develop-
ment chapters 3.1 and 3.2. Investigations of normal and aberrant Tbx4 expression in
animal models revealed that this transcription factor displays additional roles in
the regulatory pathways of lung and heart development.12-14 These findings chal-
lenge further careful examination of the human SPS phenotype to unravel a
pleiotropic role of TBX4 during human development. RECQL4 helicase activity
has several functions in limb patterning pathways including patella and radial
ray bone formation and development of other organs, such as the gastrointestinal
and urogenital system, skin, nails, and heart.3,15
168
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5.1 Clinical characterisation of human syndromes with congenital patellar
malformations
By in-depth clinical investigations we have shown that the phenotypic spectrum
of nail patella syndrome (NPS), small patella syndrome (SPS), and Meier-Gorlin
syndrome (MGS) is broader than previously described chapters 2.5, 3.1, and 4, addendum 2.
These new clinical findings are of significant importance for the care of patients
with these syndromes. Here, we briefly discuss the novel insights for diagnosis
and clinical management of NPS. A detailed discussion of phenotype studies of
NPS, SPS, and MGS and its implications for diagnosis, clinical management,
and counselling is outlined in addendum 2.
Nail patella syndrome 
Musculoskeletal investigation of our large series of NPS patients revealed not
only patella aplasia and hypoplasia, but also underdeveloped lateral femoral
condyles, prominent medial femoral condyles, and disturbed development of
proximal muscle groups of the upper limb, and tendons and ligaments of both
upper and lower limbs chapters 2.1 and 2.5.16 Other previously unrecognised character-
istics of NPS comprise the development of glaucoma without increased intra-
ocular pressure, defined as normal-tension glaucoma, and subclinical hearing
impairment chapter 2.5. Renal investigations of our unselected series of 106 NPS
patients from 32 families revealed a frequency of proteinuria in 21% of individuals
and end-stage renal disease in 1% chapter 2.5, consistent with the recent observa-
tions in a British cohort of 123 NPS patients from 43 families.16 These frequencies
are lower than those reported in a literature review on proteinuria (33%) and
terminal insufficiency (15%) in NPS 17. The discrepancy in prevalence data on
renal involvement might be explained by the selection of the study population
and design, availability of historical clinical data, and methods of laboratory
analysis. Since development of nephropathy is related to ageing, long-term 
longitudinal clinical studies of a large series of NPS families are necessary to
increase our knowledge on life-risk frequencies and the natural history of this
complication. The same holds true for glaucoma. 
The extended phenotypic spectrum of NPS requires adjustment of recommen-
dations for clinical diagnosis and management addendum 2. Novel techniques mea-
suring the overall surface variability of the optic cup floor might possibly contribute
to early detection of glaucomatous anomalies.18 Although further studies are
certainly necessary, our study is a first indication that measurement of both micro-
albuminuria and glomerular filtration rate might be valuable diagnostic tests for
early detection and possibly recognition of progression of nephropathy in NPS
chapter 2.5. Treatment with angiotensin converting enzyme inhibitors or angiotensin II
receptors blockers is known to diminish albuminuria and to slow down the
decline of renal function in different chronic nephropathies, but long-term clinical
investigations of angiotensin blockade in NPS are required to evaluate its 
specific effect in NPS.19 Clinical follow-up studies are also needed to elaborate
the benefit of intra-ocular hypotensive medication in case of NPS glaucoma.
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Small patella syndrome
In small patella syndrome (SPS), the skeletal anomalies appear to be restricted
to the lower limbs and the pelvis chapter 3.1. Both congenital patellar malformations
as well as ischiopubic ossification defects are mandatory for clinical diagnosis
chapter 3.1. In addition to absent or small patellae, knee joint anomalies comprise
smaller medial femoral and tibial condyles as compared to lateral femoral and
tibial condyles chapter 3.1.20-23 The phenotypic overlap of patellar anomalies
between SPS and NPS prompted us to investigate in detail whether other specific
dorsal limb patterning defects characteristic for NPS might be present in SPS
patients. In patients from two different Dutch SPS families, we recognised 
fingernail dystrophy including mild pitting, thinning, and/or longitudinal 
ridging skeleton extending the phenotypic spectrum of SPS with features of 
disturbed nail development.Bongers, unpublished data The facial features observed in
some SPS patients do not appear constituent characteristics of SPS chapters 3.1 and 3.2.
Meier-Gorlin syndrome
MGS syndrome is characterised not only by malformations of the appendicular
including patella aplasia and hypoplasia, but also by axial bone structure anomalies
chapter 4. Meticulous radiographic studies of additional adolescent and adult MGS
patients are needed to delineate the complete spectrum of knee joint anomalies
such as the formation of femoral condyles and trochleae and possible additional
limb patterning defects. The cardinal observation of pre- and postnatal growth
retardation with delayed bone maturation suggests that a general defect of
growth plates is implicated in this syndrome. MGS is the only disorder among
the patellar malformation syndromes described in this thesis in which a typical
facial appearance is contributive to clinical diagnosis addendum 2. Our first recog-
nition of a changing facial phenotype with ageing chapter 4 was subsequently
observed in another sporadic case with MGS by Shalev and Hall (2003)24 and has
been emphasized in our follow-up study of five additional adolescent and adult
individuals from four families, recently Bongers addendum 2.Bongers, unpublished data
Both abnormal primary and secondary sexual development was found in
both male and female MGS patients chapter 4, addendum 2.Bongers, unpublished data
Mammary hypoplasia was initially recognised in two adult female MGS patients
with disproportionate short stature25 and has subsequently been confirmed in
our current series of postmenarcheal and adult female patients with no effect of
oestrogen replacement therapy addendum 2..Bongers, unpublished data Endocrinological
studies of gonads are normal and the menarche occurs within a normal range
of age chapter 4..Bongers, unpublished data We suggest that these findings might point to 
a primary disturbed ectodermal-mesenchymal interactions in mammary gland
and genital development rather than dysregulation of hormone actions, similar
to what has been shown to cause mammary gland hypoplasia in ulnar-mammary
syndrome (UMS; MIM 181450), a pleiotropic disorder affecting limb, apocrine-
gland, tooth, hair, and genital development.26
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5.2 The molecular basis of human syndromes with congenital patellar 
malformations 
The pathogenetic cause of nail patella syndrome 
Since the elucidation of the causative gene of nail patella syndrome (NPS) in
1998, more than 156 different pathogenic LMX1B mutations concentrated in 
the LIM-domains and homeodomain have been reported in NPS, including
genomic deletions covering large portions of the gene and balanced trans-
locations, presumably disrupting LMX1B chapters 2.1, 2.2, and 2.5.1,2,27-34 Dunston et al.
(2004)33 identified the first mutations in exon 1 upstream of the LIM domains
and in exon 6, but as yet no mutations have been described in exons 7 and 8
suggesting that mutations in the latter exons do not cause the classical NPS
phenotype or are simply not present. In 13% of our NPS families, no pathogenic
mutation could be detected by sequencing of the LMX1B gene chapter 2.5 which is
congruent with previous findings by others.27-29 Mutations in the introns, the
promoter region, the 3’ untranslated region of LMX1B, or deletion of the entire
LMX1B gene could be causing NPS in these patients. However, FISH analysis
with specific probes for the chromosome 9q34.1 locus encompassing LMX1B
did not reveal evidence for a deletion of the entire LMX1B gene in our four fami-
lies in which no LMX1B mutation could be identified chapter 2.5. Mutations in
other genes, such as transcriptional co-factors, are less likely since no evidence
for locus heterogeneity has been found in NPS. Additionally, no subtelomeric 
deletions of other chromosome regions could be identified the application of
genome-wide multiplex ligation-dependent probe amplification (MLPA) in the
four above-mentioned NPS families, recently.Bongers, unpublished data We performed
mutation analysis of PAX2, known to be expressed and to play a pivotal role in
kidney and eye development,35 in one of two siblings with the classical NPS 
phenotype associated with congenital cataract in which no LMX1B mutation
could be identified, but did not detect a pathogenic mutation.Bongers, unpublished data
It is as yet unclear why heterozygous LMX1B mutations cause NPS in
humans, whereas Lmx1b heterozygous mice are completely normal. Based on
the facts that the same range of NPS symptoms is observed in patients with
LMX1B missense, nonsense or deletion mutations, and that the range and 
severity of symptoms can vary as much within as between families, it is 
hypothesised that haploinsufficiency is the main mechanism underlying 
dominant inheritance in human NPS.1,36,37 This speculation is supported by 
the lack of any dominant-negative effect observed in vitro, when expressing 
constructs with missense or truncation mutations.1,36,37 Nevertheless, other
mechanisms than haploinsufficiency, such as dominant-negative effects, 
underlying NPS pathogenesis cannot be excluded as yet. This assumption is
based on the following arguments: a) the lack of reports on an NPS phenotype
in patients with submicroscopic 9q34.1-qter deletions38 and b) the absence of
deletions of the entire gene in NPS patients thus far.Bongers, unpublished data
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Molecular investigation of nephropathy in nail patella syndrome
After the elucidation of the genetic defect causing NPS, research focused on the
pathophysiology underlying NPS nephropathy. The ultrastructural features of
glomerular basement membrane alterations and arrested development of
podocytes in NPS kidneys raised the question as to whether LMX1B might regu-
late both the group of transcription factors involved in podocyte differentiation
as well as the structural components of the podocyte cytoskeleton and slit
diaphragm. The crucial role of LMX1B as a specific-podocyte gene among other
podocyte genes mutated in hereditary nephrotic syndromes has been esta-
blished from studies in mice models. Experiments in Lmx1b-/- mice showed that
the glomerular expression of the α3 and α4 chains of type IV collagen, podocin,
and CD2-associated protein (CD2AP) was decreased at both protein and mRNA
levels.39,40 LMX1B binding sites in the putative regulatory regions of both
CD2AP and NPHS2, the gene encoding podocin, and in the putative enhancer
in COL4A4 intron 1 further suggested that LMX1B directly regulates transcrip-
tion of these podocyte genes critical for podocyte structure and function.40,41 In
contrast, immunohistochemical investigation of human NPS kidneys revealed
normal glomerular expression of type IV collagen chains and noncollagenous
molecules including podocin, CD2AP, and nephrin but identified accumulation
of type III collagen fibres instead chapter 2.3. The discrepancies between NPS mice
and –man have not yet been elucidated. It is possible that heterozygous LMX1B
mutations give rise to only a slightly reduced synthesis of podocyte-associated
molecules for which immunohistochemical detection studies are not sensitive
enough, yet still sufficient to give rise to nephropathy in humans. Additional
studies using more sensitive methods are necessary, but renal biopsies of NPS
patients are hardly available. Alternatively, the deregulated expression of as yet
unknown LMX1B target genes in podocytes may be responsible for NPS
nephropathy. The recent reports on viable urinary podocytes from both healthy
controls and patients with nephropathy offer a new and interesting possibility
to investigate the expression of podocyte genes and proteins in NPS.42,43 We
have recently started to culture urinary podocytes from individuals with NPS. 
Moreover, functional studies are needed to explore the pathogenic effect of
aberrant type III collagen expression in NPS glomerulopathy. More than a
decade ago, before the LMX1B gene was identified as being the causative gene
in NPS, it was hypothesised that NPS might be caused by mutations in the gene
encoding collagen type V. This assumption was based on the ultrastructural
anomalies in NPS kidneys and its location in the NPS candidate region on chro-
mosome 9q34. It is interesting that collagen anomalies have now come in focus
again in NPS nephropathy.
The discovery of the TBX4 gene underlying small patella syndrome
The genetic defect of small patella syndrome (SPS) was identified by a position
candidate strategy based on the position of TBX4 in the SPS critical region on
chromosome 17q22 and an SPS-like skeletal phenotype of chicken and murine
models lacking Tbx4 chapter 3.2. Haploinsufficiency is believed to be the molecular
mechanism by which some of the TBX4 mutations, predicted to create null alleles
or disrupt DNA binding activity, cause dominant SPS chapter 3.2. However, also for
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SPS a dominant negative effect/gain-of-function model cannot be excluded.
Previously, it was speculated that SPS might be allelic to familial isolated
patella aplasia-hypoplasia (PTLAH) chapter 3.3. We have shown that it is very
unlikely that the TBX4 gene located at 17q22 is underlying PTLAH chapters 3.2 and 3.3.
Neither does the TBX4 gene seem to be involved in other SPS “like” syndromes.
Thus, we sequenced TBX4 in a family with congenital coxa vara, patella aplasia
and tarsal synostosis previously described by Goeminne et al. (1970)44 and in 
a family with penoscrotal transposition/diphallus reported by Dodat et al.
(1995),45 but did not find any pathogenic mutation.Bongers, unpublished data While
these observations seem to exclude TBX4 for these disorders with congenital
patellar malformations, we cannot exclude the involvement of disruption of
long-range TBX4 regulatory elements in PTLAH and other congenital patellar
malformation syndromes. 
Search for the molecular cause of Meier-Gorlin syndrome
Thus far, both linkage analysis and position-independent candidate gene strate-
gies have not been successful in unravelling the gene defect underlying Meier-
Gorlin syndrome (MGS). We started our investigations with the gene encoding
the bone morphogenetic protein 5 (BMP5), selected as a candidate gene
because of the striking phenotypic similarities between MGS and Bmp5-/-
mice.46 We excluded the BMP5 locus as a candidate region for MGS by haplo-
type analysis in a presumed consanguineous family with three siblings with
MGS.47 Simultaneously, Cohen et al. (2002)48 performed sequencing of BMP5
but found no pathogenic mutation in one sporadic MGS patient. Although link-
age and haplotype analysis has been proven fruitful as a first step in the elucida-
tion of the gene responsible for NPS and SPS respectively, extensive genome-
wide homozygosity mapping studies and Single Nucleotide Polymorphism
(SNP) array analysis did not reveal any promising candidate loci in the same
consanguineous family with three siblings with MGS,Bongers, unpublished data raising
questions about the pedigree structure of the family and the necessity of investi-
gation of additional multisibling (consanguineous) families.
At present, the best alternative for further research is to follow a position-
independent candidate gene approach, which might benefit from advanced
insights in the MGS phenotype and the current knowledge about molecular
pathways in patella development. For example, it is plausible that other genes
that operate in LMX1B or TBX4 signalling cascades are candidates for MGS, 
as well as for GPS, PTLAH, and other ‘SPS-like’ syndromes. From phenotype
studies in MGS we here already suggested that disturbed epithelial-mesenchymal
interactions might be implicated in the molecular mechanisms underlying
mammary hypoplasia and genital anomalies. This is of interest since mammary
gland hypoplasia caused by dysregulated interactions between epithelial tissue
and mesenchyme is associated with limb patterning defects in several other
human developmental disorders, among which the ulnar-mammary syndrome
caused by TBX3 mutations.26 Tbx3, as well as its paralogue Tbx2, interact with
the fibroblast growth factor (fgf ) and Wnt signalling pathways regulating
epithelial-mesenchymal interactions in mammary gland development and pos-
terior and dorso-ventral axis patterning of the limb in mice and chicken.49,50
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Based on these findings and the expression of murine and chicken Tbx2 in a
wide range of tissues affected in MGS, we hypothesised that TBX2 might be an
interesting candidate gene for MGS.12 However, by sequencing TBX2 we could
not detect any pathogenic mutation in a selection of our MGS families, neither
in two families with PTLAH, in one previously reported family with congenital
coxa vara, patella aplasia and tarsal synostosis,45 and in a previously described
family with penoscrotal transposition/diphallus46.Bongers, unpublished data The pheno-
typic overlap of MGS with the spectrum of LMNA-associated diseases,52-54
prompted us to perform ZMPSTE24 and LMNA mutation analysis of a series of
MGS patients but did not reveal any pathogenic gene mutation.Bongers, unpublished
data From several clinical similarities between MGS, RAPADILINO, and Baller-
Gerold syndrome it is tempting to speculate that mutations in the gene encoding
RECQL4 or other genes related to the RECQL4 genetic network underlie MGS.
RECQL4 is presently being sequenced in our MGS cohort.
C
hapter 5.3
G
eneral discussion: genotype-phenotype association studies
175
5.3 Genotype-phenotype association studies 
Nail patella syndrome
To understand the highly variable expressivity of the renal NPS phenotype we
searched for modifier genes by using the yeast two-hybrid system in order to
identify proteins expressed in human fetal kidneys that interact with the LMX1B
protein. We and Dreyer et al. (2000)36 observed interaction between LMX1B and
CLIM2 chapter 2.4. CLIM2 is a known LIM co-regulator that exerts both inhibitory
as well as synergistic transcriptional activation effects on LIM homeodomain
transcription factors. However, no association between CLIM2 polymorphic
variants and proteinuria in our large NPS family with high prevalence of
nephropathy (LMX1B mutation 672+1G→A) could be demonstrated suggesting
that at least these SNPs in CLIM2 do not significantly influence the renal 
symptoms in this family chapter 2.4. Recent yeast two-hybrid screening of a human
adult kidney cDNA library carried out in our laboratory revealed the known
CLIM1 gene and two other genes encoding LMX1B interactors, which have 
not been previously characterised.van Bokhoven, unpublished data Genotype studies in
clinically well-characterised large multigenerational NPS families are again
required to evaluate their possible role as modifier genes in NPS. 
Marini et al. (2005)35 suggested PAX2 as a modifier candidate gene based 
on its function and spatiotemporal expression patterns in kidney and eye.
LMX1B/PAX2 interaction was demonstrated by direct yeast-two hybrid assay 
and coimmunoprecipitation investigations, but its role as a genetic modifier
was not investigated in NPS patients.35 Experiments investigating the interaction
domain of LMX1B with PAX2 showed that a specific deletion of the homeo-
domain resulted in only a mild reduction of LMX1B/PAX2 interaction whereas
deletion of both LIM-domains revealed putative abolition of interaction. These
findings give additional input for our hypotheses that 1). the position of muta-
tions in either one of the LIM-domains or the homeodomain might lead to dif-
ferences in the presence and severity of clinical symptoms and 2). the phenotyp-
ic variability at intrafamilial level might be influenced by LMX1B interacting
modifier proteins. 
Genotype-phenotype evaluation of in human NPS showed that nephropathy
is associated with the position of the mutation in LMX1B chapter 2.5. Both the 
frequency as well as the level of urinary protein loss was higher in patients with
mutations located in the homeodomain as compared to individuals with gene
defects in the LIM-domains chapter 2.5. Since both the occurrence of missense,
nonsense, frameshift or splice-site mutations as well as the number of distinct
types of mutations was comparable between the LIM-domains and the homeo-
domain, this finding could not be explained by differences in predicted protein
effects. For estimating the individual risk for developing nephropathy, medical
family history and the location of the mutation in the LXM1B gene might be
indicative chapter 2.5. Future studies in additional large cohorts of extensive multi-
generational families are necessary to confirm this. Statistical analysis of 
extra-renal features of NPS failed to identify a genotype-phenotype correlation.
Interestingly, ultrastructural glomerular changes typical for NPS without
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accompanying constituent nail and skeletal anomalies have been described in
14 individuals reviewed in chapter 2.1 and in a recently published sporadic
case.54 In another family with isolated “NPS-like” nephropathy with 20 affected
individuals from five generations we identified a new missense LMX1B muta-
tion located in the homeodomain of this gene.Bongers, unpublished data These findings 
suggest that this glomerular disease represents partial expression of NPS. It is
remarkable that the LMX1B mutation in this family with ‘NPS-like’ nephropa-
thy is located in the homeodomain, consistent with our assumption that muta-
tions in this domain yield a significantly higher risk for the specific develop-
ment of kidney disease. Molecular analyses of other families with isolated
“NPS-like” nephropathy are needed to further test this hypothesis. 
Small patella syndrome
No evidence for a relationship between the highly variable skeletal features of
small patella syndrome (SPS) and the type or location of TBX4 mutations could
be demonstrated in the six examined families as yet. The low number and small
size of families investigated to date emphasize the need for in-depth genotype-
phenotype evaluation of additional large SPS families.
Molecular studies in animal models have displayed an additional role of
Tbx4 in the development of the lung and allantois.13,55 Moreover, interaction 
of Tbx4 and its paralogue Tbx5 with a PDZ-LIM protein is required for heart
development in chicken.14 However, no clinical symptoms related to abnormal
lung morphogenesis or congenital heart defects have been reported in human
SPS to date. If lung and heart anomalies are indeed not present in SPS after
careful examination, it is intriguing to investigate in animal models which 
gene products might compensate for aberrant Tbx4 expression during lung 
and heart formation.
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5.4 Novel insights into the role of LMX1B and TBX4 in human limb 
patterning 
LMX1B
The limb phenotypes of NPS indicate that human LMX1B is involved in both
dorso-ventral and antero-posterior patterning and possibly rotation along the
proximo-distal axis during early embryonic development chapters 1 and 2.5.1 The
downstream targets of LMX1B in hard and soft limb tissues are poorly understood.
LMX1B mutations might affect specific endochondral ossification processes
underlying patella hypoplasia and the formation of iliac exostoses in NPS.
Based on the dorsal localisation of Lmx1b expression in developing tendons 
ligaments of the distal limb of wild type mice and flexor tendon duplication
seen in Lmx1b-/- mice forelimbs,56 we suggest that abnormal development or
attachment of the dorsal extensor tendons of the digits is underlying aberrant
flexion of the distal interphalangeal joints in the swan-neck deformity seen in
most NPS patients. 
TBX4
Phenotype studies of SPS determined that human TBX4 is implicated in both
dorso-ventral and antero-posterior limb patterning and has important functions
during late skeletal development of pubic, ischial, patellar, and (meta)tarsal
bones chapters 3.1 and 3.2. Similar to the hypothesised role of LMX1B in the molecular
pathways of endochondral ossification, we suggest that TBX4 might be involved
in the cascades mediating mesenchymal condensation, ossification, and out-
growth of pelvis, patellar, and (meta)tarsal bones. From studies in Tbx5-/- mice,
Minguillon et al. (2005)57 demonstrated that Tbx4 is capable of rescuing initiation
and maintenance of forelimb outgrowth in the absence of Tbx5. These findings
are consistent with the relatively mild manifestations of skeletal morphogenesis
in SPS patients due to heterozygous loss-of-function of TBX4 which could partly
be attributed to a high degree of functional redundancy for TBX4. Our obser-
vation of nail anomalies in SPS patients suggests that TBX4 has a function 
in the development of dorsal soft structures of the upper limb as well.Bongers,
unpublished data 
The current knowledge of the limb-specific morphologic manifestations of
these human developmental disorders and animal genetic models of these 
syndromes is integrated in a model for the genetic pathways of upper and lower
limb development, comprising patella patterning presented in figure 1. For
a complete understanding of the molecular mechanisms underlying limb
anomalies and associated organ system manifestations of NPS and SPS, 
knowledge of the molecular targets of the transcription factor genes LMX1B
and TBX4 and the complex cross talk between different pathways is essential. 
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figure 1
A model for the regulatory pathways of upper and lower limb development, based on data obtained from studies 
in animal models (chickens and mice) and humans chapter 3.2.12,57-59 During limb initiation, TBX5 and TBX4 induce
WNT2B/FGF and WNT8C/FGF signalling, respectively, which positively feedback on to FGF10 through the WNT3A/
β-catenin-dependent pathway to initiate limb bud outgrowth in chicken. At late developmental stages, TBX5, TBX4,
and LMX1B are crucial in asymmetric patterning along the antero-posterior and dorso-ventral axes. TBX5 is essential for
patterning of the anterior skeletal structures of the upper limb, whereas TBX4 is involved in development of dorsal and
posterior elements of the lower limb. LMX1B is important for patterning of dorsal and anterior skeletal and surface
structures of the upper and lower limb during later stages of development. The downstream targets of TBX5, TBX4,
and LMX1B during late stages of limb development are as yet unknown. TBX5 and TBX4 are first expressed in the 
lateral-plate mesoderm and during later developmental stages throughout the mesenchyme of the upper and lower
limb bud, respectively. In both the upper and lower limb bud, LMX1B is expressed in the dorsal mesenchyme, FGF10
in the mesenchyme, FGF8 in the apical ectodermal ridge, WNT7A in the dorsal ectoderm, and Engrailed-1 in the 
ventral ectoderm. Human protein nomenclature is used. It should be noted that the indicated signalling pathways 
represent a combination of results obtained in the various model systems and that the different developmental 
pathways could not be linked in any of the organisms as yet.
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5.5 Concluding remarks
The identification of gene defects and their products in hereditary disorders
with congenital patellar malformations proved to be important in unravelling
key molecules involved in patella development. Understanding the role of genes
underlying complex human patellar malformation syndromes might give clues
towards the selection of novel candidate genes for other human syndromes with
limb malformations or hereditary glomerulopathies. Future studies will fill in
significant gaps in the pathways involved in limb patterning and kidney develop-
ment dysregulated by mutations in the presently known transcription factor and
helicase encoding genes. Another challenge in studying human patellar malfor-
mation syndromes is to unravel the pathogenic mechanisms involved by deter-
mining the functional role of genes at the protein and cellular level in different
tissues. These insights will be of great importance to understand the phenotype
and, especially for NPS, the progression of some of the clinical symptoms. In
addition, this may well lead to novel (gene) therapeutic strategies for at least
some organ complications, such as nephropathy in NPS. 
The results of the clinical studies of the syndromes described in this thesis
are implemented in recommendations for initial and follow-up clinical investi-
gations, described in addendum 2. Both the diagnostic work-up as well as the
clinical management of human syndromes with congenital patellar malforma-
tions requires a multidisciplinary approach by different medical specialisms.
Since patellar malformation syndromes are relatively uncommon and we are
only at the beginning of understanding the natural history of these disorders,
we believe that long-term follow-up of patients should be concentrated in 
centres of expertise.
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Addendum 1
Frequency of human syndromes with congenital patellar malformations 
Nail patella syndrome (NPS) is estimated to occur in 1 in 50,000 live births. No
prevalence data are as yet known for the less frequently reported small patella
syndrome (SPS), isolated patella aplasia-hypoplasia (PTLAH), and Meier-Gorlin
syndrome (MGS). At present it is difficult to estimate which proportion of 
congenital patellar malformations is accounted for by genetic disorders. For
diagnostic registration purposes, different diagnostic category codes have been
developed for distinct knee entities at the Orthopaedic Surgery Department of
the Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands.
However, no separate code is available for patellar anomalies. Medical file studies
of 361 patients, categorised with one of the diagnose codes ‘knee luxations,
developmental disorder of the knee, disrupted growth of the knee, or skeletal 
or cartilage malformations of the knee’ by the orthopaedic surgeons of the
Radboud University Nijmegen Medical Centre between 1993-2002, revealed 47
individuals with documented patellofemoral dysplasia.Bongers, unpublished data In four
of the latter 47 patients, a syndrome diagnosis was reported in the orthopaedic
surgery files, comprising two unrelated patients with NPS, one with VATER
association, and one with Turner syndrome. Physical and radiographic exami-
nation of a selection of this series of 47 individuals with patellofemoral dysplasia
accompanied by additional congenital skeletal anomalies, uncovered three
unrelated families with SPS.Bongers, unpublished data This example illustrates that after
careful clinical examination complex genetic disorders with congenital patellar
malformations may turn out to be considerably more common among patients
with patellofemoral dysplasia. 
Addendum 2
Diagnosis and recommendations for clinical management
of human patellar malformation syndromes
2.1 Nail patella syndrome 
2.2 Small patella syndrome
2.3 Meier-Gorlin syndrome
Diagnosis and clinical management of patients with nail patella syndrome, small patella
syndrome, and Meier-Gorlin syndrome
Nail patella syndrome (NPS) and Meier-Gorlin syndrome (MGS) are pleiotropic
genetic disorders for which integrated multidisciplinary investigations by different
medical and paramedical specialists are imperative for both diagnosis and clinical
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figure 1
A schematic approach of a diagnostic work-up of patients with patella aplasia or hypoplasia for differentiating 
nail patella syndrome, small patella syndrome, isolated patella aplasia-hypoplasia, and Meier-Gorlin syndrome.
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hypoplasia
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management. In small patella syndrome (SPS) the emphasis is on examination
of skeletal manifestations and effective treatment of knee symptoms if present. 
A diagnostic work-up of individuals with patellar malformations, clinically
suspect for NPS, SPS, and MGS is presented figure 1, tables 1, 3, and 4.
Recommendations for clinical management of the main features and organ
complications of these syndromes are addressed tables 2 and 5. 
Explanatory note to the recommendations for a diagnostic work-up and clinical 
management
The recommendations described below are based mainly on our study chapter 2.5 ,60
and the investigation of Sweeney et al. (2003)16 in NPS and personal experience
with our own series of patients with SPS and MGS chapters 3.1 and 4. Bongers, unpublished
data, 61,62
Since many patients are initially referred to an orthopaedic surgeon for
symptoms related to congenital patella dysplasia, investigation of well-defined
clinical characteristics by this specialist is invaluable for recognition of additional
anomalies contributing to early diagnosis of a complex syndrome. The clinical
hallmark features of NPS, SPS, and MGS enable a relatively easy and early differen-
tiation between these well-recognisable congenital patellar malformation 
syndromes figure 1. The establishment of a precise and early diagnosis of a 
complex genetic disorder is of crucial importance since patellar anomalies may
be associated with extraskeletal organ system complications and may require 
specific clinical management.
Medical (family) history and physical examination of the nails, external ears,
and height are mandatory in a systematic approach to diagnose syndromes with
patellar malformations and the clinical distinction between NPS, SPS, and MGS
as illustrated in the scheme in figure 1. Radiographic imaging further contributes
to the diagnostic work-up of individuals with patella aplasia or hypoplasia by
the recognition of certain characteristic or pathognomonic skeletal features figure 1.
2.1 Diagnosis and clinical management of patients with nail patella syndrome
The clinical symptoms of patients with NPS are highly variable. The most relevant
clinical complications are nephropathy and glaucoma, which may be present
from birth onwards. For diagnostic purposes and clinical management, clinical
geneticists, paediatricians, nephrologists, orthopaedic surgeons, radiologists,
physiotherapists, rehabilitation specialists, ophthalmologists, and ear-, nose-
and throat specialists, may be involved.
2.1.1 Prenatal diagnosis of nail patella syndrome
Obstetric ultrasonography
When a first degree relative is known with NPS, high-resolution ultrasonography
for investigation of iliac horns, absent patellae, and talipes is possible from the
20th week of gestation onwards.63,64 Since talipes is a common congenital mal-
formation, the observation of talipes in the presence of an affected first degree
relative may be indicative, but cannot be conclusive for prenatal NPS diagnosis
by ultrasound examination. The same is true for associated uncommon findings
in NPS which occur relatively frequent in the general population, such as neural
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Organ systema Investigation Signs 
Upper limb Physical examination of digits - Nails: Triangular lunulae, anonychia, hemianonychia,
and/or hypoplastic, longitudinal ridging, splitting, spoon-
shaped and/or flaky nails of thumbs or fingers
- Skin: Absence or diminished number of skin creases on 
the dorsum of the distal interphalangeal joint of the fingers
- Swan-neck deformity of fingers
Physical examination of elbows Limited extension, supination, and/or pronation of elbows
Cubital pterygia
Radiograph of elbows Hypoplasia of the radial heads and/or capitella with/without
posterolateral dislocation of the radial heads
Lower limb and Physical examination of knees Patella aplasia/hypoplasia
pelvis Genua valga
Radiographs or ultrasonographyb Patella aplasia/hypoplasia
of knees Prominent medial femoral condyles
Underdeveloped lateral femoral condyles
Pelvis radiographs Iliac horns
Pelvis ultrasound at birth Hip dysplasia
Physical examination of the Scoliosis 
back and feet Pes planus
Talipes
Kidneys Laboratory investigation of first Symptoms of nephropathy:
morning urine specimens and Proteinuria
blood sample for: Microalbuminuria
- Urinary protein and albumin Hematuria
- Serum creatinine and albumin Changes in glomerular filtration rate
- Protein/creatinine ratio
- Albumin/creatinine ratio
- Creatinine clearance
- Microscopic evaluation of
urine sediment
Blood pressure measurement Hypertension
Eyes Visual acuity assessment (Congenital) cataract
Intra-ocular pressure measurement (Congenital) primary open-angle glaucoma
Slit-lamp biomicroscopy Normal-tension glaucoma
Gonioscopy Isolated glaucomatous optic disk anomalies
Ophthalmoscopy Ocular hypertension
Visual field investigation
Glaucoma hemifield testing
Ears Otoscopy
Pure-tone audiometry Subclinical sensorineural hearing impairment
table 1
Clinical investigation for diagnostic work-up and examination at the time of diagnosis of nail patella syndrome
a This table comprises the hallmark features and most frequent clinical characteristics of NPS and does not com-
prise the characteristics of the complete NPS phenotype.
b For patients under age 5 or 6 years ultrasonography is recommended for detecting patella aplasia or hypoplasia.66
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tube defects. Conversely, NPS cannot be excluded if no pelvis or limb malforma-
tions are detected by prenatal ultrasonography. In conclusion, the value and
suitability of ultrasonography in prenatal diagnosis of NPS is highly disputable.
Prenatal molecular testing 
With the identification of the causative gene for NPS, an accurate prenatal
molecular diagnostic technique became available for investigation in the first
trimester.65 In the consideration of prenatal investigation it should be empha-
sized to couples that the phenotype of NPS is highly variable and that no reliable
prediction of the individual risk for developing nephropathy and presence and
severity of extrarenal manifestations can be given at present. Recently, we found
strong indications that the family history for nephropathy and the location of the
LMX1B mutation are important in precipitating the individual risk for developing
renal disease chapter 2.5.60 However, these findings need to be confirmed in additional
series of patients before applying to genetic counselling. The factors involved in
the development and progression of nephropathy remain to be elucidated and
therefore the prognosis is uncertain. For these reasons, we believe that prenatal
diagnosis is highly questionable. Since 2000, we offer LMX1B mutation testing.
Thus far, we have received one request from abroad for prenatal molecular
Age Organ system Investigation Signs and symptoms Treatment
(frequency of
investigation)
From  Limbs/Skeleton Knee imaginga Knee anomalies and Referral to an orthopaedic 
bird (investigation in case symptomsb surgeon for consideration 
onwards of signs and/or Talipes of treatment if indicated
symptoms Scoliosis
and consideration 
of treatment)
Kidneys Laboratory See table 1 Initiation of treatment with 
(annual screening) investigation of first angiotensin converting enzyme
morning urine inhibitors or angiotensin II
specimens and blood receptors blockers if indicated
sample (See table 1)
Blood pressure
measurement
From Eyes (annual screening) See table 1 See table 1 Initiation of intra-ocular
10 years Ears (investigation if Otoscopy hypotensive medication 
onwards hearing impairment Pure-tone Sensorineural if indicated
is suspected) audiometry hearing impairment
table 2
Recommendations for clinical management and follow-up of patients with nail patella syndrome
a For patients under age 5 or 6 years ultrasonography is recommended for investigating the patellae.66
b For evaluation of knee symptoms, see addendum 4. 
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investigation for NPS in a family with one affected parent. In this case, we did
not approve prenatal diagnostic testing of the LMX1B gene for reasons of
unpredictable development and prognosis of NPS nephropathy.
2.1.2 Postnatal diagnosis of the nail patella syndrome
In addition to a detailed medical history of the individual and the family, investi-
gations contributive to clinical diagnosis of NPS are proposed in table 1. At the
time of initial diagnosis of NPS, nephrological evaluation including laboratory
investigations and blood pressure measurement for early detection of nephro-
pathy and a thorough ophthalmologic evaluation for recognition of cataract
and/or glaucomatous anomalies are imperative.
Molecular investigation
-  LMX1B mutation analysis.
If no pathogenic LMX1B mution can be identified by sequencing, MLPA analy-
sis should be considered for detecting a deletion of the entire LMX1B gene.
At present, mutation analysis of LMX1B is available in the routine DNA 
diagnostic laboratory. 
2.1.3 Recommendations for clinical management and follow-up of nail patella syndrome
For the initial investigation of NPS nephropathy, we propose a detailed exami-
nation by a nephrologist. If no renal symptoms are detected, annual screening
can be performed by the general practitioner as proposed in table 1. When
nephrological symptoms appear, the patient should be referred to the nephro-
logist for further follow-up and consideration of treatment. To screen individuals
with NPS for ocular anomalies, we propose detailed investigations by an 
ophthalmologist at the time of diagnosis. Since no data are available on 
the natural history of ocular findings in NPS, the age of onset and frequency 
of regular screening and the effects of ocular treatment on the progression 
of glaucoma is arguable. Since we have identified glaucomatous anomalies in 
NPS already at young age, we recommend a comprehensive annual screening 
by an ophthalmologist from the age of 10 years at present. 
Pregnant nail patella syndrome patients
During pregnancy, comprehensive examination by a nephrologist and follow-up
by a gynaecologist is mandatory, since nephropathy may develop or progress
during pregnancy and an increased incidence of pre-eclampsia has been 
reported in pregnant NPS patients.16
2.2 Diagnosis and clinical management of patients with small patella syndrome
SPS demonstrates a highly variable phenotype of pelvis and lower limb malfor-
mations within and between families. Individuals with SPS may come under the
attention of orthopaedic surgeons, physiotherapists, and/or rehabilitation 
specialists for clinical symptoms of the knees. To date, no organ complications
other than musculoskeletal have been reported. However, longitudinal studies
of SPS patients are lacking. 
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2.2.1 Postnatal diagnosis of small patella syndrome
Clinical investigation
For the clinical diagnosis of SPS, minimal diagnostic criteria comprise 1). patella
aplasia or hypoplasia combined with 2). absent or irregular ossification of the
ischiopubic junctions and/or infra-acetabular axe cut notches table 3, chapter 2.1.61
Molecular investigation
-  TBX4 mutation analysis.
TBX4 mutation analysis is presently available in the routine DNA diagnostic 
laboratory.
2.2.2 Recommendations for clinical management
In case of knee symptoms, orthopaedic evaluation and institution of treatment
by an orthopaedic surgeon, a physiotherapist or rehabilitation specialist if indi-
cated. It is important to gain insight into the anatomic anomalies of the
patellofemoral joint by knee imaging in considering the (surgical) options 
for treatment of knee symptoms.
2.3 Diagnosis and clinical management of patients with Meier-Gorlin syndrome
In the clinical management of MGS, the emphasis is on feeding and respiratory
problems in the neonatal period and infancy and growth from birth onwards.
For diagnostic purposes and clinical management the clinical geneticists, 
paediatricians, orthopaedic surgeons, physiotherapists, rehabilitation specialists,
radiologists, urologists, cardiologists, ear-, nose- and throat specialists, and
Organ systema Investigation Signs and symptoms
Lower limb Physical examination of knees Patella aplasia/hypoplasia
and pelvis Genua valga
Radiographs or ultrasonographyb of knees Patella aplasia/hypoplasiab
Prominent medial femoral condyles
Underdeveloped lateral femoral condyles
Pelvis radiographs Absent/irregular ossification of the ischiopubic 
junctions and/or infra-acetabular axe cut notchesc
Physical examination of the feet Sandal gap
Short fourth and fifth rays of the feet
Pes planus
Radiographs of the feet Short fourth and fifth metatarsals
Broad tarsal necks
Pes planus
table 3
Clinical investigation for diagnostic work-up and examination at the time of diagnosis of small patella syndrome
a This table comprises the hallmark features and most frequent clinical characteristics of SPS and does not comprise
the characteristics of the complete SPS phenotype.
b For patients under age 5 or 6 years ultrasonography is recommended for detecting patella aplasia or hypoplasia.66
c Hallmark features of small patella syndrome, essential for clinical diagnosis.
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speech therapists may be involved. Previous data on MGS are mainly derived
from transversal observations of children. Since only four adult patients have
been described and longitudinal studies are not available, the guidelines for
clinical management are most likely incomplete.
2.3.1 Prenatal diagnosis Meier-Gorlin syndrome
Obstetric ultrasonography
Intra-uterine growth retardation is well recognised in the majority of pregnancies.
Apart from absent patellae, no characteristic features can be recognised from
the middle trimester by high-resolution ultrasonography.
Prenatal molecular testing
No molecular diagnostic tool is available at present, since the gene or critical
chromosome region responsible for MGS has not been identified as yet. 
Organ systema Investigation Signs 
Craniofacial Physical examination Microcephaly
Microtia, dysmorphic external ears,
small external auditory meatuses
Beaked nose
Microstomia, full lips
Micrognathia
Skeleton Physical examination and radiographic and/or Proportionate or disproportionate 
ultrasound examination of kneesb short stature
Patella aplasia/hypoplasia
Radiographs of the lower limbs and thorax Delayed bone age 
Slender long bones
Abnormal glenoid fossae 
Hook-shaped clavicles 
Absent/narrow/short ribs
Larynx/trachea Medical history, physical examination Laryngo/tracheomalacia
Mammary glands Physical examination Hypoplasia of mammary glands
External genitalia Physical examination Males: cryptorchidism, hypospadias, hypoplasia 
of the corpora cavernosa and the urethra
Females: hyperplastic hooded prepuce of
clitoris / Underdeveloped labia minora 
Kidneys Ultrasonography Hydronephrosis
Heart Echocardiography Atrial or ventricular septal defect
Ears Otoscopy Small external auditory meatuses
Pure-tone audiometry Conductive hearing impairment
table 4
Clinical investigation for diagnostic work-up and examination at the time of diagnosis of Meier-Gorlin syndrome
a This table comprises the hallmark features and most frequent clinical characteristics of MGS and does not
comprise the characteristics of the complete MGS phenotype.
b For patients under age 5 or 6 years ultrasonography is recommended for detecting patella aplasia or hypoplasia.66
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Age Organ system Investigation Signs and symptoms Treatment
From External genitalia Physical examination Cryptorchidism Surgery (orchidopexia) 
birth if indicated
to 1 year Respiratory tract Medical history Laryngo/tracheomalacia
Physical examination Respiratory insufficiency Selective beta-2 receptor 
agonists if indicated
Respiratory tract infections Antibiotics if indicated
Gastrointestinal tract Monitoring of feeding Early feeding problems Nasal tube feeding 
and growth Poor weight gain if indicated
From Endocrine organs Evaluation of growth (Progression of ) postnatal Consider growth 
birth   growth retardation hormone therapy
to late Endocrinological laboratory
childhood investigation in case of
progressive growth 
retardation
Musculoskeletal Knee imaginga (in case of Knee anomalies and Referral to an orthopedic 
signs and/or symptoms symptoms surgeon for consideration
and consideration of (surgical) 
of treatment) treatment if indicated
Motor milestones Delayed motor 
development
Muscle weakness
Heart Cardiac follow-up if Atrial or ventricular Cardiac surgery if indicated
congenital cardiac septal defects
anomalies are present
Central nervous Evaluation of psycho- Delayed speech Speech therapy
system logical development
Ears Otoscopy Conductive hearing Follow-up of hearing 
Pure-tone audiometry impairment due to; impairment if indicated
- Atretic/small external 
auditory canal
- Recurrent otitis media
Tooth Dental examination Enamel hypoplasia
From late Endocrine organs Evaluation of growth
childhood Assessment of pubertal Sparse/absent axillary hair
onwards development, menarche,
and regularity of cycles
Ultrasound examination Mammary gland hypoplasia
of uterus and ovaries Polycystic ovariesb
if indicated Small uterusb
table 5
Recommendations for clinical management and follow-up of patients with of Meier-Gorlin syndrome
a For patients under age 5 or 6 years ultrasonography is recommended for investigating the patellae.66
b Small uterus and bilateral polycystic ovaries were observed in 2/2 female siblings in whom ultrasound examination
was performed.Bongers, unpublished data
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2.3.2 Postnatal diagnosis of Meier-Gorlin syndrome
Clinical investigation
Apart from the medical (family) history and clinical investigations described in
table 4, review of childhood photographs may be contributive for recognising
the characteristic facial phenotype of MGS at young age and a changing facial
appearance with ageing. The facial appearance at early infancy, including a
beaked nose, microstomia, full lips, and micrognathia change to a more 
prominent triangular face and a small high nasal bridge during adolescence 
and young adulthood figure 2, chapter 4.62,67 The very small ears remain an essential
and well-recognisable clinical characteristic of MGS in adults. Recently, we
observed enamel hypoplasia and small tuber calcanei in the majority of MGS
patients examined.Bongers, unpublished data
Molecular investigation
The molecular basis or critical chromosome region of the gene underlying MGS
has not been identified as yet. There is no specific biochemical marker available
for molecular diagnostic purposes.
2.3.3 Recommendations for clinical management of Meier-Gorlin syndrome
Poor feeding, recurrent and severe upper and lower respiratory tract infections,
and dyspnoea during the neonatal period and infancy improve from childhood.
If growth hormone deficiency is present, MGS patients may benefit from
growth hormone therapy.Bongers, unpublished data Thus far, significant positive effects
of growth hormone therapy have only been observed sporadically chapter 4. Bongers,
unpublished data, 62 Mean adult height in seven females was 145 cm (range 137-151
cm) and adult height in two males was 154 cm and 155 cm, respectively.Bongers,
unpublished data, 25,68 From early childhood, evaluation of psychomotor development,
including speech status and school performance is recommended.
Both primary and secondary sexual development was found affected in both
sexes chapter 4.Bongers, unpublished data Axillary hair development is sparse or absent, 
but pubic hair development is normal in both male and female patients.Bongers,
unpublished data Mammary hypoplasia was initially recognised in two adult female
MGS patients with disproportionate short stature 25 and has been confirmed in
figure 2
Changing facial appearance of the Meier-Gorlin syndrome during ageing. 
Facial characteristics at age 4 years, including micrognathia and full lips (a), change to a triangular face with a small
high nasal bridge noted at the age of 14 years (b) and 20 years (c and d ). 
a cb d
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our series of six female postmenarcheal and adult patients with no benefit of
estrogen replacement therapy in our three patients whom received treatment,
recently.Bongers, unpublished data Small uterus and bilateral polycystic ovaries were
observed in two female siblings aged 12 years and 135 years, respectively. Bongers,
unpublished data Endocrinological studies of gonads, including LHRH tests are 
normal and the menarche occurs within a normal range of age (median age at
menarche was 13 years) with regular cycles in a series of two adolescent and
four adult females. Bongers, unpublished data
At present, none of the individuals with MGS reported in literature is known 
to have given birth to a child. There is no insight into male and female fertility
of MGS patients. Future longitudinal follow-up studies of MGS patients by 
paediatricians, gynaecologists, and urologists will contribute to the knowledge
on secondary sexual development and fertility. 
Addendum 3 
Anthropometrical measurements in Dutch individuals with nail
patella syndrome
To investigate whether sporadic reports on NPS patients with a short stature
could be recognised in a large series of NPS patients, we evaluated anthropo-
metrical data of our cohort of Dutch patients described in chapter 2.5 table 6.60
We found that the mean adult height and weight of both male and female
patients were within the normal range for the Dutch population. We confirmed
that only a minority of cases had a significant short stature.
Males (adults >18 years) Females (adults >16 years)
Mean birth weight in 3202 (range 1800-4535) 3096 (range 1400-4025) 
term babies (g) n=23 n=27
Mean adult weight (kg) 70.9 (range 51-91) 62.7 (range 44 – 90) 
(+1 SD in Dutch population) (+1 SD in Dutch population)
n=31 n=47
Mean adult height (cm) 174.2 (range 162-186) 163.7 (range 148-182) 
(-1.5 SD in Dutch population) (-1 SD in Dutch population)
n=31 n=46
Mean adult head 57.9 (range 55-61) 55.8 (range 53-59) 
circumference (cm) (0 SD in Dutch population) (0 SD in Dutch population)
n=32 n=48
table 6
Anthropometrical measurements in Dutch individuals with nail patella syndrome
SD, standard deviation
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Addendum 4
Nail and orthopaedic findings in nail patella syndrome
4.1 Knee symptoms reported by Dutch individuals with nail patella syndrome 
The most frequently assigned clinical symptom for which patients with nail
patella syndrome (NPS) ask health care are knee symptoms. This is also reflected
by the fact that the majority of the index patients of NPS families are referred 
to the Department of Human Genetics by an orthopaedic surgeon. Here, we
present the results of an inventory of knee symptoms in a Dutch series of NPS
patients. This is the same NPS cohort as described in chapter 2.5.60 For quanti-
fying the severity of knee pain and function, subjects with NPS aged ≥16 years
were asked to complete a self-report questionnaire, including:
1).  Functional knee scoring devised to subjectively evaluate patellofemoral
symptoms S. Werner, personal communication and adapted from a previously reported
knee scoring scale.69 The knee rating system scores pain, patella instability,
catching, and patient’s ability to squat, walk, and climb stairs, with a total
score of 0-50, representing no problems to serious problems, respectively
tables 7,8.
2).  Validation of knee pain using a visual analogue scale (VAS)70 with a score
from 0 to 100 between the statements no pain to insufferable pain.
Response rate was 96.4% (81/84). The mean age at onset of knee symptoms 
was 15.6 years (range 0-74 years) in NPS subjects overall. The mean score of 
the functional knee measures according to Werner table 8 was 34.6 ± 13.3 in a
series of 77 subjects aged ≥16 yearstable 7. The most frequently assigned knee
symptoms were impaired sitting with flexed knees >30 minutes (72.0%, 59/82)
and pain (66.3%, 55/83) table 7. The mean VAS score for knee pain was 23.7 ±
25.6. Patella (sub)luxations were mentioned by 29% (26/90) of individuals.
Although generalised joint hyperextensibility has been recognised in NPS, none
of the present subjects had a Beighton score of ≥4, suggesting that ligamental
laxity plays no major role in patella (sub)luxations.
Functional knee score items according to Werner et al. (1999)12,a Frequency (n=84b)
Pain 66%
Occurrence of pain related to activity 46%
Feeling of patella instability 26%
Arretations-catching 52%
Problems with sitting with flexed knees >30 minutes 42%
Problems with squatting 72%
Problems with walking upstairs 48%
Problems with walking downstairs 38%
table 7
Knee symptoms in Dutch individuals with nail patella syndrome
a Table 8, Addendum 4.1.
b This cohort of patients is described in chapter 2.5.60
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Patellofemoral symptoms Frequency/severity of symptoms Score
Pain None 5
Slight and infrequent 3
Constant pain 0
Occurrence of pain No activity related pain 15
During or after running 12
After >2 km walking 9
After <2 km walking 6
During ordinary walks 3
During rest 0
Feeling of patella instability Never 5
Sometimes 3
Frequently 0
Catching Never 5
Sometimes 3
Frequently 0
Sitting with flexed knees >30 minutes No problems 5
Slightly impaired 4
Difficulties 2
Unable 0
Squatting No problems 5
Slightly impaired 4
Difficulties 2
Unable 0
Walking upstairs No problems 5
Slightly impaired 4
Difficulties 2
Unable 0
Walking downstairs No problems 5
Slightly impaired 4
Difficulties 2
Unable 0
Total score and rating Serious problems 0
Poor ≤ 32
Fair 33-42
Good 42-46
Excellent ≥ 47
No problems 50
table 8
Functional knee scoring system used to evaluate the severity of patellofemoral symptoms in nail patella syndrome
patients aged ≥16 yearsS. Werner, personal communication, 69
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4.2 Nail and orthopaedic findings in Dutch individuals with nail patella syndrome 
To gain insight in the frequency of limb manifestations of NPS, the findings of
the clinical orthopaedic scoring system developed by Farley et al. (1999)71 are
presented table 9. For objective determination of patellar anomalies and iliac
horns, the radiographic findings were included instead of palpation. This study
was performed in the series of patients described in chapter 2.5.60 Limited
extension of elbows (84.3%; 86/102), hip, and knees was found highly variable
within and between families. Iliac horns are not known to cause pain or func-
tional impairment. 
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Summary
In this thesis the results are described of clinical and molecular investigation 
of human syndromes with congenital patella aplasia or -hypoplasia as a hallmark
feature, with emphasis on nail patella syndrome, small patella syndrome, familial
isolated patella aplasia or hypoplasia, and Meier-Gorlin syndrome. 
The patella (kneecap) is the largest sesamoid bone of the human skeleton.
Disturbed development and growth of the patellae can manifest as the complete
absence (aplasia) or a small size (hypoplasia) of the patellae. Congenital patel-
lar malformations may occur as a (hereditary) isolated limb disorder or may be
present as part of a syndrome with multiple congenital anomalies (Chapter 1).
In the past decade, molecular studies of human syndromes and animal models
comprising congenital limb anomalies uncovered a number of genes underlying
such complex genetic disorders. The elucidation of the underlying genetic
defects (genotype) is of tremendous value for gaining insight in the proteins
and the molecular regulatory mechanisms crucial for normal development 
and growth of the limb. Detailed analysis of clinical features (phenotype) of
these syndromes and animal models with congenital patellar malformations
contribute to understanding the role of these genes in normal and disturbed
development of the limb and additional organs affected. In addition, the 
importance of early recognition of complex syndromes with congenital patellar
anomalies for both treatment of organ complications as well as genetic
counselling justify clinical and molecular studies of patients with congenital
patellar malformations.
Nail patella syndrome
The most common and well-known syndrome with congenital patellar malfor-
mations is the autosomal dominant nail patella syndrome (NPS). 
Chapter 2.1 summarises the literature on the clinical and molecular findings
in human NPS and animal models for NPS up to 2002. NPS is characterised by
the combination of dysplasia of the nails, patellae and elbows and the presence
of iliac horns. The most serious organ complications are nephropathy and glau-
coma. NPS nephropathy is caused by structural and functional defects of the
glomerular basement membrane and the glomerular visceral epithelial cells
(podocytes). The clinical presentation of NPS nephropathy ranges from protein-
uria and hematuria to end-stage renal disease. This syndrome is caused by 
heterozygous mutations in the gene encoding the LIM homeobox transcription
factor 1 beta (LMX1B) protein.
Chapter 2.2 presents the identification and putative effect of the first LMX1B
mutations at the protein level in eight Dutch NPS families. One of these families,
with a relative high prevalence of nephropathy, was already described in 1972 
by the late drs. ter Haar and drs. Van Dam. In this family, we detected a splice-
site mutation (672+1G→A) in the homeodomain of LMX1B. 
Chapter 2.3 describes the immunohistochemical analysis of human NPS
kidney biopsy material to investigate whether disturbed expression of other
podocyte genes than LMX1B are involved in the pathogenesis of NPS nephropa-
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thy. The occurrence and the progression of nephropathy are important for the
prognosis of NPS. Another research group showed that homozygous Lmx1b
mutations disturb the regulation of genes crucial for both structure and func-
tion of the glomerular basement membrane and podocytes in mice, including
genes encoding the α3 en α4 chains of the protein collagen type IV, podocin,
and CD2 ‘associated protein’ (CD2AP) in mice. In contrast to the findings in
kidneys of Lmx1b knockout mice, we found normal expression of the α3 and α4
chains of collagen type IV, podocin, and CD2AP in kidneys from individuals
with NPS nephropathy by immunohistochemistry. Instead, the for NPS-charac-
teristic striated fibrils in the glomerular basement membrane were shown to be
composed of collagen type III. This finding suggests that LMX1B has a function
in the regulation of collagen type III in man. 
In Chapter 2.4, molecular studies to identify and test candidate modifier
genes contributing to the variable expressivity of NPS nephropathy are reported.
Both frequency and severity of NPS nephropathy is extremely variable within
and between families. It is assumed that modifier genes play a role in the vari-
able expression of nephropathy. To identify possible modifier genes, we used
the yeast two-hybrid system. With this technique proteins that interact with
LMX1B can be isolated. Screening of a cDNA bank from human fetal kidney
tissue identified the CLIM2 protein. Mutation analysis of the CLIM2 gene was
performed in the earlier mentioned Dutch family with relative high prevalence
of nephropathy, but failed to detect any correlation between a specific allele and
NPS nephropathy. 
In Chapter 2.5, genotype-phenotype evaluations of our series of 32 Dutch
NPS families are discussed. Based on recent insights in the role of Lmx1b in the
development of multiple organ systems of animal models, in-depth clinical
nephrological, radiological, ophthalmologic, audiological, and psychological
examination and LMX1B mutation analysis was performed. A high variability of
the pleiotropic NPS phenotype was found at the individual-, intrafamilial-, and
interfamilial level. Proteinuria was detected in 21% of individuals with NPS.
Proteinuria as well as microalbuminuria was found more frequently in females
as compared to males, which is remarkable since in the general population
there is a male predominance for microalbuminuria. The observation of
normal-tension glaucoma (in 8% of patients) and hearing loss (in 46% of
patients) in our cohort added new clinical symptoms to the NPS phenotype
since these symptoms had not been described previously. Eighteen different
LMX1B mutations could be detected in the cystine-rich zinc-binding motifs
(LIM-A and LIM-B domain) and the homeodomain of the LMX1B protein. This
study provided the first indication that a patient with a mutation in the homeo-
domain has a higher risk for developing nephropathy than a patient with a
mutation in one of the LIM-domains. Moreover, the family history for NPS
nephropathy was found to be predictive for developing nephropathy for indivi-
dual family members with NPS. No correlation was found between the LMX1B
genotype and extra-renal features of the NPS phenotype.
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Small patella syndrome and isolated patella aplasia or hypoplasia
NPS needs to be distinguished from genetic disorders with patella apalasia or
hypoplasia with skeletal anomalies restricted to the lower limb, including the
small patella syndrome (SPS) and familial isolated patella aplasia hypoplasia
(PTLAH). 
In Chapter 3.1, the minimal diagnostic criteria for clinical diagnosis of SPS
and the first haplotype studies in SPS are presented. SPS is an autosomal domi-
nant skeletal dysplasia, in which patella aplasia or -hypoplasia combined with
specific pelvis anomalies are mandatory for clinical diagnosis. As a first step in
the identification of the gene defect underlying SPS, haplotype analysis revealed
possible linkage of SPS with a known locus for PTLAH on chromosome 17q22. 
In Chapter 3.2, the discovery of the gene defect underlying SPS is described.
The earlier mentioned candidate-gene interval for SPS was refined to a critical
region of 5.6 cM by haplotype analysis in additional SPS families. TBX4, encoding
a T-box transcription factor, was selected as a candidate gene based on literature
studies of the phenotype of animal models with disturbed expression of genes
localised in this candidate region on chromosome 17q22. Chickens and mice
with aberrant Tbx4 expression showed striking similarities with the SPS pheno-
type. Molecular analysis of the TBX4 gene identified six different mutations in
six unrelated SPS families. In this study the first evidence was provided that: 
a). Human TBX4 mutations disturb late stages of skeletal development of the
lower limb and the pelvis and b). TBX4 is involved in normal patterning of the
dorso-ventral axis of the lower limbs and the pelvis and the antero-posterior
axis of the feet. 
In Chapter 3.3, the results of clinical characterisation and linkage analysis 
in one PTLAH family are reported. No linkage to the genetic region on chromo-
some 17q22 was found. From this study it was concluded that PTLAH is a
genetically heterogeneous disorder. 
Meier-Gorlin syndrome
In contrast to SPS and PTLAH, the autosomal recessive Meier-Gorlin syndrome
(MGS) is not only characterised by skeletal anomalies of the lower limb, but
also by anomalies of the upper limb, the axial skeleton, and several other organ
systems. 
Chapter 4 comprises the clinical characterisation and new findings in a
series of eight additional individuals with MGS and a review of the literature 
on MGS. The classical triad of clinical features comprises typically small ears,
patella aplasia or -hypoplasia, and severe pre- and postnatal growth retardation.
Additional frequent anomalies include facial dysmorphisms, various skeletal
malformations, delayed bone maturation, and urogenital anomalies.
Congenital kidney- and heart anomalies are present in only a minority of the
patients. The characteristic facial features at young age comprise small and 
simple formed ears, full lips, a small mouth, micrognathia, and a beaked nose.
From adolescence, the most prominent facial characteristics change to a high
forehead and a small high nasal bridge. During the neonatal period the most
serious complications are feeding problems and recurrent serious respiratory
tract infections. Mental development is normal in most patients. Despite 
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comprehensive genome wide linkage studies and candidate gene analysis 
in MGS families, the gene defect has as yet not been elucidated.
The identification of the causative gene for MGS and other syndromes with 
congenital patella aplasia or hypoplasia and the unravelling of modifier genes
in complex patellar malformation syndromes will further contribute to the
understanding of normal and disturbed development of the limb and various
other organ systems affected in these syndromes, such as the kidneys in NPS.
These advanced insights are also important for: a). Clinical and molecular 
diagnosis of syndromes with congenital patella aplasia or hypoplasia and 
genetic counselling; b). Early recognition of associated organ complications;
and c). Development of new therapeutic strategies of different organ compli-
cations for some of these disorders (Chapter 5).
Samenvatting
Dit proefschrift beschrijft de resultaten van klinisch en moleculair onderzoek 
van humane syndromen met congenitale patella aplasia of -hypoplasie als
karakteristiek kenmerk, in het bijzonder het nagel patella syndroom, het ‘small’
patella syndroom, familiair geïsoleerde patella aplasia of hypoplasie en het
Meier-Gorlin syndroom. 
De patella, oftewel de knieschijf, is het grootste sesambeen van het humane
skelet. Een verstoorde ontwikkeling en groei van de patella kan zich onder
andere manifesteren als de complete afwezigheid van de patella (patella aplasie)
of een kleine omvang van de patella (patella hypoplasie). Aangeboren afwijkingen
van de patella kunnen als een (erfelijke) geïsoleerde ledemaatafwijking of als
onderdeel van een syndroom met meervoudig aangeboren afwijkingen
voorkomen (Hoofdstuk 1). Door middel van moleculaire studies van humane
syndromen en diermodellen met aangeboren ledemaatafwijkingen zijn in het
laatste decennium een toenemend aantal oorzakelijke genen van dergelijke
complexe genetische aandoeningen geïdentificeerd. De opheldering van 
onderliggende genetische defecten (genotype) levert een belangrijk inzicht in 
de eiwitten en de moleculaire regelmechanismen die tijdens de normale ontwik-
keling en groei van ledematen van cruciaal belang zijn. Gedetailleerde analyse 
van de klinische verschijnselen (fenotype) van deze syndromen en diermodellen
draagt bij aan nieuwe inzichten in de rol van deze genen in de normale en 
verstoorde ontwikkeling van de ledematen en van verschillende andere in de
ziekte betrokken orgaansystemen. Gezien het belang van vroege syndroom-
diagnostiek van aandoeningen met aangeboren patella aplasie of -hypoplasie
voor de behandeling van verschillende geassocieerde orgaancomplicaties en
erfelijkheidsadvisering is het gerechtvaardigd bij personen met deze patella
afwijkingen gedetailleerde studies te verrichten naar de oorzaak hiervan.
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Nagel patella syndroom
Het bekendste en meest voorkomende syndroom met een verstoorde ontwik-
keling en groei van de patella is het autosomaal dominant overervende nagel
patella syndroom (NPS). 
In Hoofdstuk 2.1 wordt een samenvatting gegeven van de klinische en mole-
culaire bevindingen in humaan NPS en diermodellen voor NPS die tot 2002 in de
literatuur zijn beschreven. Deze aandoening wordt gekenmerkt door de combi-
natie nagelafwijkingen, patella aplasie of -hypoplasie, elleboogafwijkingen en
bekkenhoorntjes. De meest ernstige orgaancomplicaties zijn nefropathie en
glaucoom. NPS nefropathie wordt veroorzaakt door structurele en functionele
defecten van de glomerulaire basaalmembraan (GBM) en de viscerale epitheel-
cellen die de glomeruluscapillairen omgeven (podocyten). De klinische presentatie
van nierafwijkingen kan variëren van proteïnurie en hematurie tot terminale
nierinsufficiëntie. NPS wordt veroorzaakt door heterozygote mutaties in het gen
dat codeert voor het ‘LIM homeobox transcriptie factor 1 beta’ (LMX1B) eiwit.
In Hoofdstuk 2.2 wordt de identificatie en het veronderstelde effect op 
eiwitniveau van de eerste LMX1B mutaties in acht Nederlandse NPS families
beschreven. In een eerder (1972) door wijlen drs. ter Haar en drs. van Dam en 
dr. Looij en collega’s beschreven NPS familie met een relatief hoge prevalentie
van nefropathie werd een splice-site mutatie (672+1G→A) in het homeodomein
van LMX1B opgespoord. 
Hoofdstuk 2.3 beschrijft het immunohistochemisch onderzoek van humaan
nierweefsel dat werd verricht met als doel te onderzoeken of een verstoorde
expressie van andere podocyt genen dan LMX1B van invloed zijn op de patho-
genese van NPS nefropathie. Het ontstaan en de progressie van nefropathie is
bepalend voor de prognose van NPS. Door een andere onderzoeksgroep werd
door studies in muizen het bewijs geleverd dat homozygote Lmx1b mutaties de
regulatie van genen verstoort die van cruciaal belang zijn voor de structuur en
functie van de GBM en podocyten, te weten genen die coderen voor de α3 en 
α4 ketens van het eiwit collageen type IV, voor podocine en voor CD2 ‘associated
protein’ (CD2AP). Om te onderzoeken of een overeenkomstig verstoorde genex-
pressie betrokken is in de pathogenese van NPS nefropathie, werd immunohisto-
chemisch onderzoek van nierbiopten van personen met NPS verricht. In tegen-
stelling tot de bevindingen in nieren van Lmx1b knock-out muizen, werd met
immunohistochemische analyse een normale expressie van de α3 en α4 ketens
van collageen type IV, podocine en CD2AP gevonden in humane NPS nieren.
Verder werd aangetoond dat de voor NPS-karakteristieke dwarsgestreepte fibril-
len in de GBM bestaan uit collageen type III, hetgeen suggereert dat LMX1B
een functie heeft in de regulatie van collageen type III expressie bij de mens.
In Hoofdstuk 2.4 worden de moleculaire studies gepresenteerd die als 
doel hadden kandidaat modificerende genen te identificeren en te testen die 
bijdragen aan de variabele expressie van NPS nefropathie. Zowel de prevalentie
als de ernst van NPS nefropathie is zeer variabel binnen en tussen families.
Aangenomen wordt dat modificerende genen een rol spelen in de moleculaire
mechanismen die betrokken zijn bij de variabele expressie van nefropathie.
Voor de opsporing van mogelijke modificerende genen werd gebruik gemaakt
van het ‘yeast two-hybrid’ systeem. Met deze techniek kunnen eiwitten worden
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geïsoleerd die een binding aangaan met LMX1B (Hoofdstuk 2.3). Screening 
van een cDNA bank uit humaan foetaal nierweefsel leverde het CLIM2 eiwit op.
Mutatieanalyse van het CLIM2 gen werd verricht in bovengenoemde
Nederlandse familie met een relatief hoge prevalentie van nefropathie, maar
toonde geen correlatie aan tussen een specifiek allel en NPS nefropathie. 
In Hoofdstuk 2.5 worden de resultaten van een genotype-fenotype studie 
in een cohort van 32 Nederlandse NPS families bediscussieerd. Op basis van
recente inzichten in de rol van Lmx1b in de ontwikkeling van multipele orgaan-
systemen van diermodellen werd klinisch nefrologisch-, radiologisch-,
oogheelkundig-, audiologisch-, en psychologisch onderzoek en LMX1B mutatie
analyse verricht. Deze resultaten werden geëvalueerd in een genotype-fenotype
associatie studie. Op individueel-, intrafamiliair- en interfamiliair niveau werd
een grote variatie in pleiotropie van het NPS fenotype gevonden. Nefropathie
kon bij 21% van de patiënten met NPS worden vastgesteld en opmerkelijk vaker
bij vrouwen dan bij mannen, hetgeen opvallend is omdat in de algemene popu-
latie microalbuminuria frequenter bij mannen voorkomt. Het voorkomen van
normale oogdruk glaucoom (8%) en gehoorverlies (46%) in ons cohort voegt
nieuwe klinische kenmerken toe aan het NPS fenotype aangezien deze symp-
tomen tot op heden niet eerder werden beschreven. Er werden 18 verschillende
LMX1B mutaties aangetoond in de cysteïnerijke zinkbindende domeinen (LIM-A
en LIM-B domein) en het homeodomein van het LMX1B eiwit. In deze studie
werd voor het eerst aangetoond dat een patiënt met een mutatie in het homeo-
domein een grotere kans heeft op het ontwikkelen van nefropathie dan een
patiënt met een mutatie in een van de LIM-domeinen. Daarnaast werd duidelijk
dat de familiegeschiedenis voor NPS nefropathie een voorspellende factor is
voor het ontwikkelen van nefropathie voor individuele familieleden met NPS. 
Er werd geen correlatie gevonden tussen het LMX1B genotype en extra-renale
kenmerken van het NPS fenotype.
‘Small’ patella syndroom en familiar geïsoleerde patella aplasie of hypoplasia
NPS dient te worden onderscheiden van genetische aandoeningen met patella
aplasie of -hypoplasie met uitsluitend onderste ledemaatafwijkingen, waaron-
der het ‘small’ patella syndroom (SPS) en familiair geïsoleerde patella aplasie
hypoplasie (PTLAH). 
In Hoofdstuk 3.1 worden de minimale diagnostische criteria voor de klinische
diagnose SPS en de eerste haplotype studies in SPS gepresenteerd. SPS is een
autosomaal dominante skeletdysplasie, waarbij aangeboren patella aplasie 
of -hypoplasie in combinatie met specifieke bekkenafwijkingen essentiële
bevindingen zijn voor het stellen van de klinische diagnose. Als eerste stap in 
de identificatie van het gendefect voor SPS werd genetische koppeling gevonden
met een bekend gebied voor PTLAH op chromosoom 17q22. 
In Hoofdstuk 3.2 wordt de identificatie van het gendefect dat SPS veroor-
zaakt beschreven. Het eerder genoemde kandidaatgebied voor SPS werd met
koppelingsonderzoek in additionele SPS families ingeperkt tot 5.6-cM. Op
basis van literatuurstudies van het fenotype van diermodellen met verstoorde
expressie van genen gelokaliseerd in dit gebied op chromosoom 17q22 en de
sterke overeenkomsten tussen deze diermodellen en het SPS fenotype werd
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TBX4, dat codeert voor een T-boxtranscriptiefactor, als kandidaatgen voor SPS
geselecteerd. Kippen en muizen met verstoorde Tbx4 expressie tonen sterke
overeenkomsten met het humane SPS fenotype. Met moleculaire analyse van het
TBX4 gen werden zes verschillende mutaties gevonden in zes niet verwante SPS
families. In deze studie werd voor het eerst aangetoond dat a). Humane TBX4
mutaties de late skeletontwikkeling van de onderste ledematen en de formatie
van het bekken verstoren en b). TBX4 betrokken is in de normale regulatie van
de dorso-ventrale asontwikkeling van de onderste ledematen, het bekken en de
antero-posterior asontwikkeling van de voeten. 
Hoofdstuk 3.3 bericht dat in een PTLAH familie geen koppeling met de
genetische regio op chromosoom 17q22 werd gevonden. Hiermee werd 
aangetoond dat PTLAH een heterogeen ziektebeeld is. 
Meier-Gorlin syndroom
In tegenstelling tot SPS en PTLAH komen bij het autosomaal recessieve Meier-
Gorlin syndroom (MGS) naast de skeletafwijkingen van de onderste ledematen
ook afwijkingen van de bovenste ledematen, het axiale skelet en diverse andere
orgaansystemen voor. 
In hoofdstuk 4 worden de klinische karakterisatie en nieuwe bevindingen 
in een serie van acht additionele personen met MGS beschreven en wordt een
samenvatting van de literatuur over MGS gepresenteerd. De klassieke trias van
klinische verschijnselen is opvallend kleine oren, patella aplasie of -hypoplasie
en ernstige pre- en postnatale vertraging van de groei. Andere frequent
voorkomende afwijkingen zijn faciale dysmorfiën, vertraagde botrijping,
mamma hypoplasie en urogenitale afwijkingen. Aangeboren nier- en
hartafwijkingen komen slechts bij de minderheid van de patiënten voor. 
De karakteristieke gelaatskenmerken op jonge leeftijd zijn naast de opvallend
kleine en eenvoudig gevormde oren, volle lippen, een kleine mond, een kleine
onderkaak en een gebogen neus. Vanaf de adolescentie veranderen de meest
prominente gelaatskenmerken in een hoog voorhoofd en een smalle hoge neus-
brug. Tijdens de neonatale periode treden de meest ernstige problemen op met
de voeding en zijn er recidiverende ernstige luchtweginfecties. De mentale
ontwikkeling verloopt in de meerderheid normaal. Ondanks uitgebreide
‘genome-wide’ koppelingsonderzoek en van kandidaatgen analyse in 
MGS families is het gendefect voor MGS nog niet opgehelderd.
De identificatie van het oorzakelijke gen voor MGS en andere syndromen met
aangeboren patella aplasie of -hypoplasie en de opheldering van modificerende
genen die betrokken zijn bij de variabele klinische expressie van deze syn-
dromen zullen verder bijdragen aan de kennis van de ontwikkeling van de 
ledematen en verschillende andere in de aandoening betrokken orgaansystemen,
zoals de nieren in NPS. Deze toename van kennis is tevens van belang voor: 
a). Klinische en moleculaire diagnostiek van syndromen met aangeboren patella
aplasie of -hypoplasie en erfelijkheidsadvisering; b). Vroegtijdige herkenning
van geassocieerde orgaancomplicaties en c). Ontwikkeling van nieuwe thera-
peutische mogelijkheden van verschillende orgaancomplicaties van een aantal
van deze syndromen (Hoofdstuk 5).
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